[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is a rare skin condition that is associated with various types of cancer, including breast, lung, and ovarian cancer. Here are some synonyms for Acrokeratosis paraneoplastica:\n1. Paraneoplastic acrokeratosis - This term is used to describe the condition when it occurs in association with cancer.\n2. Acrokeratosis paraneoplastica syndrome - This term is used to describe the condition in a broader sense, including both the skin changes and the underlying cancer.\n3. Cancer-associated acrokeratosis - This term is used to describe the condition when it occurs in association with cancer.\n4. Cutaneous paraneoplastic syndrome - This term is used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer.\n5. Paraneoplastic cutaneous syndrome - This term is used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin.\n6. Cancer-associated cutaneous syndrome - This term is used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin.\n7. Cutaneous oncogenic syndrome - This term is used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin.\n8. Paraneoplastic cutaneous neoplasia - This term is used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin.\n9. Cancer-associated cutaneous neoplasia - This term is used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin.\n10. Cutaneous oncogenic neoplasia - This term is used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin.\nIt's important to note that these terms are not interchangeable, and each term has its own specific meaning and",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is associated with various types of cancer, including breast, lung, and ovarian cancer.\n2. \"Paraneoplastic acrokeratosis\" is a term used to describe Acrokeratosis paraneoplastica when it occurs in association with cancer.\n3. \"Acrokeratosis paraneoplastica syndrome\" is a term that includes both the skin changes and the underlying cancer.\n4. \"Cutaneous paraneoplastic syndrome\" is a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer.\n5. \"Cancer-associated cutaneous neoplasia\" is a term used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is associated with various types of cancer, including breast, lung, and ovarian cancer.",
      "\"Paraneoplastic acrokeratosis\" is a term used to describe Acrokeratosis paraneoplastica when it occurs in association with cancer.",
      "\"Acrokeratosis paraneoplastica syndrome\" is a term that includes both the skin changes and the underlying cancer.",
      "\"Cutaneous paraneoplastic syndrome\" is a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer.",
      "\"Cancer-associated cutaneous neoplasia\" is a term used to describe a group of conditions, including Acrokeratosis paraneoplastica, that occur in association with cancer and affect the skin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: \"Cancer-associated cutaneous neoplasia\" typically refers to skin neoplasms (tumors) that are directly associated with cancer, whereas Acrokeratosis paraneoplastica is a paraneoplastic syndrome that manifests with skin changes due to the presence of an underlying malignancy, but it is not a neoplasm itself.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can cause developmental delays and intellectual disability, but they are not the same. Weaver syndrome is caused by a mutation in the PTEN gene, while Sotos syndrome is caused by a mutation in the NSD1 gene. While both disorders can cause similar symptoms, such as delayed speech and language development, seizures, and distinctive facial features, they have different genetic causes and may have different clinical presentations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both rare genetic disorders.\n2. Both Weaver syndrome and Sotos syndrome can cause developmental delays and intellectual disability.\n3. Weaver syndrome is caused by a mutation in the PTEN gene.\n4. Sotos syndrome is caused by a mutation in the NSD1 gene.\n5. Both disorders can cause symptoms such as delayed speech and language development, seizures, and distinctive facial features.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both rare genetic disorders.",
      "Both Weaver syndrome and Sotos syndrome can cause developmental delays and intellectual disability.",
      "Weaver syndrome is caused by a mutation in the PTEN gene.",
      "Sotos syndrome is caused by a mutation in the NSD1 gene.",
      "Both disorders can cause symptoms such as delayed speech and language development, seizures, and distinctive facial features."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Weaver syndrome is caused by a mutation in the EZH2 gene, not the PTEN gene.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Joint Annotation Standards for Plant Annotation Resources) is a database of transcription factor binding site (TFBS) annotations for various organisms, including plants. Here are the releases of the JASPAR database:\n1. JASPAR Release 1.0 (2004): This was the first release of the JASPAR database, which contained TFBS annotations for Arabidopsis thaliana and Oryza sativa (rice).\n2. JASPAR Release 2.0 (2007): This release expanded the database to include TFBS annotations for additional plant species, including Brachypodium distachyon, Populus trichocarpa, and Zea mays.\n3. JASPAR Release 3.0 (2010): This release added TFBS annotations for additional plant species, including Medicago truncatula, Sorghum bicolor, and Solanum lycopersicum.\n4. JASPAR Release 4.0 (2013): This release included significant improvements to the database, including the integration of new data and the development of a new annotation pipeline.\n5. JASPAR Release 5.0 (2016): This release added TFBS annotations for additional plant species, including Fagopyrum esculentum, Glycine max, and Pisum sativum.\n6. JASPAR Release 6.0 (2019): This release included significant improvements to the database, including the integration of new data and the development of a new annotation pipeline.\n7. JASPAR Release 7.0 (2022): This is the latest release of the JASPAR database, which includes TFBS annotations for over 100 plant species, as well as improved data quality and annotation standards.\nIt's worth noting that the JASPAR database is actively maintained and updated, so there may be additional releases beyond the ones listed here.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1.0 was launched in 2004 with TFBS annotations for Arabidopsis thaliana and Oryza sativa.\n2. JASPAR Release 2.0 was launched in 2007 and included TFBS annotations for additional plant species such as Brachypodium distachyon, Populus trichocarpa, and Zea mays.\n3. JASPAR Release 3.0 was launched in 2010 and added TFBS annotations for Medicago truncatula, Sorghum bicolor, and Solanum lycopersicum.\n4. JASPAR Release 4.0 was launched in 2013 and featured significant improvements including the integration of new data and a new annotation pipeline.\n5. JASPAR Release 7.0 was launched in 2022 and includes TFBS annotations for over 100 plant species.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1.0 was launched in 2004 with TFBS annotations for Arabidopsis thaliana and Oryza sativa.",
      "JASPAR Release 2.0 was launched in 2007 and included TFBS annotations for additional plant species such as Brachypodium distachyon, Populus trichocarpa, and Zea mays.",
      "JASPAR Release 3.0 was launched in 2010 and added TFBS annotations for Medicago truncatula, Sorghum bicolor, and Solanum lycopersicum.",
      "JASPAR Release 4.0 was launched in 2013 and featured significant improvements including the integration of new data and a new annotation pipeline.",
      "JASPAR Release 7.0 was launched in 2022 and includes TFBS annotations for over 100 plant species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: JASPAR Release 2.0 was launched in 2006, not 2007, and while it did include additional data, the specific plant species mentioned are not documented in the release notes available to me.\n3. UNKNOWN: Without specific release notes or documentation, the details about the exact plant species added in JASPAR Release 3.0 cannot be confirmed.\n4. UNKNOWN: The details about the improvements and features of JASPAR Release 4.0 cannot be confirmed without specific release notes or documentation.\n5. FALSE [correction]: JASPAR Release 7.0 was launched in 2020, not 2022, and while it includes a large number of TFBS annotations, the exact number of plant species covered is not specified in the information available to me.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The function of the viral KP4 protein is to inhibit the host cell's immune response by blocking the activation of the innate immune receptor, Toll-like receptor 4 (TLR4). This allows the virus to evade the host's immune system and establish a persistent infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. The viral KP4 protein functions to inhibit the host cell's immune response.\n2. KP4 protein blocks the activation of the innate immune receptor, Toll-like receptor 4 (TLR4).\n3. The inhibition of TLR4 by KP4 protein allows the virus to evade the host's immune system.\n4. The action of KP4 protein can lead to the establishment of a persistent infection in the host.",
    "llama-2-7b-chat-hf_fact": [
      "The viral KP4 protein functions to inhibit the host cell's immune response.",
      "KP4 protein blocks the activation of the innate immune receptor, Toll-like receptor 4 (TLR4).",
      "The inhibition of TLR4 by KP4 protein allows the virus to evade the host's immune system.",
      "The action of KP4 protein can lead to the establishment of a persistent infection in the host."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific context or a reference to a particular study or source that defines the KP4 protein and its functions, it is not possible to determine the accuracy of these statements. The KP4 protein could refer to a specific protein in a particular virus, but without additional information, the truthfulness of these statements cannot be assessed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (1,1-diethyl-2-methyl-3-[4-(2-furoylamino)phenyl]-butanedione) is a thyroid hormone analog that has been utilized in both experimental and clinical studies.\nDITPA is a synthetic compound that mimics the action of triiodothyronine (T3), one of the two main hormones produced by the thyroid gland. T3 plays a crucial role in regulating metabolism, growth, and development, and DITPA has been shown to have similar effects in the body.\nDITPA has been used in various experimental studies to investigate the mechanisms of thyroid hormone action, as well as to test the effects of thyroid hormone deficiency or excess. For example, DITPA has been used to study the effects of T3 on cardiovascular function, muscle strength, and bone metabolism in animal models.\nIn clinical settings, DITPA has been used to treat certain thyroid disorders, such as hypothyroidism (underactive thyroid) and thyroid cancer. However, its use is relatively rare due to the availability of other more effective and safer treatments.\nIt is important to note that while DITPA can mimic the effects of T3, it is not a perfect substitute for the hormone and can have different effects on the body. Therefore, its use in clinical settings should only be done under the close supervision of a healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA mimics the action of triiodothyronine (T3), a hormone produced by the thyroid gland.\n3. DITPA has been used in experimental studies to investigate thyroid hormone action and test the effects of thyroid hormone deficiency or excess.\n4. In clinical settings, DITPA has been used to treat conditions like hypothyroidism and thyroid cancer.\n5. DITPA is not a perfect substitute for T3 and can have different effects on the body.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA mimics the action of triiodothyronine (T3), a hormone produced by the thyroid gland.",
      "DITPA has been used in experimental studies to investigate thyroid hormone action and test the effects of thyroid hormone deficiency or excess.",
      "In clinical settings, DITPA has been used to treat conditions like hypothyroidism and thyroid cancer.",
      "DITPA is not a perfect substitute for T3 and can have different effects on the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DITPA has been used in experimental and clinical studies, but it is not a standard treatment for conditions like hypothyroidism and thyroid cancer. Standard treatments for hypothyroidism typically involve levothyroxine, which is a synthetic form of thyroxine (T4), and thyroid cancer treatments can include surgery, radioactive iodine, and thyroid hormone suppression therapy, among others.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (Cognitive User Generated Equivalence Relations) is a tool used in the field of Artificial Intelligence and Machine Learning. It is a technique for generating equivalent sentences or phrases that convey the same meaning as a given input, but with a different wording or structure. COUGER is used to improve the readability and understandability of natural language processing models, and to help them generalize better to unseen data.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for Cognitive User Generated Equivalence Relations.\n2. COUGER is used in the field of Artificial Intelligence and Machine Learning.\n3. The tool generates equivalent sentences or phrases that convey the same meaning as a given input.\n4. COUGER aims to improve the readability and understandability of natural language processing models.\n5. COUGER helps natural language processing models to generalize better to unseen data.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for Cognitive User Generated Equivalence Relations.",
      "COUGER is used in the field of Artificial Intelligence and Machine Learning.",
      "The tool generates equivalent sentences or phrases that convey the same meaning as a given input.",
      "COUGER aims to improve the readability and understandability of natural language processing models.",
      "COUGER helps natural language processing models to generalize better to unseen data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER stands for Cognitive User Engagement and Recommendation.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The acronym COUGER is not a standard term widely recognized in the field of AI and Machine Learning. The correction provided for statement 1 is based on a possible interpretation, but without a specific context or reference, the true meaning of COUGER and its applications cannot be confirmed. Statements 3, 4, and 5 are also difficult to verify without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat Tick-borne Encephalitis (TBE). The most commonly used drugs are:\n1. Antiviral medications: These drugs can help reduce the replication of the virus in the body and may help alleviate symptoms. Examples of antiviral medications used to treat TBE include ribavirin, pleconaril, and brincidofovir.\n2. Corticosteroids: These medications can help reduce inflammation in the brain and may help improve neurological symptoms. Corticosteroids are often prescribed in combination with antiviral medications.\n3. Immunoglobulins: These medications contain antibodies that can help neutralize the virus and reduce the risk of complications. Immunoglobulins are often given intravenously and can provide short-term protection against TBE.\n4. Supportive care: Patients with TBE may require hospitalization to manage severe symptoms, such as fever, headache, and muscle weakness. Supportive care may include intravenous fluids, oxygen therapy, and physical therapy.\nIt's important to note that the effectiveness of these drugs can vary, and the best treatment approach may depend on the severity and duration of the infection, as well as the individual patient's overall health. In some cases, a combination of drugs may be used to treat TBE. It's important to consult a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Antiviral medications are used to treat Tick-borne Encephalitis and may help reduce the replication of the virus.\n2. Corticosteroids are prescribed to reduce inflammation in the brain and improve neurological symptoms for Tick-borne Encephalitis patients.\n3. Immunoglobulins containing antibodies are used to neutralize the Tick-borne Encephalitis virus and reduce the risk of complications.\n4. Supportive care, including hospitalization, intravenous fluids, oxygen therapy, and physical therapy, may be required for patients with severe symptoms of Tick-borne Encephalitis.\n5. The effectiveness of drugs for Tick-borne Encephalitis can vary depending on the severity and duration of the infection, as well as the patient's overall health.",
    "llama-2-7b-chat-hf_fact": [
      "Antiviral medications are used to treat Tick-borne Encephalitis and may help reduce the replication of the virus.",
      "Corticosteroids are prescribed to reduce inflammation in the brain and improve neurological symptoms for Tick-borne Encephalitis patients.",
      "Immunoglobulins containing antibodies are used to neutralize the Tick-borne Encephalitis virus and reduce the risk of complications.",
      "Supportive care, including hospitalization, intravenous fluids, oxygen therapy, and physical therapy, may be required for patients with severe symptoms of Tick-borne Encephalitis.",
      "The effectiveness of drugs for Tick-borne Encephalitis can vary depending on the severity and duration of the infection, as well as the patient's overall health."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are no specific antiviral medications approved for the treatment of Tick-borne Encephalitis; treatment is mainly supportive.\n2. TRUE\n3. FALSE [correction]: Immunoglobulins containing antibodies may be used as a preventive measure after a tick bite or for unvaccinated individuals who have been exposed to the virus, but they are not used to neutralize the virus once the disease has manifested.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers available for DNA shape annotations, but one of the most popular and widely used is the ChromHMM database. ChromHMM is a database of chromatin conformation capture (3C) data, which provides information on the three-dimensional structure of chromosomes and the interactions between different regions of the genome. It is available at the University of California, San Diego (UCSD) Genome Browser website.\nOther genome browsers that provide DNA shape annotations include:\n1. The Genome Browser at the University of California, Santa Cruz (UCSC): This database provides a variety of genomic data, including 3C data, and allows users to visualize and analyze the structure of the genome.\n2. The Ensembl Genome Browser: This is a comprehensive genome browser that provides a wide range of genomic data, including 3C data, and allows users to visualize and analyze the structure of the genome.\n3. The UCSC Genome Browser: This is a popular genome browser that provides a variety of genomic data, including 3C data, and allows users to visualize and analyze the structure of the genome.\n4. The HISAT2 Genome Browser: This is a genome browser that provides a variety of genomic data, including 3C data, and allows users to visualize and analyze the structure of the genome.\n5. The TopHat2 Genome Browser: This is a genome browser that provides a variety of genomic data, including 3C data, and allows users to visualize and analyze the structure of the genome.\nIt's worth noting that these databases are constantly updated and new ones are being developed, so it's always a good idea to check the latest information and see which one is the most suitable for your research.",
    "llama-2-7b-chat-hf_fact_raw": "1. ChromHMM is a database that provides information on the three-dimensional structure of chromosomes and the interactions between different regions of the genome.\n2. The ChromHMM database is available at the University of California, San Diego (UCSD) Genome Browser website.\n3. The Genome Browser at the University of California, Santa Cruz (UCSC) provides a variety of genomic data, including 3C data.\n4. The Ensembl Genome Browser is a comprehensive genome browser that offers a wide range of genomic data, including 3C data.\n5. The UCSC Genome Browser, HISAT2 Genome Browser, and TopHat2 Genome Browser are other genome browsers that provide 3C data and allow visualization and analysis of the genome structure.",
    "llama-2-7b-chat-hf_fact": [
      "ChromHMM is a database that provides information on the three-dimensional structure of chromosomes and the interactions between different regions of the genome.",
      "The ChromHMM database is available at the University of California, San Diego (UCSD) Genome Browser website.",
      "The Genome Browser at the University of California, Santa Cruz (UCSC) provides a variety of genomic data, including 3C data.",
      "The Ensembl Genome Browser is a comprehensive genome browser that offers a wide range of genomic data, including 3C data.",
      "The UCSC Genome Browser, HISAT2 Genome Browser, and TopHat2 Genome Browser are other genome browsers that provide 3C data and allow visualization and analysis of the genome structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChromHMM is not a database but a computational tool that uses chromatin state data to learn the hidden chromatin states of the genome and does not provide information on the three-dimensional structure of chromosomes or the interactions between different regions of the genome.\n2. FALSE [correction]: ChromHMM is not a database and thus is not available at the UCSD Genome Browser website. However, the UCSD may provide access to ChromHMM-generated data.\n3. TRUE: The Genome Browser at UCSC does provide a variety of genomic data, which may include data from chromosome conformation capture experiments such as 3C.\n4. TRUE: The Ensembl Genome Browser is a comprehensive resource that offers a wide range of genomic data, and it may include data from 3C-based experiments.\n5. FALSE [correction]: HISAT2 and TopHat2 are not genome browsers; they are software tools for aligning sequences to the genome (HISAT2) and analyzing RNA sequencing data (TopHat2). The UCSC Genome Browser does provide access to genomic data and visualization tools, but HISAT2 and TopHat2 are not genome browsers and do not provide 3C data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. EZH2-related syndrome: This is a rare genetic disorder characterized by developmental delays, intellectual disability, and various physical abnormalities.\n2. Gorlin syndrome: This is a rare genetic disorder that can cause various developmental abnormalities, including facial dysmorphism, skeletal abnormalities, and various types of cancer.\n3. Nevoid basal cell carcinoma syndrome (NBCCS): This is a rare genetic disorder that can cause various skin cancers, including basal cell carcinoma, as well as other abnormalities such as developmental delays and intellectual disability.\n4. Cowden syndrome: This is a rare genetic disorder that can cause various developmental abnormalities, including facial dysmorphism, cardiovascular abnormalities, and various types of cancer.\n5. Bannayan-Riley-Ruvalcaba syndrome: This is a rare genetic disorder that can cause various developmental abnormalities, including facial dysmorphism, skeletal abnormalities, and various types of cancer.\nIt's important to note that these syndromes are rare and the prevalence of EZH2 mutations in these disorders may vary. Additionally, not all individuals with EZH2 mutations will develop these syndromes, and some individuals without EZH2 mutations may still develop these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with EZH2-related syndrome, which is characterized by developmental delays, intellectual disability, and physical abnormalities.\n2. Gorlin syndrome, which includes facial dysmorphism, skeletal abnormalities, and various types of cancer, is associated with mutations in the EZH2 gene.\n3. Mutations in the EZH2 gene are linked to Nevoid basal cell carcinoma syndrome (NBCCS), which can cause skin cancers and other abnormalities.\n4. Cowden syndrome, which can cause developmental abnormalities and various types of cancer, is associated with mutations in the EZH2 gene.\n5. Bannayan-Riley-Ruvalcaba syndrome is associated with mutations in the EZH2 gene and can cause developmental abnormalities and various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with EZH2-related syndrome, which is characterized by developmental delays, intellectual disability, and physical abnormalities.",
      "Gorlin syndrome, which includes facial dysmorphism, skeletal abnormalities, and various types of cancer, is associated with mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene are linked to Nevoid basal cell carcinoma syndrome (NBCCS), which can cause skin cancers and other abnormalities.",
      "Cowden syndrome, which can cause developmental abnormalities and various types of cancer, is associated with mutations in the EZH2 gene.",
      "Bannayan-Riley-Ruvalcaba syndrome is associated with mutations in the EZH2 gene and can cause developmental abnormalities and various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Gorlin syndrome, also known as Nevoid basal cell carcinoma syndrome (NBCCS), is associated with mutations in the PTCH1 gene, not the EZH2 gene.\n3. FALSE [correction]: Mutations in the EZH2 gene are not linked to Nevoid basal cell carcinoma syndrome (NBCCS); instead, NBCCS is associated with mutations in the PTCH1 gene.\n4. FALSE [correction]: Cowden syndrome is associated with mutations in the PTEN gene, not the EZH2 gene.\n5. FALSE [correction]: Bannayan-Riley-Ruvalcaba syndrome is associated with mutations in the PTEN gene, not the EZH2 gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that undergo a dimer-to-tetramer transition. Here are some examples:\n1. Hemoglobin: Hemoglobin is a tetrameric protein composed of four subunits, each of which is a dimer. The dimer-to-tetramer transition is an important step in the assembly of hemoglobin in red blood cells.\n2. Myoglobin: Myoglobin is a monomeric protein found in muscle cells that undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.\n3. Carbonic anhydrase: Carbonic anhydrase is an enzyme that catalyzes the reversible reaction of carbon dioxide hydration to bicarbonate. The enzyme exists as a dimer in solution but undergoes a dimer-to-tetramer transition upon binding to the substrate.\n4. Chloride channel: Chloride channels are transmembrane proteins that play a crucial role in regulating chloride ion transport across cell membranes. These proteins undergo a dimer-to-tetramer transition in response to changes in chloride ion concentrations.\n5. Nitric oxide synthase: Nitric oxide synthase is an enzyme that catalyzes the conversion of L-arginine to citrulline and nitric oxide. The enzyme exists as a dimer in solution but undergoes a dimer-to-tetramer transition in response to the binding of calcium ions.\n6. Phosphofructokinase-1: Phosphofructokinase-1 is an enzyme involved in the glycolytic pathway that undergoes a dimer-to-tetramer transition in response to changes in the concentration of ATP and fructose-6-phosphate.\n7. Pyruvate kinase: Pyruvate kinase is an enzyme that catalyzes the conversion of pyruvate to acetyl-CoA and ATP. The enzyme exists as a dimer in solution but undergoes a dimer-to-tetramer transition in response to changes in",
    "llama-2-7b-chat-hf_fact_raw": "1. Hemoglobin is a tetrameric protein composed of four subunits, each of which is a dimer.\n2. Myoglobin is a monomeric protein that undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.\n3. Carbonic anhydrase exists as a dimer in solution but undergoes a dimer-to-tetramer transition upon binding to the substrate.\n4. Chloride channels undergo a dimer-to-tetramer transition in response to changes in chloride ion concentrations.\n5. Nitric oxide synthase exists as a dimer in solution but undergoes a dimer-to-tetramer transition in response to the binding of calcium ions.",
    "llama-2-7b-chat-hf_fact": [
      "Hemoglobin is a tetrameric protein composed of four subunits, each of which is a dimer.",
      "Myoglobin is a monomeric protein that undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.",
      "Carbonic anhydrase exists as a dimer in solution but undergoes a dimer-to-tetramer transition upon binding to the substrate.",
      "Chloride channels undergo a dimer-to-tetramer transition in response to changes in chloride ion concentrations.",
      "Nitric oxide synthase exists as a dimer in solution but undergoes a dimer-to-tetramer transition in response to the binding of calcium ions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hemoglobin is a tetrameric protein composed of four subunits, but each subunit is not a dimer; each is a single polypeptide chain.\n2. FALSE [correction]: Myoglobin is a monomeric protein that does not undergo a dimer-to-tetramer transition; it remains monomeric regardless of oxygen availability.\n3. UNKNOWN: The statement about carbonic anhydrase is specific and would require specialized knowledge about the quaternary structure of this particular enzyme under various conditions. Without additional context, the behavior of carbonic anhydrase in solution and upon substrate binding cannot be confirmed.\n4. UNKNOWN: The behavior of chloride channels in response to changes in chloride ion concentrations is specific and would require detailed knowledge about the particular type of chloride channel being referenced. Without additional context, this statement cannot be confirmed.\n5. FALSE [correction]: Nitric oxide synthase exists as a dimer in solution, and it does bind calcium ions, but it does not undergo a dimer-to-tetramer transition upon calcium binding. The presence of calcium/calmodulin is required for the activation of the enzyme, but the oligomeric state remains a dimer.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Bcl-2",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 is a protein that has been found to interact with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 is a protein that has been found to interact with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people.\nA 2014 meta-analysis of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults (RR=0.77, 95% CI=0.65-0.90). Another meta-analysis published in 2019 found that vitamin D supplementation reduced the risk of falls by 31% in older adults (RR=0.69, 95% CI=0.56-0.86).\nIt is thought that vitamin D may help to reduce the risk of falls by improving muscle strength and balance, as well as by reducing the risk of falls due to muscle weakness and loss of coordination. However, it is important to note that the exact mechanism by which vitamin D reduces the risk of falls is not fully understood and may involve multiple factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people.\n2. A 2014 meta-analysis of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.\n3. The 2014 meta-analysis reported a relative risk (RR) of 0.77 with a 95% confidence interval (CI) of 0.65-0.90 for falls reduction due to vitamin D supplementation.\n4. A 2019 meta-analysis found that vitamin D supplementation reduced the risk of falls by 31% in older adults.\n5. The 2019 meta-analysis reported a relative risk (RR) of 0.69 with a 95% confidence interval (CI) of 0.56-0.86 for falls reduction due to vitamin D supplementation.",
    "llama-2-7b-chat-hf_fact": [
      "Clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people.",
      "A 2014 meta-analysis of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.",
      "The 2014 meta-analysis reported a relative risk (RR) of 0.77 with a 95% confidence interval (CI) of 0.65-0.90 for falls reduction due to vitamin D supplementation.",
      "A 2019 meta-analysis found that vitamin D supplementation reduced the risk of falls by 31% in older adults.",
      "The 2019 meta-analysis reported a relative risk (RR) of 0.69 with a 95% confidence interval (CI) of 0.56-0.86 for falls reduction due to vitamin D supplementation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Clinical trials have indeed shown that vitamin D supplementation can reduce the incidence of falls in older people.\n2. TRUE: A 2014 meta-analysis of randomized controlled trials did find that vitamin D supplementation was associated with a significant reduction in the risk of falls among older adults.\n3. UNKNOWN: Without access to the specific 2014 meta-analysis, the exact relative risk (RR) and confidence interval (CI) cannot be verified.\n4. UNKNOWN: Without access to the specific 2019 meta-analysis, the exact percentage reduction in the risk of falls cannot be verified.\n5. UNKNOWN: Without access to the specific 2019 meta-analysis, the exact relative risk (RR) and confidence interval (CI) cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that Jarid2 and miR-155 are associated in the regulation of Th17 cell differentiation.\nJarid2 has been shown to bind to and demethylate the promoter region of the miR-155 gene, leading to its activation and the subsequent regulation of Th17 cell differentiation. Specifically, Jarid2 has been shown to demethylate the promoter region of miR-155 in Th17 cells, leading to its transcriptional activation and the repression of Th17 cell differentiation.\nAdditionally, miR-155 has been shown to target and regulate the expression of genes involved in Th17 cell differentiation, such as the transcription factor retinoic acid-related orphan receptor gamma t (ROR-γt), which is a key regulator of Th17 cell differentiation.\nOverall, the association between Jarid2 and miR-155 in Th17 cells suggests that Jarid2 may play a role in regulating the differentiation of Th17 cells by modulating the expression of miR-155 and its target genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 can bind to and demethylate the promoter region of the miR-155 gene.\n2. The demethylation of the miR-155 promoter by Jarid2 leads to the transcriptional activation of miR-155.\n3. The activation of miR-155 by Jarid2 represses Th17 cell differentiation.\n4. miR-155 targets and regulates the expression of genes involved in Th17 cell differentiation.\n5. The transcription factor retinoic acid-related orphan receptor gamma t (ROR-γt) is a key regulator of Th17 cell differentiation and is targeted by miR-155.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 can bind to and demethylate the promoter region of the miR-155 gene.",
      "The demethylation of the miR-155 promoter by Jarid2 leads to the transcriptional activation of miR-155.",
      "The activation of miR-155 by Jarid2 represses Th17 cell differentiation.",
      "miR-155 targets and regulates the expression of genes involved in Th17 cell differentiation.",
      "The transcription factor retinoic acid-related orphan receptor gamma t (ROR-γt) is a key regulator of Th17 cell differentiation and is targeted by miR-155."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 does not have demethylase activity. It is a component of the Polycomb Repressive Complex 2 (PRC2) which can influence methylation, but Jarid2 itself does not demethylate DNA.\n2. UNKNOWN: While Jarid2 is involved in the regulation of gene expression, the specific mechanism by which it might lead to the transcriptional activation of miR-155, if it does, is not clearly stated and would require specific experimental evidence.\n3. UNKNOWN: The effect of miR-155 activation by Jarid2 on Th17 cell differentiation would require specific experimental evidence to confirm.\n4. TRUE: miR-155 is known to target and regulate the expression of various genes, and it has been implicated in the regulation of immune cell differentiation, including Th17 cells.\n5. TRUE: The transcription factor ROR-γt is indeed a key regulator of Th17 cell differentiation, and there is evidence that miR-155 can target and regulate the expression of genes related to ROR-γt activity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 8 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 8 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 8 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and gene expression. The phosphorylation consensus motifs for CK1 are:\n1. Arg-X-Ser/Thr: This motif is recognized by the catalytic subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n2. Arg-Arg-X-Ser/Thr: This motif is also recognized by the catalytic subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n3. Ser-X-Gly/Thr: This motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n4. Gly-X-Ser/Thr: This motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n5. Pro-X-Ser/Thr: This motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n6. Tyr-X-Ser/Thr: This motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n7. His-X-Ser/Thr: This motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n8. Arg-X-X-Ser/Thr: This motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n9. Gly-X-X-Ser/Thr: This motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of serine/threonine residues.\n10. Pro-X-X-Ser/Thr",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase.\n2. The phosphorylation consensus motif \"Arg-X-Ser/Thr\" is recognized by the catalytic subunit of CK1 for phosphorylation of serine/threonine residues.\n3. The phosphorylation consensus motif \"Arg-Arg-X-Ser/Thr\" is recognized by the catalytic subunit of CK1 for phosphorylation of serine/threonine residues.\n4. The phosphorylation consensus motif \"Ser-X-Gly/Thr\" is recognized by the regulatory subunit of CK1 for phosphorylation of serine/threonine residues.\n5. The phosphorylation consensus motif \"Gly-X-Ser/Thr\" is recognized by the regulatory subunit of CK1 for phosphorylation of serine/threonine residues.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase.",
      "The phosphorylation consensus motif \"Arg-X-Ser/Thr\" is recognized by the catalytic subunit of CK1 for phosphorylation of serine/threonine residues.",
      "The phosphorylation consensus motif \"Arg-Arg-X-Ser/Thr\" is recognized by the catalytic subunit of CK1 for phosphorylation of serine/threonine residues.",
      "The phosphorylation consensus motif \"Ser-X-Gly/Thr\" is recognized by the regulatory subunit of CK1 for phosphorylation of serine/threonine residues.",
      "The phosphorylation consensus motif \"Gly-X-Ser/Thr\" is recognized by the regulatory subunit of CK1 for phosphorylation of serine/threonine residues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The phosphorylation consensus motif \"Ser/Thr-X-X-Ser/Thr\" is recognized by the catalytic subunit of CK1 for phosphorylation of serine/threonine residues.\n3. TRUE\n4. FALSE [correction]: Casein Kinase 1 (CK1) does not have a regulatory subunit; it functions as a monomeric enzyme.\n5. FALSE [correction]: Casein Kinase 1 (CK1) does not have a regulatory subunit; it functions as a monomeric enzyme, and the correct consensus motif for CK1 is \"Ser/Thr-X-X-Ser/Thr\".",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH gene encodes for a protein called Aspartate beta-hydroxylase, which is involved in the biosynthesis of the neurotransmitter serotonin. There are two main isoforms of this protein:\n1. Aspartate beta-hydroxylase (ASPH): This is the main isoform of the protein, which is produced through the alternative splicing of the ASPH gene. It is primarily involved in the biosynthesis of serotonin.\n2. Tissue-nonspecific alkaline phosphatase (TNAP): This isoform is produced through the alternative splicing of the ASPH gene and is involved in the regulation of cellular processes such as cell proliferation, differentiation, and survival.\nAdditionally, there are other less common isoforms of the ASPH protein, such as the pro-form and the C-terminal fragment, which are produced through post-translational modifications.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes for a protein called Aspartate beta-hydroxylase.\n2. Aspartate beta-hydroxylase is involved in the biosynthesis of the neurotransmitter serotonin.\n3. There are two main isoforms of Aspartate beta-hydroxylase: the main isoform and Tissue-nonspecific alkaline phosphatase (TNAP).\n4. The main isoform of Aspartate beta-hydroxylase is produced through alternative splicing of the ASPH gene.\n5. Tissue-nonspecific alkaline phosphatase (TNAP) is involved in the regulation of cellular processes such as cell proliferation, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes for a protein called Aspartate beta-hydroxylase.",
      "Aspartate beta-hydroxylase is involved in the biosynthesis of the neurotransmitter serotonin.",
      "There are two main isoforms of Aspartate beta-hydroxylase: the main isoform and Tissue-nonspecific alkaline phosphatase (TNAP).",
      "The main isoform of Aspartate beta-hydroxylase is produced through alternative splicing of the ASPH gene.",
      "Tissue-nonspecific alkaline phosphatase (TNAP) is involved in the regulation of cellular processes such as cell proliferation, differentiation, and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Aspartate beta-hydroxylase is involved in the post-translational modification of proteins by hydroxylating aspartyl and asparaginyl residues, not in the biosynthesis of serotonin.\n3. FALSE [correction]: The two main isoforms of Aspartate beta-hydroxylase are the embryonic isoform (also known as fetal B or HAAH) and the adult isoform. Tissue-nonspecific alkaline phosphatase (TNAP) is a different enzyme and not an isoform of Aspartate beta-hydroxylase.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "December 28, 2014",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on December 28, 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on December 28, 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "The loss of the protein Lon1 in Arabidopsis can lead to a range of developmental and physiological abnormalities, including:\n1. Delayed seed germination and seedling growth: Lon1 is involved in the regulation of seed germination and seedling growth, and its loss can lead to delayed germination and slower growth rates.\n2. Altered leaf morphology: Lon1 regulates the formation of leaf shape and size, and its loss can result in abnormal leaf shapes and sizes.\n3. Reduced stem elongation: Lon1 is involved in the regulation of stem elongation, and its loss can lead to reduced stem growth.\n4. Impaired flowering time: Lon1 regulates the transition from vegetative to reproductive growth, and its loss can lead to delayed flowering times.\n5. Increased sensitivity to stress: Lon1 has been shown to play a role in plant stress responses, and its loss can make plants more sensitive to environmental stressors such as drought and heat.\n6. Altered hormone levels: Lon1 regulates the levels of several plant hormones, including auxin and ethylene, and its loss can lead to changes in hormone levels and subsequent changes in plant growth and development.\n7. Changes in root architecture: Lon1 regulates the formation of lateral roots, and its loss can lead to changes in root architecture and reduced root growth.\n8. Increased susceptibility to pathogens: Lon1 has been shown to play a role in plant defense responses, and its loss can make plants more susceptible to pathogens.\n9. Altered shoot branching: Lon1 regulates the formation of shoot branches, and its loss can lead to altered shoot branching patterns.\n10. Changes in floral organ number: Lon1 regulates the number of floral organs, and its loss can lead to changes in floral organ number and morphology.",
    "llama-2-7b-chat-hf_fact_raw": "1. Loss of the protein Lon1 in Arabidopsis can lead to delayed seed germination and seedling growth.\n2. The absence of Lon1 in Arabidopsis can result in altered leaf morphology.\n3. Reduced stem elongation is a consequence of Lon1 loss in Arabidopsis.\n4. Arabidopsis plants lacking Lon1 may experience impaired flowering time.\n5. Loss of Lon1 in Arabidopsis can increase plant sensitivity to environmental stressors.",
    "llama-2-7b-chat-hf_fact": [
      "Loss of the protein Lon1 in Arabidopsis can lead to delayed seed germination and seedling growth.",
      "The absence of Lon1 in Arabidopsis can result in altered leaf morphology.",
      "Reduced stem elongation is a consequence of Lon1 loss in Arabidopsis.",
      "Arabidopsis plants lacking Lon1 may experience impaired flowering time.",
      "Loss of Lon1 in Arabidopsis can increase plant sensitivity to environmental stressors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: The statements provided are specific and consistent with the types of phenotypic consequences that can result from the loss of a protein involved in plant development and stress responses. However, without specific experimental evidence or literature to reference, the responses are based on general knowledge of plant physiology and the functions of proteins like Lon1. If any of the statements were not supported by empirical evidence, the response would need to be corrected accordingly.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone called H3K56ac is present in the yeast genome. It plays a role in the regulation of chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone called H3K56ac is present in the yeast genome.\n2. H3K56ac plays a role in the regulation of chromatin structure.\n3. H3K56ac is involved in the regulation of gene expression in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone called H3K56ac is present in the yeast genome.",
      "H3K56ac plays a role in the regulation of chromatin structure.",
      "H3K56ac is involved in the regulation of gene expression in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The linker histone is not called H3K56ac; H3K56ac refers to a specific acetylation modification of the histone H3 protein at the lysine 56 position.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, some studies have found that drinking tomato juice can help lower cholesterol levels. The lycopene in tomatoes may help reduce the amount of \"bad\" LDL cholesterol in the blood.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies have found that drinking tomato juice can help lower cholesterol levels.\n2. Lycopene in tomatoes may help reduce the amount of \"bad\" LDL cholesterol in the blood.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies have found that drinking tomato juice can help lower cholesterol levels.",
      "Lycopene in tomatoes may help reduce the amount of \"bad\" LDL cholesterol in the blood."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 both play a role in regulating mRNA stability by binding to the 3' untranslated region (UTR) of target mRNAs and preventing their degradation by the RNA exosome complex. This leads to an increase in mRNA stability and a subsequent increase in protein production.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are involved in regulating mRNA stability.\n2. They bind to the 3' untranslated region (UTR) of target mRNAs.\n3. Their binding prevents degradation of mRNAs by the RNA exosome complex.\n4. The result of their action is an increase in mRNA stability.\n5. Increased mRNA stability leads to an increase in protein production.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are involved in regulating mRNA stability.",
      "They bind to the 3' untranslated region (UTR) of target mRNAs.",
      "Their binding prevents degradation of mRNAs by the RNA exosome complex.",
      "The result of their action is an increase in mRNA stability.",
      "Increased mRNA stability leads to an increase in protein production."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hsp70 and Hsp110 are primarily known as molecular chaperones involved in protein folding, not in regulating mRNA stability.\n2. FALSE [correction]: Hsp70 and Hsp110 typically do not bind to the 3' untranslated region (UTR) of mRNAs; they are more commonly associated with binding to nascent polypeptide chains and assisting in protein folding.\n3. FALSE [correction]: Since Hsp70 and Hsp110 are not primarily involved in regulating mRNA stability, they are not known to prevent degradation of mRNAs by the RNA exosome complex.\n4. FALSE [correction]: The primary action of Hsp70 and Hsp110 is to assist in protein folding, not to increase mRNA stability.\n5. UNKNOWN: While increased mRNA stability can lead to an increase in protein production, the statement is vague without context and does not directly relate to the functions of Hsp70 and Hsp110.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "There are three isoforms of deiodinases present in skeletal muscle:\n1. Type 1 iodothyronine deiodinase (D1): found primarily in the brain and peripheral tissues, including skeletal muscle. D1 is responsible for the conversion of T4 to T3.\n2. Type 2 iodothyronine deiodinase (D2): found primarily in the liver, heart, and skeletal muscle. D2 is responsible for the conversion of T4 to reverse T3 (rT3), which can inhibit the activity of T3.\n3. Type 3 iodothyronine deiodinase (D3): found primarily in the brain and peripheral tissues, including skeletal muscle. D3 is responsible for the conversion of T3 to T2, which is then converted to rT3 by D2.\nIt's worth noting that the activity of these enzymes can be influenced by various factors, such as thyroid hormone levels, nutrient availability, and exercise status.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 1 iodothyronine deiodinase (D1) is present in skeletal muscle and is responsible for the conversion of T4 to T3.\n2. Type 2 iodothyronine deiodinase (D2) is present in skeletal muscle and is responsible for the conversion of T4 to reverse T3 (rT3).\n3. Type 3 iodothyronine deiodinase (D3) is present in skeletal muscle and is responsible for the conversion of T3 to T2.\n4. The activity of deiodinases in skeletal muscle can be influenced by thyroid hormone levels, nutrient availability, and exercise status.",
    "llama-2-7b-chat-hf_fact": [
      "Type 1 iodothyronine deiodinase (D1) is present in skeletal muscle and is responsible for the conversion of T4 to T3.",
      "Type 2 iodothyronine deiodinase (D2) is present in skeletal muscle and is responsible for the conversion of T4 to reverse T3 (rT3).",
      "Type 3 iodothyronine deiodinase (D3) is present in skeletal muscle and is responsible for the conversion of T3 to T2.",
      "The activity of deiodinases in skeletal muscle can be influenced by thyroid hormone levels, nutrient availability, and exercise status."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Type 1 iodothyronine deiodinase (D1) is not primarily present in skeletal muscle; it is mainly found in the liver and kidney and is involved in the conversion of T4 to T3 as well as reverse T3 (rT3).\n2. TRUE\n3. FALSE [correction]: Type 3 iodothyronine deiodinase (D3) is present in various tissues, including the central nervous system and placenta, and is responsible for the inactivation of T4 to rT3 and T3 to T2.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Caspases are a family of proteolytic enzymes that play a central role in the inflammatory response. Here are some examples of inflammatory caspase proteins:\n1. Caspase-1: Also known as interleukin-1 beta (IL-1β) converting enzyme (ICE), caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-3: Also known as cytosolic fractionation protein 1 (CFP1), caspase-3 is involved in the cleavage of a variety of cellular proteins, including the pro-inflammatory cytokine interleukin-6 (IL-6).\n3. Caspase-7: Also known as apoptosis-related cysteine peptidase 1 (ARC1), caspase-7 is involved in the regulation of apoptosis and the inflammatory response.\n4. Caspase-8: Also known as Fas-associated death domain protein (FADD), caspase-8 is involved in the regulation of apoptosis and the inflammatory response, particularly in response to the death receptor Fas.\n5. Caspase-9: Also known as interleukin-1 beta-converting enzyme (ICE), caspase-9 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β.\n6. Caspase-12: Also known as inflammasome-activating protein (IAP), caspase-12 is involved in the activation of the inflammasome, a multi-protein complex that plays a central role in the inflammatory response.\n7. Caspase-13: Also known as cytokine-induced protein 1 (CYP1), caspase-13 is involved in the regulation of the inflammatory response and the processing of pro-inflammatory cytokines.\n8. Caspase-14: Also known as p47 phosphatase (PTP4A), caspase-",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n2. Caspase-3 is involved in the cleavage of a variety of cellular proteins, including the pro-inflammatory cytokine IL-6.\n3. Caspase-7 is involved in the regulation of apoptosis and the inflammatory response.\n4. Caspase-8 is involved in the regulation of apoptosis and the inflammatory response, particularly in response to the death receptor Fas.\n5. Caspase-12 is involved in the activation of the inflammasome, which plays a central role in the inflammatory response.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.",
      "Caspase-3 is involved in the cleavage of a variety of cellular proteins, including the pro-inflammatory cytokine IL-6.",
      "Caspase-7 is involved in the regulation of apoptosis and the inflammatory response.",
      "Caspase-8 is involved in the regulation of apoptosis and the inflammatory response, particularly in response to the death receptor Fas.",
      "Caspase-12 is involved in the activation of the inflammasome, which plays a central role in the inflammatory response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-3 is involved in the cleavage of a variety of cellular proteins, but it is not typically associated with the pro-inflammatory cytokine IL-6. Instead, it plays a central role in the execution phase of apoptosis.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Caspase-12 is associated with the modulation of inflammation and innate immunity, but it is not involved in the activation of the inflammasome. Caspase-1 is the caspase typically associated with inflammasome activation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, Aurora B kinase and Ring1B are known to interact and regulate each other's function in various cellular processes, including cell cycle progression and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and Ring1B are known to interact with each other.\n2. Aurora B kinase and Ring1B regulate each other's function.\n3. The interaction between Aurora B kinase and Ring1B is involved in cellular processes.\n4. Aurora B kinase and Ring1B interaction affects cell cycle progression.\n5. Aurora B kinase and Ring1B interaction influences gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and Ring1B are known to interact with each other.",
      "Aurora B kinase and Ring1B regulate each other's function.",
      "The interaction between Aurora B kinase and Ring1B is involved in cellular processes.",
      "Aurora B kinase and Ring1B interaction affects cell cycle progression.",
      "Aurora B kinase and Ring1B interaction influences gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements about Aurora B kinase and Ring1B are specific to molecular biology, and without the specific context or research findings, it's difficult to confirm the accuracy of statements 1 and 2. However, it is generally known that interactions between proteins like Aurora B kinase and Ring1B are involved in cellular processes (3), can affect cell cycle progression (4), and influence gene expression (5). These are common functions of regulatory proteins in cellular biology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice sites:\n* GU-rich sequences (GUGA, GUGG, GUGC, etc.)\n* GU-rich sequences with a 5' GT or GG dinucleotide (e.g. GUGGGT, GUGCGG)\n* AU-rich sequences (AUGA, AUGC, AUGG, etc.)\n* AU-rich sequences with a 5' GT or GG dinucleotide (e.g. AUGCGT, AUGGGT)\nAcceptor splice sites:\n* GU-rich sequences (GUGA, GUGG, GUGC, etc.)\n* GU-rich sequences with a 3' GT or GG dinucleotide (e.g. GUGGTG, GUGCGG)\n* AU-rich sequences (AUGA, AUGC, AUGG, etc.)\n* AU-rich sequences with a 3' GT or GG dinucleotide (e.g. AUGCGG, AUGGGT)\nIt's worth noting that the specific non-canonical sequence motifs found at donor and acceptor splice sites can vary between different species and even within the same species, and the frequency of these motifs can also be influenced by the presence of intronic sequences and other regulatory elements.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich sequences such as GUGA, GUGG, and GUGC are frequent non-canonical motifs at donor splice sites in vertebrates.\n2. GU-rich sequences with a 5' GT or GG dinucleotide, like GUGGGT and GUGCGG, are common at donor splice sites in vertebrates.\n3. AU-rich sequences such as AUGA, AUGC, and AUGG are frequent non-canonical motifs at donor splice sites in vertebrates.\n4. AU-rich sequences with a 5' GT or GG dinucleotide, such as AUGCGT and AUGGGT, are common at donor splice sites in vertebrates.\n5. Non-canonical sequence motifs at acceptor splice sites in vertebrates include GU-rich and AU-rich sequences with a 3' GT or GG dinucleotide.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich sequences such as GUGA, GUGG, and GUGC are frequent non-canonical motifs at donor splice sites in vertebrates.",
      "GU-rich sequences with a 5' GT or GG dinucleotide, like GUGGGT and GUGCGG, are common at donor splice sites in vertebrates.",
      "AU-rich sequences such as AUGA, AUGC, and AUGG are frequent non-canonical motifs at donor splice sites in vertebrates.",
      "AU-rich sequences with a 5' GT or GG dinucleotide, such as AUGCGT and AUGGGT, are common at donor splice sites in vertebrates.",
      "Non-canonical sequence motifs at acceptor splice sites in vertebrates include GU-rich and AU-rich sequences with a 3' GT or GG dinucleotide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GU-rich sequences with a 5' GT or GG dinucleotide, like GUGGGT and GUGCGG, are not common at donor splice sites in vertebrates because the canonical motif at the 5' end of donor splice sites is GT, not GG.\n3. FALSE [correction]: AU-rich sequences such as AUGA, AUGC, and AUGG are not frequent non-canonical motifs at donor splice sites in vertebrates. The canonical motif at donor splice sites is GU at the 5' end.\n4. FALSE [correction]: AU-rich sequences with a 5' GT or GG dinucleotide, such as AUGCGT and AUGGGT, are not common at donor splice sites in vertebrates. The canonical motif at the 5' end of donor splice sites is GT, and AU-rich sequences are not typically associated with splice sites.\n5. FALSE [correction]: Non-canonical sequence motifs at acceptor splice sites in vertebrates do not include GU-rich and AU-rich sequences with a 3' GT or GG dinucleotide. The canonical motif at the 3' end of acceptor splice sites is AG, not GT or GG.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The event of cellular nutrient availability and growth factor signaling results in the acetylation of S6K1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cellular nutrient availability can result in the acetylation of S6K1.\n2. Growth factor signaling can result in the acetylation of S6K1.",
    "llama-2-7b-chat-hf_fact": [
      "Cellular nutrient availability can result in the acetylation of S6K1.",
      "Growth factor signaling can result in the acetylation of S6K1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "The cause of episodic ataxia type 6 is currently unknown.\nIt is important to note that the exact cause of each type of episodic ataxia is still being researched and understood, and new genetic mutations and causes are being identified. The information provided is based on current scientific knowledge and may change as new research and discoveries are made.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to DNA, and they play a role in various epigenetic processes, including gene regulation and chromatin modification.\nIn animals, chromomethylases are involved in the regulation of gene expression, particularly during development and cell differentiation. They are also involved in the maintenance of chromatin structure and the repression of gene expression in certain tissues or cell types.\nThere are several types of chromomethylases found in animal genomes, including histone H3 lysine 4 trimethyltransferases (H3K4me3), histone H3 lysine 27 trimethyltransferases (H3K27me3), and histone H3 lysine 9 trimethyltransferases (H3K9me3). These enzymes are known to be involved in the regulation of gene expression, cell fate determination, and the maintenance of cell identity.\nDysregulation of chromomethylases has been implicated in various diseases, including cancer, where they can lead to the misregulation of gene expression and the loss of cellular identity. Therefore, understanding the function and regulation of chromomethylases in animal genomes is important for the development of new therapeutic strategies for the treatment of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are enzymes that add a methyl group to DNA.\n3. In animals, chromomethylases are involved in the regulation of gene expression during development and cell differentiation.\n4. Types of chromomethylases found in animal genomes include histone H3 lysine 4 trimethyltransferases (H3K4me3), histone H3 lysine 27 trimethyltransferases (H3K27me3), and histone H3 lysine 9 trimethyltransferases (H3K9me3).\n5. Dysregulation of chromomethylases has been implicated in various diseases, including cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are enzymes that add a methyl group to DNA.",
      "In animals, chromomethylases are involved in the regulation of gene expression during development and cell differentiation.",
      "Types of chromomethylases found in animal genomes include histone H3 lysine 4 trimethyltransferases (H3K4me3), histone H3 lysine 27 trimethyltransferases (H3K27me3), and histone H3 lysine 9 trimethyltransferases (H3K9me3).",
      "Dysregulation of chromomethylases has been implicated in various diseases, including cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are not present in animal genomes; they are typically found in plants. In animals, the equivalent enzymes are called DNA methyltransferases.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The enzymes listed (H3K4me3, H3K27me3, and H3K9me3) are histone methyltransferases, not chromomethylases. They modify histones rather than DNA.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Here are some R/Bioconductor packages used for transcription factor binding site (TFBS) analysis:\n1. TFBSpred: This package uses a machine learning approach to predict TFBSs in a given DNA sequence. It can predict both protein-binding sites and transcription factor binding sites.\n2. TFSEARCH: This package uses a combination of position weight matrices (PWMs) and support vector machines (SVMs) to predict TFBSs. It can also be used to identify TFBSs in a given DNA sequence.\n3. TRANSFAC: This package is a comprehensive database of TFBSs that can be used to predict TFBSs in a given DNA sequence. It contains a large collection of PWMs for various transcription factors.\n4. MatInspector: This package uses a combination of PWMs and SVMs to predict TFBSs. It can also be used to identify TFBSs in a given DNA sequence.\n5. GTF2TFBS: This package uses a machine learning approach to predict TFBSs from GTF (Genome Track Format) files. It can be used to predict TFBSs for a given set of transcription factors.\n6. TFBS-predict: This package uses a combination of PWMs and SVMs to predict TFBSs in a given DNA sequence. It can also be used to identify TFBSs in a given DNA sequence.\n7. TF-Pilot: This package uses a machine learning approach to predict TFBSs in a given DNA sequence. It can also be used to identify TFBSs in a given DNA sequence.\n8. DeepSEA: This package uses a deep learning approach to predict TFBSs in a given DNA sequence. It can also be used to identify TFBSs in a given DNA sequence.\n9. TFBS-Caller: This package uses a machine learning approach to predict TFBSs in a given DNA sequence. It can also be used to identify TFBSs in a given DNA sequence.\n10. TF-Rank: This package uses a machine learning approach to predict TFBSs in a given DNA sequence. It can also be used to identify TFBSs in a given DNA sequence.\nPlease note that this is not an",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSpred is an R/Bioconductor package that predicts transcription factor binding sites using a machine learning approach.\n2. TFSEARCH is an R/Bioconductor package that predicts transcription factor binding sites using position weight matrices and support vector machines.\n3. TRANSFAC is an R/Bioconductor package that is a database of transcription factor binding sites and contains a collection of position weight matrices.\n4. MatInspector is an R/Bioconductor package that predicts transcription factor binding sites using position weight matrices and support vector machines.\n5. GTF2TFBS is an R/Bioconductor package that predicts transcription factor binding sites from Genome Track Format files using a machine learning approach.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSpred is an R/Bioconductor package that predicts transcription factor binding sites using a machine learning approach.",
      "TFSEARCH is an R/Bioconductor package that predicts transcription factor binding sites using position weight matrices and support vector machines.",
      "TRANSFAC is an R/Bioconductor package that is a database of transcription factor binding sites and contains a collection of position weight matrices.",
      "MatInspector is an R/Bioconductor package that predicts transcription factor binding sites using position weight matrices and support vector machines.",
      "GTF2TFBS is an R/Bioconductor package that predicts transcription factor binding sites from Genome Track Format files using a machine learning approach."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TFSEARCH is not an R/Bioconductor package. It is a standalone tool that predicts transcription factor binding sites using position weight matrices, but it does not use support vector machines.\n3. FALSE [correction]: TRANSFAC is not an R/Bioconductor package. It is a database of transcription factor binding sites and contains a collection of position weight matrices, but it is not a package within the R/Bioconductor ecosystem.\n4. FALSE [correction]: MatInspector is not an R/Bioconductor package. It is a software tool that is part of the Genomatix Software Suite and it uses position weight matrices to predict transcription factor binding sites, but it does not use support vector machines and is not part of R/Bioconductor.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Sarcopenia is the progressive loss of muscle mass and strength that occurs with aging. While there are no definitive cures for sarcopenia, there are several clinical trials underway to investigate potential prevention and treatment strategies. Here are some examples of ongoing clinical trials for the prevention of sarcopenia:\n1. The Fitness and Nutrition for Independent Living (FINI) Trial: This trial is investigating the effectiveness of a comprehensive exercise and nutrition program in preventing sarcopenia in older adults.\n2. The Resistance Training and Nutrition Intervention to Prevent Sarcopenia (REPS) Trial: This trial is evaluating the impact of resistance training and nutritional interventions on muscle mass and function in older adults.\n3. The Sarcopenia Prevention and Management (SPAMS) Trial: This trial is investigating the effectiveness of a multicomponent intervention including exercise, nutrition, and social support in preventing sarcopenia in older adults.\n4. The Nutrition and Exercise for Independent Living (NEIL) Trial: This trial is evaluating the impact of a nutrition and exercise program on muscle mass, function, and quality of life in older adults.\n5. The Sarcopenia Prevention and Treatment with Metformin (SPTM) Trial: This trial is investigating the potential of metformin, a commonly used diabetes medication, to prevent or treat sarcopenia.\n6. The Exercise and Nutrition for Healthy Aging (ENHA) Trial: This trial is evaluating the impact of a comprehensive exercise and nutrition program on muscle mass, function, and overall health in older adults.\n7. The Sarcopenia Prevention and Management in Older Adults (SPAMA) Trial: This trial is investigating the effectiveness of a multicomponent intervention including exercise, nutrition, and social support in preventing and managing sarcopenia in older adults.\n8. The Nutrition and Exercise for Sarcopenia Prevention (NESP) Trial: This trial is evaluating the impact of a nutr",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fitness and Nutrition for Independent Living (FINI) Trial is investigating the effectiveness of exercise and nutrition programs in preventing sarcopenia in older adults.\n2. The Resistance Training and Nutrition Intervention to Prevent Sarcopenia (REPS) Trial is evaluating the impact of resistance training and nutritional interventions on muscle mass and function in older adults.\n3. The Sarcopenia Prevention and Management (SPAMS) Trial is investigating a multicomponent intervention including exercise, nutrition, and social support for preventing sarcopenia in older adults.\n4. The Nutrition and Exercise for Independent Living (NEIL) Trial is evaluating the impact of a nutrition and exercise program on muscle mass, function, and quality of life in older adults.\n5. The Sarcopenia Prevention and Treatment with Metformin (SPTM) Trial is investigating the potential of metformin to prevent or treat sarcopenia.",
    "llama-2-7b-chat-hf_fact": [
      "The Fitness and Nutrition for Independent Living (FINI) Trial is investigating the effectiveness of exercise and nutrition programs in preventing sarcopenia in older adults.",
      "The Resistance Training and Nutrition Intervention to Prevent Sarcopenia (REPS) Trial is evaluating the impact of resistance training and nutritional interventions on muscle mass and function in older adults.",
      "The Sarcopenia Prevention and Management (SPAMS) Trial is investigating a multicomponent intervention including exercise, nutrition, and social support for preventing sarcopenia in older adults.",
      "The Nutrition and Exercise for Independent Living (NEIL) Trial is evaluating the impact of a nutrition and exercise program on muscle mass, function, and quality of life in older adults.",
      "The Sarcopenia Prevention and Treatment with Metformin (SPTM) Trial is investigating the potential of metformin to prevent or treat sarcopenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about these trials, it is not possible to determine the accuracy of the statements provided. The names of the trials sound plausible, but without access to the actual research or announcements related to these trials, I cannot confirm or deny the statements' validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, including:\n1. The Membrane Protein Database (MPD): This database contains information on the structure, function, and evolution of membrane proteins, including their molecular recognition features.\n2. The Protein Data Bank (PDB): This database contains the 3D structures of proteins, including membrane proteins, and their molecular recognition features.\n3. The Membrane Protein Structural Database (MPSD): This database contains the 3D structures of membrane proteins, along with information on their molecular recognition features.\n4. The Membrane Protein Interaction Database (MPI): This database contains information on the interactions between membrane proteins and other molecules, including ligands, substrates, and other proteins.\n5. The Membrane Protein Functional Site Database (MPFS): This database contains information on the functional sites of membrane proteins, including their binding sites, active sites, and other functional regions.\n6. The Membrane Protein-Ligand Interaction Database (MP-LIB): This database contains information on the interactions between membrane proteins and their ligands, including the binding affinity and specificity of these interactions.\n7. The Membrane Protein-Protein Interaction Database (MP-PIB): This database contains information on the interactions between membrane proteins and other proteins, including the binding affinity and specificity of these interactions.\n8. The Membrane Protein-Nucleic Acid Interaction Database (MP-NAI): This database contains information on the interactions between membrane proteins and nucleic acids, including the binding affinity and specificity of these interactions.\n9. The Membrane Protein-Small Molecule Interaction Database (MP-SMI): This database contains information on the interactions between membrane proteins and small molecules, including the binding affinity and specificity of these interactions.\n10. The Membrane Protein-Drug Interaction Database (MP-DIB): This database contains information on the interactions between membrane proteins and drugs, including the binding affinity and specificity of these interactions.\nThese databases provide valuable information on the molecular recognition features of membrane proteins, which can be used to understand their function and develop",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Database (MPD) contains information on the structure, function, and evolution of membrane proteins.\n2. The Protein Data Bank (PDB) contains the 3D structures of proteins, including membrane proteins.\n3. The Membrane Protein Structural Database (MPSD) contains the 3D structures of membrane proteins.\n4. The Membrane Protein Interaction Database (MPI) contains information on the interactions between membrane proteins and other molecules.\n5. The Membrane Protein Functional Site Database (MPFS) contains information on the functional sites of membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Database (MPD) contains information on the structure, function, and evolution of membrane proteins.",
      "The Protein Data Bank (PDB) contains the 3D structures of proteins, including membrane proteins.",
      "The Membrane Protein Structural Database (MPSD) contains the 3D structures of membrane proteins.",
      "The Membrane Protein Interaction Database (MPI) contains information on the interactions between membrane proteins and other molecules.",
      "The Membrane Protein Functional Site Database (MPFS) contains information on the functional sites of membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The correct name is the Membrane Proteins of Known 3D Structure Database (MPSTRUC), which contains the 3D structures of membrane proteins.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The existence and content of databases like the Membrane Protein Interaction Database (MPI) and the Membrane Protein Functional Site Database (MPFS) cannot be confirmed without specific knowledge or a current database reference. These databases may exist under different names or may not be as widely recognized as the MPD and PDB.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. The main metabolic pathway of rivaroxaban involves the enzyme CYP2C9, which is primarily found in the liver and kidneys. The kidneys are responsible for metabolizing about 70% of the drug, while the liver metabolizes the remaining 30%.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys.\n2. The enzyme CYP2C9 is involved in the main metabolic pathway of rivaroxaban.\n3. The enzyme CYP2C9 is found in the liver and kidneys.\n4. The kidneys are responsible for metabolizing about 70% of rivaroxaban.\n5. The liver metabolizes the remaining 30% of rivaroxaban.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys.",
      "The enzyme CYP2C9 is involved in the main metabolic pathway of rivaroxaban.",
      "The enzyme CYP2C9 is found in the liver and kidneys.",
      "The kidneys are responsible for metabolizing about 70% of rivaroxaban.",
      "The liver metabolizes the remaining 30% of rivaroxaban."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized in the liver, not the kidneys.\n2. FALSE [correction]: The main enzyme involved in the metabolism of rivaroxaban is CYP3A4/5, not CYP2C9.\n3. TRUE\n4. FALSE [correction]: The kidneys are responsible for excreting about 66% of a rivaroxaban dose, but this does not equate to metabolism. Only a small portion is metabolized before excretion.\n5. FALSE [correction]: While the liver is involved in the metabolism of rivaroxaban, the specific percentage of metabolism by the liver is not well-defined as 30%. The liver does play a significant role in the metabolism of the drug, but the exact percentage can vary.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 regulates genes involved in cardiac contractility, ion channels, and hypertrophy in the heart. Some examples of genes regulated by TRalpha2 in the heart include:\n1. MYH7: Encodes the myosin heavy chain protein, which is essential for cardiac muscle contraction.\n2. TNNI3: Encodes the troponin I protein, which regulates the interaction between actin and myosin filaments in cardiac muscle.\n3. TNNT2: Encodes the troponin T protein, which also regulates the interaction between actin and myosin filaments in cardiac muscle.\n4. KCNJ8: Encodes the potassium channel protein, which is involved in the regulation of the cardiac action potential duration and refractoriness.\n5. CAV1: Encodes the caveolin protein, which is involved in the regulation of ion channels and signaling pathways in cardiac cells.\n6. ACTC1: Encodes the actin-cytoskeleton protein, which is involved in the regulation of cardiac contractility and cell shape.\n7. TPM1: Encodes the titin protein, which is the largest protein in the heart and plays a crucial role in the regulation of cardiac contractility and mechanics.\n8. GJA1: Encodes the gap junction protein, which is involved in the regulation of electrical and metabolic coupling between cardiac cells.\n9. ATP1A1: Encodes the ATPase protein, which is involved in the regulation of ion transport and signaling pathways in cardiac cells.\n10. KCNE3: Encodes the potassium channel protein, which is involved in the regulation of the cardiac action potential duration and refractoriness.\nThese genes are just a few examples of the many genes that are regulated by TRalpha2 in the heart. The specific genes regulated by TRalpha2 can vary depending on the cell type and the specific physiological context.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 regulates the gene MYH7, which encodes the myosin heavy chain protein essential for cardiac muscle contraction.\n2. TRalpha2 regulates the gene TNNI3, which encodes the troponin I protein that regulates the interaction between actin and myosin filaments in cardiac muscle.\n3. TRalpha2 regulates the gene TNNT2, which encodes the troponin T protein that also regulates the interaction between actin and myosin filaments in cardiac muscle.\n4. TRalpha2 regulates the gene KCNJ8, which encodes the potassium channel protein involved in the regulation of cardiac action potential duration and refractoriness.\n5. TRalpha2 regulates the gene CAV1, which encodes the caveolin protein involved in the regulation of ion channels and signaling pathways in cardiac cells.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 regulates the gene MYH7, which encodes the myosin heavy chain protein essential for cardiac muscle contraction.",
      "TRalpha2 regulates the gene TNNI3, which encodes the troponin I protein that regulates the interaction between actin and myosin filaments in cardiac muscle.",
      "TRalpha2 regulates the gene TNNT2, which encodes the troponin T protein that also regulates the interaction between actin and myosin filaments in cardiac muscle.",
      "TRalpha2 regulates the gene KCNJ8, which encodes the potassium channel protein involved in the regulation of cardiac action potential duration and refractoriness.",
      "TRalpha2 regulates the gene CAV1, which encodes the caveolin protein involved in the regulation of ion channels and signaling pathways in cardiac cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific claims about the regulatory functions of TRalpha2, a variant of the thyroid hormone receptor, on various genes that encode proteins involved in cardiac muscle function. Without specific scientific literature or data to confirm or refute these claims, it is not possible to accurately determine the truthfulness of these statements. They require specialized knowledge in molecular biology and an understanding of the current research on TRalpha2 and its role in gene regulation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Here are some examples of biomedical question answering systems:\n1. PubMed Central (PMC): A free full-text database of biomedical literature maintained by the National Library of Medicine.\n2. Google Scholar (GS): A search engine for scholarly literature across many disciplines and sources, including biomedicine.\n3. PubMed: A free database of biomedical literature maintained by the National Library of Medicine, with a focus on citations and abstracts.\n4. BioMed Central (BMC): A publisher of open-access biomedical journals and a database of peer-reviewed articles.\n5. Semantic Scholar: A free academic search engine that uses natural language processing and machine learning to extract information from biomedical literature.\n6. Microsoft Academic: A search engine for academic publications, including biomedicine, with features such as citation analysis and collaboration tracking.\n7. ScienceDirect: A database of scientific and technical journals and books published by Elsevier, including many in the field of biomedicine.\n8. JSTOR: A digital library of academic journals, books, and primary sources, including many in the field of biomedicine.\n9. NCBI Bookshelf: A collection of book-length publications from the National Center for Biotechnology Information, including the Gene Ontology and the Online Mendelian Inheritance in Man (OMIM) database.\n10. DrugBank: A comprehensive public database of drugs, including information on their mechanisms of action, pharmacology, and drug interactions.\n11. UniProt: A comprehensive protein resource that provides access to protein sequences, structures, and functional information.\n12. Protein Data Bank (PDB): A database of 3D structures of proteins, nucleic acids, and other biological molecules, with information on their structures, functions, and interactions.\n13. Gene Ontology (GO): A standardized vocabulary for describing the functions of genes and the biological processes they are involved in.\n14. Online Mendelian Inheritance in Man (OMIM): A comprehensive database of genetic disorders and their associated genes, with information on their causes, symptoms, and genetic testing.\n15. HGNC: The Human Genome Variation",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central (PMC) is a free full-text database of biomedical literature maintained by the National Library of Medicine.\n2. Google Scholar is a search engine for scholarly literature across many disciplines, including biomedicine.\n3. PubMed is a free database of biomedical literature, focusing on citations and abstracts, and is maintained by the National Library of Medicine.\n4. BioMed Central (BMC) is a publisher of open-access biomedical journals and a database of peer-reviewed articles.\n5. Semantic Scholar is a free academic search engine that uses natural language processing and machine learning to extract information from biomedical literature.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central (PMC) is a free full-text database of biomedical literature maintained by the National Library of Medicine.",
      "Google Scholar is a search engine for scholarly literature across many disciplines, including biomedicine.",
      "PubMed is a free database of biomedical literature, focusing on citations and abstracts, and is maintained by the National Library of Medicine.",
      "BioMed Central (BMC) is a publisher of open-access biomedical journals and a database of peer-reviewed articles.",
      "Semantic Scholar is a free academic search engine that uses natural language processing and machine learning to extract information from biomedical literature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Semantic Scholar is a free academic search engine that uses natural language processing and machine learning to extract information from scholarly literature across many disciplines, not just biomedical literature.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the betalain pathway is called MYB11. This transcription factor belongs to the R2R3-MYB family of transcription factors and is specifically involved in the regulation of the biosynthesis of betalains in plants. MYB11 is known to bind to the promoter regions of genes involved in the betalain pathway and activate their transcription, leading to an increase in betalain production.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transcription factor MYB11 activates the betalain pathway.\n2. MYB11 belongs to the R2R3-MYB family of transcription factors.\n3. MYB11 is involved in the regulation of the biosynthesis of betalains in plants.\n4. MYB11 binds to the promoter regions of genes involved in the betalain pathway.\n5. Activation of genes by MYB11 leads to an increase in betalain production.",
    "llama-2-7b-chat-hf_fact": [
      "The transcription factor MYB11 activates the betalain pathway.",
      "MYB11 belongs to the R2R3-MYB family of transcription factors.",
      "MYB11 is involved in the regulation of the biosynthesis of betalains in plants.",
      "MYB11 binds to the promoter regions of genes involved in the betalain pathway.",
      "Activation of genes by MYB11 leads to an increase in betalain production."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe statements about MYB11 are specific to plant molecular biology, and without the specific context or research findings, it's difficult to confirm the exact role of MYB11 in the betalain pathway (statement 1) or its binding to promoter regions of genes (statement 4). However, it is known that the R2R3-MYB family of transcription factors (statement 2) is involved in the regulation of various plant biosynthetic pathways, including pigmentation pathways such as the betalain pathway (statement 3). If MYB11 is indeed a transcription factor that activates the betalain pathway, then it would lead to an increase in betalain production (statement 5), as that is the general role of transcription factors in gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "The preferred technologies for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses include:\n1. Immunoaffinity enrichment: This method uses antibodies specific to phosphorylated peptides or protein domains to capture and enrich phosphorylated peptides from complex protein mixtures.\n2. IMAC (Immobilized Metal Affinity Chromatography): This method uses metal ions (e.g. Ni2+ or Cu2+) immobilized on a resin to capture phosphorylated peptides based on their high affinity for the metal ions.\n3. TiO2-based enrichment: This method uses titanium dioxide (TiO2) beads to capture phosphorylated peptides based on their high affinity for the negatively charged phosphate groups.\n4. Hydrophilic interaction liquid chromatography (HILIC): This method separates phosphorylated peptides based on their hydrophilic properties, allowing for their enrichment and isolation.\n5. Reversed-phase HPLC: This method separates phosphorylated peptides based on their hydrophobic properties, allowing for their enrichment and isolation.\n6. Microfluidic-based enrichment: This method uses microfluidic devices to capture and enrich phosphorylated peptides based on their size and charge.\n7. Nanoscale enrichment: This method uses nanoparticles or nanostructures to capture and enrich phosphorylated peptides based on their size and charge.\n8. Enzyme-linked immunosorbent assay (ELISA): This method uses enzymes to capture and enrich phosphorylated peptides based on their high affinity for the enzymes.\n9. Protein G beads: This method uses protein G beads to capture and enrich phosphorylated peptides based on their high affinity for the protein G beads.\n10. Magnetic nanoparticle-based enrichment: This method uses magnetic nanoparticles to capture and enrich phosphorylated peptides based on their",
    "llama-2-7b-chat-hf_fact_raw": "1. Immunoaffinity enrichment uses antibodies specific to phosphorylated peptides to enrich them from complex protein mixtures.\n2. IMAC (Immobilized Metal Affinity Chromatography) captures phosphorylated peptides using metal ions immobilized on a resin.\n3. TiO2-based enrichment uses titanium dioxide beads to capture phosphorylated peptides.\n4. Hydrophilic interaction liquid chromatography (HILIC) separates phosphorylated peptides based on their hydrophilic properties.\n5. Reversed-phase HPLC separates phosphorylated peptides based on their hydrophobic properties.",
    "llama-2-7b-chat-hf_fact": [
      "Immunoaffinity enrichment uses antibodies specific to phosphorylated peptides to enrich them from complex protein mixtures.",
      "IMAC (Immobilized Metal Affinity Chromatography) captures phosphorylated peptides using metal ions immobilized on a resin.",
      "TiO2-based enrichment uses titanium dioxide beads to capture phosphorylated peptides.",
      "Hydrophilic interaction liquid chromatography (HILIC) separates phosphorylated peptides based on their hydrophilic properties.",
      "Reversed-phase HPLC separates phosphorylated peptides based on their hydrophobic properties."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is used to rate the severity of obesity in adults. It categorizes obesity based on body mass index (BMI) and other factors, such as waist circumference and body fat distribution. The Palmini classification system includes the following categories:\n* Class I: BMI 30-34.9\n* Class II: BMI 35-39.9\n* Class III: BMI 40-44.9\n* Class IV: BMI 45-49.9\n* Class V: BMI 50 or higher\nEach class is further divided into subcategories based on additional factors such as waist circumference and body fat distribution. The Palmini classification system is used to help healthcare providers assess and manage obesity, and to determine the appropriate treatment and lifestyle changes for individuals with obesity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate the severity of obesity in adults.\n2. The Palmini classification categorizes obesity based on body mass index (BMI) and other factors like waist circumference and body fat distribution.\n3. Class I in the Palmini classification is defined as a BMI of 30-34.9.\n4. Class II in the Palmini classification is defined as a BMI of 35-39.9.\n5. Class V in the Palmini classification is defined as a BMI of 50 or higher.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate the severity of obesity in adults.",
      "The Palmini classification categorizes obesity based on body mass index (BMI) and other factors like waist circumference and body fat distribution.",
      "Class I in the Palmini classification is defined as a BMI of 30-34.9.",
      "Class II in the Palmini classification is defined as a BMI of 35-39.9.",
      "Class V in the Palmini classification is defined as a BMI of 50 or higher."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to rate the severity of obesity in adults; it is used for classifying the outcomes of epilepsy surgery.\n2. FALSE [correction]: Since the Palmini classification is not for obesity, it does not categorize obesity based on BMI, waist circumference, or body fat distribution.\n3. FALSE [correction]: Class I in the Palmini classification does not refer to a BMI range as it is not related to obesity.\n4. FALSE [correction]: Class II in the Palmini classification does not refer to a BMI range as it is not related to obesity.\n5. FALSE [correction]: Class V in the Palmini classification does not refer to a BMI range as it is not related to obesity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, viruses are involved in the etiology of human subacute thyroiditis. The most common viral causes of subacute thyroiditis are:\n1. Influenza virus\n2. Adenovirus\n3. Herpesvirus\n4. Enterovirus\n5. Parvovirus B19\nThese viruses can cause inflammation and damage to the thyroid gland, leading to the symptoms of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses are involved in the etiology of human subacute thyroiditis.\n2. Influenza virus is a common viral cause of subacute thyroiditis.\n3. Adenovirus is a common viral cause of subacute thyroiditis.\n4. Herpesvirus is a common viral cause of subacute thyroiditis.\n5. Enterovirus and Parvovirus B19 are common viral causes of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses are involved in the etiology of human subacute thyroiditis.",
      "Influenza virus is a common viral cause of subacute thyroiditis.",
      "Adenovirus is a common viral cause of subacute thyroiditis.",
      "Herpesvirus is a common viral cause of subacute thyroiditis.",
      "Enterovirus and Parvovirus B19 are common viral causes of subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Viruses are suspected to be involved in the etiology of subacute thyroiditis, also known as de Quervain's thyroiditis.\n2. FALSE [correction]: Influenza virus is not typically listed among the common viral causes of subacute thyroiditis.\n3. UNKNOWN: While adenovirus can cause a variety of infections, its role as a common cause of subacute thyroiditis is not well established and may vary depending on the source.\n4. FALSE [correction]: Herpesvirus is not typically listed among the common viral causes of subacute thyroiditis.\n5. TRUE: Enterovirus and Parvovirus B19 have been associated with subacute thyroiditis, although their role is not fully understood and may not be considered \"common\" causes depending on the source.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 can interact with and regulate EIF2AK2-dependent suppression of autophagy.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 can interact with EIF2AK2.\n2. STAT3 is involved in the suppression of autophagy that is dependent on EIF2AK2.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 can interact with EIF2AK2.",
      "STAT3 is involved in the suppression of autophagy that is dependent on EIF2AK2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Signal Transducer and Activator of Transcription 3 (STAT3) can interact with Eukaryotic Translation Initiation Factor 2-Alpha Kinase 2 (EIF2AK2), also known as PKR. This interaction has been studied in the context of various cellular processes and signaling pathways.\n\n2. UNKNOWN: The involvement of STAT3 in the suppression of autophagy that is dependent on EIF2AK2 is a specific statement that requires detailed knowledge of the molecular interactions and pathways involved. Without specific information or a reference to a scientific study that confirms this interaction and its effect on autophagy, it is not possible to determine the truthfulness of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool used for genomic analysis, particularly for the analysis of next-generation sequencing (NGS) data. It is designed to facilitate the analysis of large-scale genomic data sets and to provide a comprehensive view of the genomic landscape. Here are some of the key uses of Theatre:\n1. Genome assembly: Theatre can be used to assemble genomes from NGS data, including both DNA and RNA sequencing data. It can handle a wide range of input data types, including reads from different sequencing technologies.\n2. Variant calling: Theatre can be used to identify genetic variants, including single nucleotide polymorphisms (SNPs), insertions, deletions, and structural variants, from NGS data. It can also be used to prioritize variants based on their potential impact on gene function.\n3. Gene expression analysis: Theatre can be used to analyze gene expression data, including RNA-seq data, to identify differentially expressed genes and to understand the regulatory mechanisms underlying gene expression.\n4. Epigenomics analysis: Theatre can be used to analyze epigenetic marks, such as DNA methylation and histone modifications, from NGS data. It can help identify patterns of epigenetic marks and understand their functional implications.\n5. Genome-wide association studies (GWAS): Theatre can be used to identify genetic variants associated with complex diseases and traits by analyzing genome-wide data.\n6. Transcriptome analysis: Theatre can be used to analyze RNA-seq data to identify differentially expressed genes, alternative splicing events, and novel transcripts.\n7. Genome annotation: Theatre can be used to annotate genomes by identifying functional elements such as genes, promoters, and regulatory elements.\n8. Comparative genomics: Theatre can be used to compare genomes across different species or strains to identify evolutionary changes, gene content, and regulatory elements.\n9. Genome engineering: Theatre can be used to design and engineer genomes for various applications, including gene therapy and synthetic biology.\n10. Data visualization: Theatre provides a range of visualization tools to visualize and explore genomic data, including 3D visualization, genomic tracks, and network analysis.\nOverall, Theatre is a powerful tool for genom",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for genomic analysis, particularly for the analysis of next-generation sequencing (NGS) data.\n2. Theatre can be used to assemble genomes from NGS data, including both DNA and RNA sequencing data.\n3. Theatre can be used to identify genetic variants, such as single nucleotide polymorphisms (SNPs), insertions, deletions, and structural variants, from NGS data.\n4. Theatre can be used to analyze gene expression data, including RNA-seq data, to identify differentially expressed genes.\n5. Theatre can be used for genome-wide association studies (GWAS) to identify genetic variants associated with complex diseases and traits.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for genomic analysis, particularly for the analysis of next-generation sequencing (NGS) data.",
      "Theatre can be used to assemble genomes from NGS data, including both DNA and RNA sequencing data.",
      "Theatre can be used to identify genetic variants, such as single nucleotide polymorphisms (SNPs), insertions, deletions, and structural variants, from NGS data.",
      "Theatre can be used to analyze gene expression data, including RNA-seq data, to identify differentially expressed genes.",
      "Theatre can be used for genome-wide association studies (GWAS) to identify genetic variants associated with complex diseases and traits."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are about a software tool named \"Theatre\" used for genomic analysis. However, without specific information about a software tool with that name, it is not possible to verify the accuracy of these statements. The capabilities described are typical of genomic analysis software, but without confirmation that \"Theatre\" is a real and recognized tool with these capabilities, the truthfulness of the statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The time complexity of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2), where n is the length of the sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm is used for the alignment of two sequences.\n2. The time complexity of the Smith-Waterman algorithm is O(n^2).\n3. The variable 'n' in the time complexity O(n^2) represents the length of the sequences being aligned.",
    "llama-2-7b-chat-hf_fact": [
      "The Smith-Waterman algorithm is used for the alignment of two sequences.",
      "The time complexity of the Smith-Waterman algorithm is O(n^2).",
      "The variable 'n' in the time complexity O(n^2) represents the length of the sequences being aligned."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The variable 'n' in the time complexity O(n^2) represents the lengths of the two sequences being aligned, where 'n' is the product of the lengths of the two sequences if they are of different lengths. If the sequences are of the same length, then 'n' can represent the length of one sequence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the SLC24 family of solute carrier proteins. Specifically, it is a member of the SLC24A1 subfamily, which is also known as the VRAC (Vacuolar ATPase-interacting cation channel) family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC24 family of solute carrier proteins.\n2. FLVCR1 belongs to the SLC24A1 subfamily.\n3. The SLC24A1 subfamily is also known as the VRAC (Vacuolar ATPase-interacting cation channel) family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC24 family of solute carrier proteins.",
      "FLVCR1 belongs to the SLC24A1 subfamily.",
      "The SLC24A1 subfamily is also known as the VRAC (Vacuolar ATPase-interacting cation channel) family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is a member of the SLC49 family of solute carrier proteins, not the SLC24 family.\n2. FALSE [correction]: FLVCR1 does not belong to the SLC24A1 subfamily; it is part of the SLC49 family.\n3. FALSE [correction]: The SLC24A1 subfamily is not known as the VRAC family. The SLC24 family includes sodium/potassium/calcium exchanger proteins, while VRAC refers to the Volume-Regulated Anion Channel, which is not directly related to the SLC24A1 subfamily.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 interacting partners discovered using the biotinylation tagging approach include:\n1. NCOR1 (nuclear receptor corepressor 1)\n2. HDAC1 (histone deacetylase 1)\n3. HDAC2 (histone deacetylase 2)\n4. HDAC3 (histone deacetylase 3)\n5. RBAP28 (RNA-binding protein 28)\n6. RBFOX1 (RNA-binding protein with multiple splicing sites 1)\n7. TAF15 (TATA box binding protein 15)\n8. TFIIS (transcription factor IIS)\n9. TFIIA (transcription factor IIA)\n10. TFIIB (transcription factor IIB)\nThese interactions were identified by using a biotinylation tagging approach, where GATA-1 was tagged with a biotinylation tag and co-expressed with these proteins. The interacting proteins were then isolated using biotin affinity chromatography and identified through mass spectrometry.",
    "llama-2-7b-chat-hf_fact_raw": "1. NCOR1 (nuclear receptor corepressor 1) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.\n2. HDAC1 (histone deacetylase 1) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.\n3. HDAC2 (histone deacetylase 2) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.\n4. HDAC3 (histone deacetylase 3) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.\n5. RBAP28 (RNA-binding protein 28) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_fact": [
      "NCOR1 (nuclear receptor corepressor 1) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.",
      "HDAC1 (histone deacetylase 1) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.",
      "HDAC2 (histone deacetylase 2) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.",
      "HDAC3 (histone deacetylase 3) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.",
      "RBAP28 (RNA-binding protein 28) is an interacting partner of GATA-1 discovered using the biotinylation tagging approach."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and pertain to scientific findings that would require access to specific research or scientific literature to verify. Without the context of the specific study or data, it is not possible to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 interacting with GATA1 can lead to the recruitment of RNA polymerase II to the promoter region of GATA1-regulated genes, which are involved in erythroid cell development and differentiation. This interaction is important for the proper regulation of red blood cell production.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interaction with GATA1 can lead to the recruitment of RNA polymerase II.\n2. The recruitment of RNA polymerase II occurs at the promoter region of GATA1-regulated genes.\n3. GATA1-regulated genes are involved in erythroid cell development and differentiation.\n4. The interaction between TAF10 and GATA1 is important for the regulation of red blood cell production.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interaction with GATA1 can lead to the recruitment of RNA polymerase II.",
      "The recruitment of RNA polymerase II occurs at the promoter region of GATA1-regulated genes.",
      "GATA1-regulated genes are involved in erythroid cell development and differentiation.",
      "The interaction between TAF10 and GATA1 is important for the regulation of red blood cell production."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems for chronic pain management. These systems provide healthcare professionals and patients with evidence-based information and tools to help manage chronic pain. Some examples of decision support systems for chronic pain management include:\n1. PainCare: This system provides healthcare professionals with a comprehensive database of pain management information, including clinical guidelines, treatment options, and patient education materials.\n2. Chronic Pain Management System (CPMS): This system offers a range of tools and resources for healthcare professionals to manage chronic pain, including a pain assessment tool, treatment planning software, and a patient education module.\n3. Pain Management Collaborative (PMC): This system is designed to help healthcare professionals work together to improve pain management outcomes for patients. It includes a range of tools and resources, including a pain assessment tool, treatment planning software, and a communication platform for healthcare professionals.\n4. PainPathways: This system provides healthcare professionals with a comprehensive database of pain management information, including clinical guidelines, treatment options, and patient education materials. It also includes a range of tools and resources for managing chronic pain, including a pain assessment tool, treatment planning software, and a patient education module.\n5. e-Pain: This system is an online platform that provides healthcare professionals with a range of tools and resources for managing chronic pain, including a pain assessment tool, treatment planning software, and a patient education module.\n6. Pain-Q: This system is a decision support tool that helps healthcare professionals assess and manage chronic pain in patients. It includes a range of tools and resources, including a pain assessment tool, treatment planning software, and a patient education module.\n7. Pain-Care: This system is a decision support tool that helps healthcare professionals assess and manage chronic pain in patients. It includes a range of tools and resources, including a pain assessment tool, treatment planning software, and a patient education module.\n8. Chronic Pain Management System (CPMS): This system offers a range of tools and resources for healthcare professionals to manage chronic pain, including a pain assessment tool, treatment planning software, and a patient education module.\n9. Pain Management Collaborative (PMC): This system is designed to help health",
    "llama-2-7b-chat-hf_fact_raw": "1. PainCare is a decision support system that provides healthcare professionals with a database of pain management information, including clinical guidelines and treatment options.\n2. The Chronic Pain Management System (CPMS) offers tools and resources for healthcare professionals, such as a pain assessment tool and treatment planning software.\n3. The Pain Management Collaborative (PMC) is a system that includes tools and a communication platform for healthcare professionals to improve pain management outcomes.\n4. PainPathways provides a comprehensive database of pain management information and includes tools like a pain assessment tool and treatment planning software.\n5. e-Pain is an online platform offering tools and resources for managing chronic pain, including a pain assessment tool and treatment planning software.",
    "llama-2-7b-chat-hf_fact": [
      "PainCare is a decision support system that provides healthcare professionals with a database of pain management information, including clinical guidelines and treatment options.",
      "The Chronic Pain Management System (CPMS) offers tools and resources for healthcare professionals, such as a pain assessment tool and treatment planning software.",
      "The Pain Management Collaborative (PMC) is a system that includes tools and a communication platform for healthcare professionals to improve pain management outcomes.",
      "PainPathways provides a comprehensive database of pain management information and includes tools like a pain assessment tool and treatment planning software.",
      "e-Pain is an online platform offering tools and resources for managing chronic pain, including a pain assessment tool and treatment planning software."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information about these specific systems, it is not possible to verify the accuracy of the statements provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that is primarily localized to the endoplasmic reticulum (ER) and the Golgi apparatus in the cell.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein.\n2. Angiogenin is primarily localized to the endoplasmic reticulum (ER) in the cell.\n3. Angiogenin is also localized to the Golgi apparatus in the cell.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein.",
      "Angiogenin is primarily localized to the endoplasmic reticulum (ER) in the cell.",
      "Angiogenin is also localized to the Golgi apparatus in the cell."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Angiogenin is not primarily localized to the endoplasmic reticulum (ER); it is typically found in the cytoplasm and secreted outside of cells where it can assist in angiogenesis.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a drug that selectively activates the cardiac ion channel Kv1.5, leading to a decrease in the influx of sodium ions into cardiac cells. This results in a decrease in the activation of protein kinase C (PKC) and other signaling pathways that are activated by the influx of sodium ions. As a result, ranolazine can reduce the heart's response to stress and improve cardiac function in conditions such as angina and heart failure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine selectively activates the cardiac ion channel Kv1.5.\n2. Activation of Kv1.5 by ranolazine leads to a decrease in the influx of sodium ions into cardiac cells.\n3. The decrease in sodium ion influx results in reduced activation of protein kinase C (PKC).\n4. Ranolazine can reduce the heart's response to stress.\n5. Ranolazine is used to improve cardiac function in conditions such as angina and heart failure.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine selectively activates the cardiac ion channel Kv1.5.",
      "Activation of Kv1.5 by ranolazine leads to a decrease in the influx of sodium ions into cardiac cells.",
      "The decrease in sodium ion influx results in reduced activation of protein kinase C (PKC).",
      "Ranolazine can reduce the heart's response to stress.",
      "Ranolazine is used to improve cardiac function in conditions such as angina and heart failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine selectively inhibits the late phase of the inward sodium channel (I_Na) in cardiac cells, not the Kv1.5 channel.\n2. FALSE [correction]: Ranolazine inhibits the late sodium current, which leads to a decrease in the influx of sodium ions into cardiac cells, but this is not through activation of Kv1.5.\n3. UNKNOWN: The specific molecular mechanisms by which ranolazine affects protein kinase C (PKC) activity are not clearly stated, and the relationship between sodium ion influx and PKC activation can be complex.\n4. TRUE: Ranolazine can reduce the heart's response to stress by decreasing myocardial oxygen demand, which is beneficial in conditions like angina.\n5. TRUE: Ranolazine is used to treat chronic angina and can improve cardiac function in conditions where the heart's oxygen demand is not met, such as angina. However, its use in heart failure is not well established and is not a primary indication.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not independent of the growth phase of bacteria. Vsr endonuclease is a restriction endonuclease that is involved in the degradation of DNA in response to stress, and its activity is regulated by a variety of factors, including the growth phase of the bacteria.\nDuring the logarithmic growth phase of bacteria, Vsr endonuclease is actively induced and its activity is highest. This is thought to be due to the high levels of DNA damage that occur during this phase of growth, as the bacterial cell is rapidly dividing and repairing its DNA.\nIn contrast, during the stationary phase of bacterial growth, Vsr endonuclease activity is significantly reduced. This is thought to be due to the fact that the bacterial cell is no longer actively dividing and repairing its DNA, and instead is focused on surviving and persisting in the environment.\nOverall, the regulation of Vsr endonuclease is complex and involves a variety of factors, including the growth phase of the bacteria, as well as other environmental and genetic factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.\n2. Vsr endonuclease is involved in the degradation of DNA in response to stress.\n3. Vsr endonuclease activity is highest during the logarithmic growth phase of bacteria.\n4. The activity of Vsr endonuclease is actively induced during the logarithmic growth phase due to high levels of DNA damage.\n5. Vsr endonuclease activity is significantly reduced during the stationary phase of bacterial growth.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.",
      "Vsr endonuclease is involved in the degradation of DNA in response to stress.",
      "Vsr endonuclease activity is highest during the logarithmic growth phase of bacteria.",
      "The activity of Vsr endonuclease is actively induced during the logarithmic growth phase due to high levels of DNA damage.",
      "Vsr endonuclease activity is significantly reduced during the stationary phase of bacterial growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Vsr endonuclease is involved in DNA mismatch repair, not primarily in the degradation of DNA in response to stress.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Some computational tools used for the prediction of beta-barrel transmembrane proteins include:\n1. TMHMM: TMHMM is a widely used tool for predicting the structure and function of transmembrane proteins, including beta-barrel proteins. It uses a combination of sequence analysis and structural modeling to predict the transmembrane helices and the orientation of the protein in the membrane.\n2. PredictProtein: PredictProtein is a web server that uses a combination of sequence analysis and machine learning algorithms to predict the structure and function of transmembrane proteins, including beta-barrel proteins. It can also predict the transmembrane helices and the orientation of the protein in the membrane.\n3. PHD: PHD is a web server that uses a combination of sequence analysis and structural modeling to predict the structure and function of transmembrane proteins, including beta-barrel proteins. It can also predict the transmembrane helices and the orientation of the protein in the membrane.\n4. TOPOGAN: TOPOGAN is a web server that uses a combination of sequence analysis and machine learning algorithms to predict the structure and function of transmembrane proteins, including beta-barrel proteins. It can also predict the transmembrane helices and the orientation of the protein in the membrane.\n5. BARDI: BARDI is a web server that uses a combination of sequence analysis and structural modeling to predict the structure and function of beta-barrel transmembrane proteins. It can also predict the transmembrane helices and the orientation of the protein in the membrane.\n6. Transmembrane Predictor: Transmembrane Predictor is a web server that uses a combination of sequence analysis and machine learning algorithms to predict the structure and function of transmembrane proteins, including beta-barrel proteins. It can also predict the transmembrane helices and the orientation of the protein in the membrane.\n7. PredictBTD: PredictBTD is a web server that uses a combination of sequence analysis and structural modeling to predict the structure and function of transmembrane proteins, including beta-barrel proteins. It can also predict the transmembrane helices and the orientation of the protein in the membrane.\n8. TM-",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is a tool used for predicting the structure and function of transmembrane proteins, including beta-barrel proteins.\n2. PredictProtein is a web server that predicts the structure and function of transmembrane proteins using sequence analysis and machine learning algorithms.\n3. PHD is a web server that predicts the structure and function of transmembrane proteins, including beta-barrel proteins, through sequence analysis and structural modeling.\n4. TOPOGAN is a web server that predicts the structure and function of transmembrane proteins, including beta-barrel proteins, using sequence analysis and machine learning algorithms.\n5. BARDI is a web server that predicts the structure and function of beta-barrel transmembrane proteins using sequence analysis and structural modeling.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is a tool used for predicting the structure and function of transmembrane proteins, including beta-barrel proteins.",
      "PredictProtein is a web server that predicts the structure and function of transmembrane proteins using sequence analysis and machine learning algorithms.",
      "PHD is a web server that predicts the structure and function of transmembrane proteins, including beta-barrel proteins, through sequence analysis and structural modeling.",
      "TOPOGAN is a web server that predicts the structure and function of transmembrane proteins, including beta-barrel proteins, using sequence analysis and machine learning algorithms.",
      "BARDI is a web server that predicts the structure and function of beta-barrel transmembrane proteins using sequence analysis and structural modeling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TMHMM is a tool used for predicting transmembrane helices in proteins, not specifically beta-barrel proteins.\n2. TRUE\n3. FALSE [correction]: PHD is a suite of tools for predicting secondary structure, solvent accessibility, and transmembrane helices, but it is not specifically described as a web server for predicting the structure and function of beta-barrel proteins.\n4. UNKNOWN: TOPOGAN is not a widely recognized tool or web server in bioinformatics for predicting transmembrane proteins, and without additional context, it is not possible to verify the accuracy of this statement.\n5. UNKNOWN: BARDI is not a widely recognized tool or web server in bioinformatics for predicting beta-barrel transmembrane proteins, and without additional context, it is not possible to verify the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "The Galassi classification is used for classifying the severity of obstructive sleep apnea (OSA).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Oculomotor Dysfunction, is a rare genetic disorder that affects the brain and nervous system. The common features of Shapiro syndrome include:\n1. Oculomotor dysfunction: The most common symptom of Shapiro syndrome is difficulty with eye movements, including double vision, strabismus (crossed eyes), and nystagmus (involuntary eye movements).\n2. Intellectual disability: Individuals with Shapiro syndrome often have mild to moderate intellectual disability, which can range from mild to moderate.\n3. Speech and language difficulties: Shapiro syndrome can cause difficulties with speech and language, including articulation problems, stuttering, and difficulty with word retrieval.\n4. Autism-like features: Some individuals with Shapiro syndrome may exhibit autism-like features, such as social and communication difficulties, and repetitive behaviors.\n5. Seizures: Shapiro syndrome can cause seizures, which can range from mild to severe.\n6. Sleep disturbances: Individuals with Shapiro syndrome may experience sleep disturbances, including insomnia and sleep apnea.\n7. Vision problems: Shapiro syndrome can cause a range of vision problems, including blurred vision, cataracts, and glaucoma.\n8. Hearing loss: Some individuals with Shapiro syndrome may experience hearing loss or impairment.\n9. Skeletal abnormalities: Shapiro syndrome can cause skeletal abnormalities, including scoliosis, kyphosis, and other bone deformities.\n10. Other features: Other features of Shapiro syndrome can include delayed development, delayed speech and language skills, and a distinctive facial appearance with a long, narrow face and a prominent forehead.\nIt's important to note that not all individuals with Shapiro syndrome will exhibit all of these features, and the severity of the condition can vary widely between individuals. A diagnosis of Shapiro syndrome is typically made through a combination of clinical evaluation, genetic testing, and imaging studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is a rare genetic disorder that affects the brain and nervous system.\n2. Common symptoms of Shapiro syndrome include oculomotor dysfunction, such as double vision, strabismus, and nystagmus.\n3. Individuals with Shapiro syndrome often have mild to moderate intellectual disability.\n4. Shapiro syndrome can cause seizures in affected individuals.\n5. A diagnosis of Shapiro syndrome is typically made through clinical evaluation, genetic testing, and imaging studies.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is a rare genetic disorder that affects the brain and nervous system.",
      "Common symptoms of Shapiro syndrome include oculomotor dysfunction, such as double vision, strabismus, and nystagmus.",
      "Individuals with Shapiro syndrome often have mild to moderate intellectual disability.",
      "Shapiro syndrome can cause seizures in affected individuals.",
      "A diagnosis of Shapiro syndrome is typically made through clinical evaluation, genetic testing, and imaging studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is not primarily a genetic disorder; it is a rare neurologic condition characterized by recurrent episodes of hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. UNKNOWN: While oculomotor dysfunction can occur in various neurological conditions, it is not specifically listed as a common symptom of Shapiro syndrome. Shapiro syndrome is more commonly associated with hypothermia and agenesis of the corpus callosum.\n3. UNKNOWN: Intellectual disability may occur in individuals with various neurological conditions, but there is no specific information stating that it is a common feature of Shapiro syndrome.\n4. UNKNOWN: Seizures can be a symptom of many neurological conditions, but without specific information linking seizures to Shapiro syndrome, the truth of this statement cannot be determined.\n5. TRUE: A diagnosis of Shapiro syndrome is typically made through clinical evaluation, which may include observing the symptoms of hypothermia and sweating, and imaging studies to confirm agenesis of the corpus callosum. Genetic testing is not typically used to diagnose Shapiro syndrome as it is not primarily a genetic disorder.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1-related disorder, also known as BRAG1-related intellectual disability syndrome. This is a rare genetic disorder that is characterized by intellectual disability, developmental delays, and various other physical and behavioral symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAG1-related disorder is linked to mutations within BRAG1.\n2. BRAG1-related disorder is characterized by intellectual disability.\n3. BRAG1-related disorder can cause developmental delays.\n4. BRAG1-related disorder may present with various physical and behavioral symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "BRAG1-related disorder is linked to mutations within BRAG1.",
      "BRAG1-related disorder is characterized by intellectual disability.",
      "BRAG1-related disorder can cause developmental delays.",
      "BRAG1-related disorder may present with various physical and behavioral symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is the protein called protein phosphatase 1 inhibitor (PP1I).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, in Bacillus subtilis is a process by which the bacterium increases its genetic diversity in response to environmental stress, such as nutrient limitation, by inducing mutations in its genome. The mechanisms underlying adaptive mutagenesis in B. subtilis include:\n1. DNA damage: B. subtilis has evolved mechanisms to repair DNA damage, such as DNA double-strand breaks, through the action of DNA repair enzymes. However, these mechanisms can also introduce mutations into the genome, leading to genetic diversity.\n2. MutS and MutL proteins: B. subtilis has two proteins, MutS and MutL, that are involved in DNA mismatch repair. These proteins can also introduce mutations into the genome by misrecognizing incorrect base pairs during DNA replication and repair.\n3. RecA-mediated homologous recombination: B. subtilis has a highly efficient homologous recombination system, which can introduce mutations into the genome by repairing DNA double-strand breaks through homologous recombination.\n4. RecO protein: RecO is a recombinase protein that is involved in the repair of DNA double-strand breaks. It can also introduce mutations into the genome by misrecognizing incorrect base pairs during DNA repair.\n5. DNA damage checkpoint: B. subtilis has a DNA damage checkpoint that is activated in response to DNA damage. This checkpoint can induce mutations in the genome by delaying cell cycle progression and allowing for the accumulation of mutations.\n6. Transposon mutagenesis: B. subtilis has a number of transposable elements, such as the Tn916 transposon, that can introduce mutations into the genome by transposing through the genome and excavating a new insertion site.\n7. Rho-independent transcription terminators: B. subtilis has a number of rho-independent transcription terminators, such as the σ factor σ28, that can introduce mutations into the genome by terminating transcription prematurely.\n8. DNA glycosylases: B. subtilis has a number of",
    "llama-2-7b-chat-hf_fact_raw": "1. Bacillus subtilis increases its genetic diversity in response to environmental stress by inducing mutations in its genome.\n2. DNA repair enzymes in B. subtilis can introduce mutations into the genome while repairing DNA damage such as DNA double-strand breaks.\n3. MutS and MutL proteins in B. subtilis are involved in DNA mismatch repair and can introduce mutations during DNA replication and repair.\n4. B. subtilis uses RecA-mediated homologous recombination to repair DNA double-strand breaks, which can introduce mutations into the genome.\n5. The DNA damage checkpoint in B. subtilis can induce mutations in the genome by delaying cell cycle progression.",
    "llama-2-7b-chat-hf_fact": [
      "Bacillus subtilis increases its genetic diversity in response to environmental stress by inducing mutations in its genome.",
      "DNA repair enzymes in B. subtilis can introduce mutations into the genome while repairing DNA damage such as DNA double-strand breaks.",
      "MutS and MutL proteins in B. subtilis are involved in DNA mismatch repair and can introduce mutations during DNA replication and repair.",
      "B. subtilis uses RecA-mediated homologous recombination to repair DNA double-strand breaks, which can introduce mutations into the genome.",
      "The DNA damage checkpoint in B. subtilis can induce mutations in the genome by delaying cell cycle progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Bacillus subtilis, like many bacteria, can increase its genetic diversity in response to environmental stress, which may include inducing mutations in its genome as a strategy to adapt to changing conditions.\n2. TRUE: DNA repair enzymes in B. subtilis and other organisms can sometimes introduce mutations into the genome while repairing DNA damage, such as DNA double-strand breaks, due to errors that occur during the repair process.\n3. FALSE [correction]: MutS and MutL proteins in B. subtilis are involved in DNA mismatch repair, but their primary function is to correct errors during DNA replication and repair, not to introduce mutations. They work to maintain genetic fidelity, not to increase mutations.\n4. TRUE: B. subtilis uses RecA-mediated homologous recombination to repair DNA double-strand breaks. While the primary goal of this process is to accurately repair the DNA, it can sometimes result in mutations, especially if there are sequence differences between the recombining DNA molecules.\n5. FALSE [correction]: The DNA damage checkpoint in B. subtilis and other organisms primarily functions to maintain genomic integrity by halting cell cycle progression until the damage can be repaired. It does not directly induce mutations in the genome; rather, it allows time for the repair systems to correct the damage. If the damage is not correctly repaired, mutations may result, but this is not the purpose of the checkpoint.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "I believe you meant \"what causes eczema?\"\nEczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by dry, itchy, and scaly patches on the skin. The exact cause of eczema is not fully understood, but it is believed to involve a combination of genetic and environmental factors. Some of the known triggers of eczema include:\n1. Genetics: Eczema can run in families, and people with a family history of eczema are more likely to develop the condition.\n2. Allergies: Allergies to certain substances, such as pollen, dust mites, or pet dander, can trigger eczema symptoms.\n3. Irritants: Exposure to irritants such as soaps, detergents, or fragrances can cause eczema flare-ups.\n4. Environmental factors: Cold, dry air; hot, humid weather; and exposure to pollution can all trigger eczema symptoms.\n5. Skin infections: Bacterial, viral, or fungal infections can cause eczema symptoms to worsen.\n6. Hormonal changes: Hormonal changes during pregnancy, menstruation, or menopause can affect the skin and cause eczema symptoms.\n7. Autoimmune disorders: People with autoimmune disorders such as thyroid disease or lupus may be more prone to developing eczema.\n8. Nutritional deficiencies: Deficiencies in certain nutrients, such as vitamin D or omega-3 fatty acids, may contribute to the development of eczema.\n9. Stress: Stress can exacerbate eczema symptoms, and people with eczema may be more sensitive to stress than others.\n10. Other medical conditions: Certain medical conditions, such as diabetes, thyroid disorders, or gastrointestinal disorders, can increase the risk of developing eczema.\nIt's important to note that eczema is a complex condition, and the triggers can vary from person to person. Identifying and avoiding triggers, as well as following a treatment plan, can help manage symptoms and improve quality",
    "llama-2-7b-chat-hf_fact_raw": "1. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition.\n2. The exact cause of eczema involves a combination of genetic and environmental factors.\n3. People with a family history of eczema are more likely to develop the condition.\n4. Allergies to substances such as pollen, dust mites, or pet dander can trigger eczema symptoms.\n5. Exposure to irritants like soaps, detergents, or fragrances can cause eczema flare-ups.",
    "llama-2-7b-chat-hf_fact": [
      "Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition.",
      "The exact cause of eczema involves a combination of genetic and environmental factors.",
      "People with a family history of eczema are more likely to develop the condition.",
      "Allergies to substances such as pollen, dust mites, or pet dander can trigger eczema symptoms.",
      "Exposure to irritants like soaps, detergents, or fragrances can cause eczema flare-ups."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is used to treat a variety of conditions, including:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is used to lower blood pressure in people with hypertension.\n2. Heart failure: Hydrochlorothiazide can help reduce the amount of fluid in the body and improve breathing in people with heart failure.\n3. Edema (swelling): Hydrochlorothiazide can help reduce swelling in the feet, ankles, and hands caused by fluid buildup.\n4. Kidney disease: Hydrochlorothiazide can help reduce the risk of kidney damage in people with kidney disease.\n5. Liver disease: Hydrochlorothiazide can help reduce the risk of liver damage in people with liver disease.\n6. Nephrotic syndrome: Hydrochlorothiazide can help reduce the amount of protein in the urine in people with nephrotic syndrome.\n7. Hyperuricemia (high uric acid levels): Hydrochlorothiazide can help reduce uric acid levels in the blood in people with hyperuricemia.\n8. Gout: Hydrochlorothiazide can help reduce the frequency and severity of gout attacks in people with gout.\n9. Cystitis (bladder infection): Hydrochlorothiazide can help treat bladder infections caused by bacteria.\n10. Prostatitis (prostate infection): Hydrochlorothiazide can help treat prostate infections caused by bacteria.\nIt's important to note that hydrochlorothiazide can have side effects, especially if taken in high doses or for a long time. Therefore, it's important to use it only as directed by a healthcare professional and to monitor your health closely while taking this medication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide is used to help reduce the amount of fluid in the body in people with heart failure.\n3. Hydrochlorothiazide can help reduce swelling in the feet, ankles, and hands caused by fluid buildup (edema).\n4. Hydrochlorothiazide can help reduce the risk of kidney damage in people with kidney disease.\n5. Hydrochlorothiazide can help reduce uric acid levels in the blood in people with hyperuricemia.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide is used to help reduce the amount of fluid in the body in people with heart failure.",
      "Hydrochlorothiazide can help reduce swelling in the feet, ankles, and hands caused by fluid buildup (edema).",
      "Hydrochlorothiazide can help reduce the risk of kidney damage in people with kidney disease.",
      "Hydrochlorothiazide can help reduce uric acid levels in the blood in people with hyperuricemia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is not typically used to reduce the risk of kidney damage in people with kidney disease. In fact, it must be used cautiously in patients with kidney disease as it can affect kidney function.\n5. FALSE [correction]: Hydrochlorothiazide can actually increase uric acid levels in the blood, which could be problematic for people with hyperuricemia or gout.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-coated meshes and implants have been used to support the urethra and bladder neck, helping to prevent leakage of urine. These implants are typically made of a porous material that allows the body to grow new tissue around it, securing it in place and promoting healing.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence.\n2. Silicon-coated meshes and implants are used to support the urethra and bladder neck.\n3. The purpose of these silicon-coated implants is to help prevent leakage of urine.\n4. The implants made for this purpose are typically porous to allow the body to grow new tissue around them.\n5. The growth of new tissue around the implants is intended to secure them in place and promote healing.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence.",
      "Silicon-coated meshes and implants are used to support the urethra and bladder neck.",
      "The purpose of these silicon-coated implants is to help prevent leakage of urine.",
      "The implants made for this purpose are typically porous to allow the body to grow new tissue around them.",
      "The growth of new tissue around the implants is intended to secure them in place and promote healing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of urinary incontinence.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is some evidence to suggest that the lunar cycle, or the phases of the moon, may be associated with an increased risk of rupture of intracranial aneurysms.\nIntracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain that can rupture and cause bleeding, leading to stroke or brain hemorrhage. While the exact cause of intracranial aneurysms is not fully understood, research has suggested that certain factors, such as genetics, high blood pressure, and atherosclerosis, may contribute to their development.\nSome studies have suggested that the lunar cycle may also play a role in the rupture of intracranial aneurysms. For example, a study published in the journal \"Neurology\" in 2013 found that the risk of aneurysm rupture was higher during the full moon than during other phases of the lunar cycle. Another study published in the \"Journal of Neurosurgery\" in 2017 found similar results, with an increased risk of aneurysm rupture during the full moon and new moon phases.\nIt is thought that the gravitational forces of the moon may affect the blood vessels in the brain, leading to increased pressure and stress on the aneurysms, which can increase the risk of rupture. However, it is important to note that these findings are based on observational studies and more research is needed to confirm these associations and to understand the underlying mechanisms.\nIt is worth noting that the association between the lunar cycle and aneurysm rupture is not a cause for panic, and it is unlikely that the risk of rupture will be significantly higher during any particular phase of the moon. However, if you have a history of aneurysms or are at risk for them, it is important to work closely with your healthcare provider to manage any underlying conditions and to monitor your health closely.",
    "llama-2-7b-chat-hf_fact_raw": "1. Intracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain that can rupture and cause bleeding.\n2. Factors such as genetics, high blood pressure, and atherosclerosis may contribute to the development of intracranial aneurysms.\n3. A study published in the journal \"Neurology\" in 2013 found that the risk of aneurysm rupture was higher during the full moon than during other phases of the lunar cycle.\n4. Another study published in the \"Journal of Neurosurgery\" in 2017 found an increased risk of aneurysm rupture during the full moon and new moon phases.\n5. The gravitational forces of the moon are thought to potentially affect the blood vessels in the brain, leading to increased pressure and stress on the aneurysms.",
    "llama-2-7b-chat-hf_fact": [
      "Intracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain that can rupture and cause bleeding.",
      "Factors such as genetics, high blood pressure, and atherosclerosis may contribute to the development of intracranial aneurysms.",
      "A study published in the journal \"Neurology\" in 2013 found that the risk of aneurysm rupture was higher during the full moon than during other phases of the lunar cycle.",
      "Another study published in the \"Journal of Neurosurgery\" in 2017 found an increased risk of aneurysm rupture during the full moon and new moon phases.",
      "The gravitational forces of the moon are thought to potentially affect the blood vessels in the brain, leading to increased pressure and stress on the aneurysms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no scientific consensus that supports the claim that the risk of aneurysm rupture is higher during the full moon than during other phases of the lunar cycle. Studies on this topic have produced mixed results, and many do not support a link between lunar phases and aneurysm rupture.\n4. UNKNOWN: Without access to the specific study from the \"Journal of Neurosurgery\" in 2017, it is not possible to confirm the accuracy of this statement.\n5. FALSE [correction]: The gravitational forces of the moon are known to affect tides on Earth, but there is no scientific evidence to support the claim that these forces affect blood vessels in the brain or lead to increased pressure and stress on aneurysms. This idea is speculative and not supported by mainstream medical research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein plays a crucial role in regulating the splicing process. It is a splicing factor that is involved in the recognition and binding of the 3' splice site of pre-mRNAs, and helps to facilitate the splicing reaction. Specifically, HuR binds to the 3' splice site of the pre-mRNA and helps to recruit the spliceosome to the site, which is necessary for the removal of introns and the formation of the mature mRNA.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein is involved in regulating the splicing process.\n2. HuR acts as a splicing factor.\n3. HuR is involved in the recognition and binding of the 3' splice site of pre-mRNAs.\n4. HuR helps to recruit the spliceosome to the 3' splice site.\n5. The function of HuR is necessary for the removal of introns and the formation of mature mRNA.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein is involved in regulating the splicing process.",
      "HuR acts as a splicing factor.",
      "HuR is involved in the recognition and binding of the 3' splice site of pre-mRNAs.",
      "HuR helps to recruit the spliceosome to the 3' splice site.",
      "The function of HuR is necessary for the removal of introns and the formation of mature mRNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein is primarily known for its role in regulating mRNA stability and translation, not the splicing process.\n2. FALSE [correction]: HuR is not typically characterized as a splicing factor; it is an RNA-binding protein that influences mRNA stability.\n3. FALSE [correction]: HuR is not involved in the recognition and binding of the 3' splice site of pre-mRNAs; this is a role typically associated with splicing factors.\n4. FALSE [correction]: HuR does not help to recruit the spliceosome to the 3' splice site as it is not directly involved in the splicing process.\n5. FALSE [correction]: The function of HuR is not necessary for the removal of introns and the formation of mature mRNA through splicing; its main role is in post-transcriptional regulation, affecting mRNA stability and translation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha c-terminal peptide (ProT) is a small peptide hormone that has been found to have a variety of functions in the body. Some of the known functions of ProT include:\n1. Regulation of protein synthesis: ProT has been shown to stimulate protein synthesis in various tissues, including muscle, liver, and kidney.\n2. Anti-inflammatory effects: ProT has been found to have anti-inflammatory properties, and may play a role in reducing inflammation in various tissues.\n3. Neuroprotection: ProT has been shown to have neuroprotective effects, and may help to protect against neurodegenerative diseases such as Alzheimer's and Parkinson's.\n4. Cardiovascular health: ProT has been found to have a protective effect on the cardiovascular system, and may help to reduce the risk of heart disease.\n5. Anti-aging effects: ProT has been found to have anti-aging effects, and may help to promote longevity and overall health.\n6. Immune system regulation: ProT has been found to have a role in regulating the immune system, and may help to prevent autoimmune diseases.\n7. Cancer treatment: ProT has been found to have anti-tumor effects, and may be useful in the treatment of various types of cancer.\n8. Wound healing: ProT has been found to have a role in wound healing, and may help to promote the healing process.\n9. Bone health: ProT has been found to have a role in bone health, and may help to promote bone growth and density.\n10. Reproductive health: ProT has been found to have a role in reproductive health, and may help to regulate the menstrual cycle and fertility.\nIt is important to note that while these functions have been observed in various studies, more research is needed to fully understand the mechanisms of action and the full range of functions of ProT in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (ProT) stimulates protein synthesis in various tissues, including muscle, liver, and kidney.\n2. ProT has anti-inflammatory properties and may play a role in reducing inflammation in various tissues.\n3. ProT has neuroprotective effects and may help protect against neurodegenerative diseases such as Alzheimer's and Parkinson's.\n4. ProT has a protective effect on the cardiovascular system and may help reduce the risk of heart disease.\n5. ProT has been found to have anti-tumor effects and may be useful in the treatment of various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (ProT) stimulates protein synthesis in various tissues, including muscle, liver, and kidney.",
      "ProT has anti-inflammatory properties and may play a role in reducing inflammation in various tissues.",
      "ProT has neuroprotective effects and may help protect against neurodegenerative diseases such as Alzheimer's and Parkinson's.",
      "ProT has a protective effect on the cardiovascular system and may help reduce the risk of heart disease.",
      "ProT has been found to have anti-tumor effects and may be useful in the treatment of various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe statements about Prothymosin alpha (ProT) and its effects are highly specific and would require access to scientific research for verification. While some of the statements may be supported by research, without specific references, it's not possible to confirm their accuracy. Statements 2 and 3 are generally consistent with scientific literature indicating that ProT has anti-inflammatory and neuroprotective effects. However, the effects on protein synthesis in various tissues (statement 1), the cardiovascular system (statement 4), and anti-tumor effects (statement 5) would need to be verified with specific studies. Since I cannot access the latest research or the specific passage these statements are extracted from, I can only confirm the general knowledge that ProT has anti-inflammatory and neuroprotective properties.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRQARRR. This sequence is located in the N-terminal region of the cystatin C protein and is responsible for the formation of fibrils in vitro.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide RRQARRR plays a pivotal role in human cystatin C fibrillization.\n2. The amino acid sequence RRQARRR is located in the N-terminal region of the cystatin C protein.\n3. The sequence RRQARRR is responsible for the formation of fibrils in vitro.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide RRQARRR plays a pivotal role in human cystatin C fibrillization.",
      "The amino acid sequence RRQARRR is located in the N-terminal region of the cystatin C protein.",
      "The sequence RRQARRR is responsible for the formation of fibrils in vitro."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The amino acid sequence RRQARRR is located in the C-terminal region of the cystatin C protein.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α does increase after the administration of amifostine (ethyol).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is an enzyme that deposits the histone mark H3K4me3.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is an enzyme.\n2. Set7 deposits the histone mark H3K4me3.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is an enzyme.",
      "Set7 deposits the histone mark H3K4me3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 deposits the histone mark H3K4me1, not H3K4me3.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin is a protein that contains 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin contains 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin contains 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the DNAJC11 gene is localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the DNAJC11 gene is localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the DNAJC11 gene is localized to the mitochondria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "No, ultraconserved elements are not typically depleted among copy number variants (CNVs). In fact, many copy number variants (CNVs) contain ultraconserved elements, which are segments of DNA that are highly conserved across different species and are often associated with important regulatory functions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are segments of DNA that are highly conserved across different species.\n2. Ultraconserved elements are often associated with important regulatory functions.\n3. Many copy number variants (CNVs) contain ultraconserved elements.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are segments of DNA that are highly conserved across different species.",
      "Ultraconserved elements are often associated with important regulatory functions.",
      "Many copy number variants (CNVs) contain ultraconserved elements."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Histone proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone proteins are the substrate of the haspin kinase during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "Histone proteins are the substrate of the haspin kinase during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate by using the host cell's machinery to replicate their RNA genome. Here is the general mechanism of viroid replication:\n1. Attachment: The viroid attaches to the host cell membrane through specific sequences or structures.\n2. Penetration: The viroid enters the host cell through a process called endocytosis, in which the cell engulfs the viroid in a membrane-bound vesicle.\n3. Uncoating: Once inside the host cell, the viroid is released from the vesicle and the RNA genome is exposed.\n4. Replication: The viroid uses the host cell's RNA polymerase enzyme to replicate its RNA genome. This process is thought to occur in the cytoplasm of the host cell.\n5. Transcription: The replicated viroid RNA is then transcribed into complementary RNA (cRNA) by the host cell's RNA polymerase enzyme.\n6. Translation: The cRNA is then translated into protein by the host cell's ribosomes.\n7. Release: The new viroid particles are released from the host cell through a process called lysis, in which the cell membrane is broken open.\n8. Infectious cycle: The new viroid particles can then infect other host cells and repeat the replication cycle.\nIt's worth noting that the exact mechanisms of viroid replication can vary depending on the specific viroid and the host cell, and some viroids may have additional steps in their replication cycle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules that replicate using the host cell's machinery.\n2. The viroid replication process involves attachment to the host cell membrane.\n3. Viroids enter the host cell through a process called endocytosis.\n4. Viroid replication is facilitated by the host cell's RNA polymerase enzyme in the cytoplasm.\n5. New viroid particles are released from the host cell through a process called lysis.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules that replicate using the host cell's machinery.",
      "The viroid replication process involves attachment to the host cell membrane.",
      "Viroids enter the host cell through a process called endocytosis.",
      "Viroid replication is facilitated by the host cell's RNA polymerase enzyme in the cytoplasm.",
      "New viroid particles are released from the host cell through a process called lysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids do not attach to the host cell membrane as part of their replication process; they replicate within the host cell's nucleus or chloroplasts.\n3. UNKNOWN: The exact mechanism of viroid entry into host cells is not well understood, and while endocytosis is a common method for many pathogens, it is not clearly established for viroids.\n4. TRUE: Viroid replication is indeed facilitated by the host cell's RNA polymerase, but it can occur in the nucleus or chloroplasts, not necessarily in the cytoplasm.\n5. FALSE [correction]: Viroids do not form particles; they are naked RNA molecules. They spread to other cells through cell-to-cell movement rather than being released through lysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, elevated levels of fibronectin in the blood can be a biomarker for Duchenne muscular dystrophy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin can be a biomarker for Duchenne muscular dystrophy.\n2. Elevated levels of fibronectin in the blood are associated with Duchenne muscular dystrophy.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin can be a biomarker for Duchenne muscular dystrophy.",
      "Elevated levels of fibronectin in the blood are associated with Duchenne muscular dystrophy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. The ENCODE (ENCyclopedia Of DNA Elements) Project: This project is a large-scale effort to map all of the functional elements in the human genome, including promoters, enhancers, and other regulatory elements.\n2. The Roadmap Epigenomics Project: This project is a comprehensive analysis of the epigenetic landscape of multiple tissues and cell types from humans and other organisms.\n3. The Mammalian Epigenome Project: This project is a systematic analysis of the epigenetic marks in various mammalian species, including humans, mice, and rats.\n4. The Epigenomics of Disease Project: This project aims to identify epigenetic changes that occur in response to disease, including cancer, diabetes, and neurological disorders.\n5. The Epigenetic Regulation of Gene Expression Project: This project focuses on understanding the mechanisms by which epigenetic marks regulate gene expression and how these mechanisms are disrupted in disease.\n6. The Epigenetic Modifications in Stem Cells Project: This project investigates the epigenetic marks that are present in stem cells and how these marks are involved in the regulation of stem cell function and differentiation.\n7. The Epigenetic Changes in Aging Project: This project aims to identify epigenetic changes that occur with aging and how these changes contribute to the aging process.\n8. The Epigenetic Regulation of Immune Cell Function Project: This project focuses on understanding the epigenetic regulation of immune cell function and how epigenetic changes contribute to immune dysfunction in disease.\n9. The Epigenetic Regulation of Neuronal Function Project: This project investigates the epigenetic regulation of neuronal function and how epigenetic changes contribute to neurological disorders.\n10. The Epigenetic Regulation of Cancer Project: This project focuses on understanding the epigenetic changes that occur in cancer and how these changes contribute to tumor development and progression.\nThese are some of the major epigenome projects that contribute to the data contained in the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) Project.\n2. The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.\n3. Data from the Mammalian Epigenome Project is contained in the DeepBlue epigenomic data server.\n4. The DeepBlue epigenomic data server includes data from the Epigenomics of Disease Project.\n5. The Epigenetic Regulation of Gene Expression Project contributes data to the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) Project.",
      "The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.",
      "Data from the Mammalian Epigenome Project is contained in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server includes data from the Epigenomics of Disease Project.",
      "The Epigenetic Regulation of Gene Expression Project contributes data to the DeepBlue epigenomic data server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The DeepBlue epigenomic data server does contain data from the ENCODE Project, which is a major source of epigenomic data.\n2. TRUE: The Roadmap Epigenomics Project, which aims to produce a public resource of human epigenomic data, is included in the DeepBlue epigenomic data server.\n3. UNKNOWN: Without specific information about a project named \"Mammalian Epigenome Project,\" it is difficult to determine the accuracy of this statement. The name does not correspond to one of the most well-known epigenomics projects, but it could be a lesser-known study or an alternative name for a project whose data is included in DeepBlue.\n4. UNKNOWN: Similar to statement 3, without specific information about an \"Epigenomics of Disease Project,\" it is difficult to determine the accuracy of this statement. It is not a widely recognized project name in the context of epigenomic data servers, so the statement's validity cannot be confirmed without additional context.\n5. UNKNOWN: The \"Epigenetic Regulation of Gene Expression Project\" is not a widely recognized project name, and without additional context, it is not possible to confirm whether this project contributes data to the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Self-Organizing Maps (SOMs) are a type of neural network that can be used for analyzing synonymous codon usage. One tool that employs SOMs for this purpose is the \"Synonymous Codon Usage Analysis\" tool in the \"GeneMarkS\" suite of bioinformatics tools.",
    "llama-2-7b-chat-hf_fact_raw": "1. Self-Organizing Maps (SOMs) are a type of neural network used for analyzing synonymous codon usage.\n2. The \"Synonymous Codon Usage Analysis\" tool uses SOMs for analyzing synonymous codon usage.\n3. The \"Synonymous Codon Usage Analysis\" tool is part of the \"GeneMarkS\" suite of bioinformatics tools.",
    "llama-2-7b-chat-hf_fact": [
      "Self-Organizing Maps (SOMs) are a type of neural network used for analyzing synonymous codon usage.",
      "The \"Synonymous Codon Usage Analysis\" tool uses SOMs for analyzing synonymous codon usage.",
      "The \"Synonymous Codon Usage Analysis\" tool is part of the \"GeneMarkS\" suite of bioinformatics tools."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Self-Organizing Maps (SOMs) are a type of neural network used for various types of data visualization and clustering tasks, not specifically for analyzing synonymous codon usage.\n2. UNKNOWN\n3. FALSE [correction]: The \"Synonymous Codon Usage Analysis\" tool is not part of the \"GeneMarkS\" suite. \"GeneMarkS\" is a gene prediction tool, while synonymous codon usage analysis tools are typically separate applications or part of broader bioinformatics suites.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Minimal Information About a Non-coding RNA Sequence) is a database and analysis tool for non-coding RNA (ncRNA) sequences. It was developed to provide a standardized framework for the annotation and analysis of ncRNA sequences, which are RNA molecules that do not code for proteins but instead perform regulatory functions in the cell. MINDY-1 includes information on the structure, function, and expression of ncRNAs, as well as tools for predicting their targets and functions. It is a valuable resource for researchers studying the role of ncRNAs in various biological processes and diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a database and analysis tool for non-coding RNA sequences.\n2. MINDY-1 was developed to provide a standardized framework for the annotation and analysis of ncRNA sequences.\n3. Non-coding RNAs are RNA molecules that do not code for proteins but perform regulatory functions in the cell.\n4. MINDY-1 includes information on the structure, function, and expression of ncRNAs.\n5. MINDY-1 offers tools for predicting the targets and functions of ncRNAs.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a database and analysis tool for non-coding RNA sequences.",
      "MINDY-1 was developed to provide a standardized framework for the annotation and analysis of ncRNA sequences.",
      "Non-coding RNAs are RNA molecules that do not code for proteins but perform regulatory functions in the cell.",
      "MINDY-1 includes information on the structure, function, and expression of ncRNAs.",
      "MINDY-1 offers tools for predicting the targets and functions of ncRNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about MINDY-1, I cannot verify the statements related to it. However, the statement about non-coding RNAs is a general fact and is true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "PhyloBayes.",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a software package used for the analysis of conserved genomic loci.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a software package used for the analysis of conserved genomic loci."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PhyloBayes is a software package used for Bayesian phylogenetic analysis, which can include a variety of data types, not limited to conserved genomic loci. It is particularly known for its use in analyzing molecular sequences using sophisticated statistical models.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with the following three diseases:\n1. PIEZO2-related disorder: A rare genetic disorder characterized by intellectual disability, seizures, and distinctive facial features.\n2. Hypertelorism: A condition where the distance between the centers of the eyes is greater than normal.\n3. Microphthalmia: A condition where the eyes are smaller than normal.\nIt's worth noting that these are the only three diseases that have been directly linked to the PIEZO2 gene, but there may be other diseases that have not yet been identified or confirmed.",
    "llama-2-7b-chat-hf_fact_raw": "1. PIEZO2-related disorder is characterized by intellectual disability, seizures, and distinctive facial features.\n2. Hypertelorism is a condition associated with the PIEZO2 gene where there is an abnormally large distance between the centers of the eyes.\n3. Microphthalmia, a condition where the eyes are smaller than normal, is associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "PIEZO2-related disorder is characterized by intellectual disability, seizures, and distinctive facial features.",
      "Hypertelorism is a condition associated with the PIEZO2 gene where there is an abnormally large distance between the centers of the eyes.",
      "Microphthalmia, a condition where the eyes are smaller than normal, is associated with the PIEZO2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PIEZO2-related disorders are primarily characterized by musculoskeletal abnormalities, such as arthrogryposis and distal arthrogryposis, which affect joint movement and muscle development. Intellectual disability and seizures are not typical features of PIEZO2-related disorders.\n2. TRUE\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the efficient trimming of antigenic peptides to the optimal length for major histocompatibility complex (MHC) class I presentation, which is essential for the immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the trimming of antigenic peptides.\n2. The trimming of antigenic peptides is to the optimal length for MHC class I presentation.\n3. This process is essential for the immune response.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the trimming of antigenic peptides.",
      "The trimming of antigenic peptides is to the optimal length for MHC class I presentation.",
      "This process is essential for the immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "In non-damaged gallbladders, R-spondin 1 and Noggin have been shown to play a role in maintaining the quiescence of gallbladder stem cells. They inhibit the activation of these stem cells, preventing them from differentiating into functional cells and ensuring the gallbladder remains in a quiescent state. This is important for maintaining the proper functioning of the gallbladder and preventing the formation of gallstones.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 and Noggin play a role in maintaining the quiescence of gallbladder stem cells in non-damaged gallbladders.\n2. They inhibit the activation of gallbladder stem cells.\n3. R-spondin 1 and Noggin prevent gallbladder stem cells from differentiating into functional cells.\n4. The inhibition of gallbladder stem cell activation by R-spondin 1 and Noggin helps to maintain the proper functioning of the gallbladder.\n5. The action of R-spondin 1 and Noggin in non-damaged gallbladders helps prevent the formation of gallstones.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 and Noggin play a role in maintaining the quiescence of gallbladder stem cells in non-damaged gallbladders.",
      "They inhibit the activation of gallbladder stem cells.",
      "R-spondin 1 and Noggin prevent gallbladder stem cells from differentiating into functional cells.",
      "The inhibition of gallbladder stem cell activation by R-spondin 1 and Noggin helps to maintain the proper functioning of the gallbladder.",
      "The action of R-spondin 1 and Noggin in non-damaged gallbladders helps prevent the formation of gallstones."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the biological functions of R-spondin 1 and Noggin in relation to gallbladder stem cells. Without the appropriate scientific context or research findings, it is not possible to accurately determine the truthfulness of these statements. They require specialized knowledge in the field of molecular biology and an understanding of the current scientific literature on gallbladder stem cell maintenance and function.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that consists of four subunits: p47, p40, p37, and p22. Each of these subunits plays a specific role in the enzyme's function.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.\n2. NOX5 consists of four subunits.\n3. The subunits of NOX5 include p47, p40, p37, and p22.\n4. Each subunit of NOX5 plays a specific role in the enzyme's function.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.",
      "NOX5 consists of four subunits.",
      "The subunits of NOX5 include p47, p40, p37, and p22.",
      "Each subunit of NOX5 plays a specific role in the enzyme's function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterotetrameric enzyme; it is a homologous enzyme that does not require cytosolic subunits for activity.\n2. FALSE [correction]: NOX5 does not consist of four subunits; it functions as a single protein without the need for additional subunits like those found in other NOX family members.\n3. FALSE [correction]: The subunits p47, p40, p37, and p22 are not subunits of NOX5; they are regulatory subunits associated with other NOX enzymes, such as NOX2.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are involved in the regulation of iron metabolism in the body. Furin is an enzyme that helps to activate hepcidin, a hormone that regulates iron absorption and release from cells. Hepcidin inhibits iron absorption in the duodenum and promotes iron release from cells, leading to reduced iron availability in the body. This helps to prevent iron overload and maintain iron homeostasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is an enzyme involved in the regulation of iron metabolism in the body.\n2. Hepcidin is a hormone that regulates iron absorption and release from cells.\n3. Furin helps to activate hepcidin.\n4. Hepcidin inhibits iron absorption in the duodenum.\n5. Hepcidin promotes iron release from cells, which leads to reduced iron availability in the body.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is an enzyme involved in the regulation of iron metabolism in the body.",
      "Hepcidin is a hormone that regulates iron absorption and release from cells.",
      "Furin helps to activate hepcidin.",
      "Hepcidin inhibits iron absorption in the duodenum.",
      "Hepcidin promotes iron release from cells, which leads to reduced iron availability in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is an enzyme that processes various proteins but is not directly involved in the regulation of iron metabolism in the body.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: Hepcidin inhibits iron release from cells, which leads to reduced iron availability in the body.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis gene cluster, also known as the \"phosphoglucose pathway\". This gene cluster contains 11 genes that are involved in the breakdown of glucose to produce energy in the form of ATP. The genes in this cluster include:\n1. HXK1 (hexokinase): encodes an enzyme that phosphorylates glucose to initiate glycolysis\n2. PFK1 (phosphofructokinase): converts glucose-6-phosphate to fructose-6-phosphate\n3. LCT1 (fructose-bisphosphate aldolase): converts fructose-6-phosphate to glyceraldehyde-3-phosphate and dihydroxyacetone phosphate\n4. GAP (phosphoglucose isomerase): converts glyceraldehyde-3-phosphate to glyceraldehyde-3-phosphate\n5. PGK1 (phosphoglycerate kinase): converts glyceraldehyde-3-phosphate to 3-phosphoglycerate\n6. PGAM1 (phosphoglycerate mutase): converts 3-phosphoglycerate to 2-phosphoglycerate\n7. ENO1 (enolase): converts 2-phosphoglycerate to enolpyruvate\n8. ENO2 (enolase): converts enolpyruvate to pyruvate\n9. HSD17B4 (histidine decarboxylase): converts pyruvate to acetyl-CoA\n10. ACACA (acetyl-CoA carboxylase): converts acetyl-CoA to malonyl-CoA\n11. MAT1 (malate dehydrogenase): converts malonyl-CoA to oxaloacetate\nThis gene cluster is responsible for the breakdown of glucose to produce energy in the form of ATP, and is the largest metabolic gene cluster in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis gene cluster.\n2. The glycolysis gene cluster in yeast contains 11 genes.\n3. The glycolysis gene cluster is involved in the breakdown of glucose to produce energy in the form of ATP.\n4. HXK1 (hexokinase) is a gene in the glycolysis cluster that encodes an enzyme initiating glycolysis by phosphorylating glucose.\n5. PFK1 (phosphofructokinase) is a gene in the glycolysis cluster that converts glucose-6-phosphate to fructose-6-phosphate.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis gene cluster.",
      "The glycolysis gene cluster in yeast contains 11 genes.",
      "The glycolysis gene cluster is involved in the breakdown of glucose to produce energy in the form of ATP.",
      "HXK1 (hexokinase) is a gene in the glycolysis cluster that encodes an enzyme initiating glycolysis by phosphorylating glucose.",
      "PFK1 (phosphofructokinase) is a gene in the glycolysis cluster that converts glucose-6-phosphate to fructose-6-phosphate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about the largest metabolic gene cluster in yeast being the glycolysis gene cluster is not easily verifiable without specific scientific data or references. Gene clusters can vary in size and importance, and the term \"largest\" could refer to the number of genes, the length of DNA, or other factors.\n\n2. FALSE [correction]: The glycolysis pathway involves 10 principal enzymatic steps, but it is not clear that all these enzymes are encoded by genes in a single \"glycolysis gene cluster\" in yeast. Additionally, the number of genes in a cluster can vary depending on the specific definition of a gene cluster and the organism in question.\n\n3. TRUE: The glycolysis gene cluster, if defined as the set of genes encoding enzymes in the glycolysis pathway, is indeed involved in the breakdown of glucose to produce energy in the form of ATP.\n\n4. TRUE: HXK1 (hexokinase) is a gene that encodes an enzyme which initiates glycolysis by phosphorylating glucose to form glucose-6-phosphate.\n\n5. FALSE [correction]: PFK1 (phosphofructokinase) is a gene that encodes an enzyme which converts fructose-6-phosphate to fructose-1,6-bisphosphate, not glucose-6-phosphate to fructose-6-phosphate. The enzyme that converts glucose-6-phosphate to fructose-6-phosphate is phosphoglucose isomerase.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT lncRNA is involved in the regulation of gene expression, particularly in the development and progression of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA is involved in the regulation of gene expression.\n2. LIMT lncRNA plays a role in the development and progression of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA is involved in the regulation of gene expression.",
      "LIMT lncRNA plays a role in the development and progression of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis. Some of the popular ones are:\n1. `SNPset`: This package provides a comprehensive set of tools for SNP enrichment analysis, including gene-based and genomic-based methods.\n2. `GSEA`: This package is a popular tool for gene set enrichment analysis (GSEA) that can be used for SNP enrichment analysis.\n3. `enrichr`: This package provides a comprehensive set of tools for SNP enrichment analysis, including gene-based and genomic-based methods.\n4. `MAS5`: This package is a comprehensive tool for SNP enrichment analysis that can be used for both gene-based and genomic-based methods.\n5. `SNPAnalyze`: This package provides a comprehensive set of tools for SNP enrichment analysis, including gene-based and genomic-based methods.\n6. `GSEA-SNP`: This package is a modified version of the popular GSEA package that is specifically designed for SNP enrichment analysis.\n7. `SNPEnrich`: This package provides a comprehensive set of tools for SNP enrichment analysis, including gene-based and genomic-based methods.\n8. `Enrich`: This package provides a comprehensive set of tools for SNP enrichment analysis, including gene-based and genomic-based methods.\n9. `SNP-seq`: This package provides a comprehensive set of tools for SNP enrichment analysis, including gene-based and genomic-based methods.\n10. `SNP-seq-GSEA`: This package is a modified version of the popular SNP-seq package that is specifically designed for SNP enrichment analysis using the GSEA method.\nIt's worth noting that the choice of the package depends on the specific requirements and the type of data you are working with.",
    "llama-2-7b-chat-hf_fact_raw": "1. The `SNPset` package is used for SNP enrichment analysis and includes gene-based and genomic-based methods.\n2. The `GSEA` package can be used for gene set enrichment analysis and SNP enrichment analysis.\n3. The `enrichr` package is used for SNP enrichment analysis with gene-based and genomic-based methods.\n4. The `GSEA-SNP` package is a modified version of the `GSEA` package designed specifically for SNP enrichment analysis.\n5. The `SNPEnrich` package provides tools for SNP enrichment analysis, including gene-based and genomic-based methods.",
    "llama-2-7b-chat-hf_fact": [
      "The `SNPset` package is used for SNP enrichment analysis and includes gene-based and genomic-based methods.",
      "The `GSEA` package can be used for gene set enrichment analysis and SNP enrichment analysis.",
      "The `enrichr` package is used for SNP enrichment analysis with gene-based and genomic-based methods.",
      "The `GSEA-SNP` package is a modified version of the `GSEA` package designed specifically for SNP enrichment analysis.",
      "The `SNPEnrich` package provides tools for SNP enrichment analysis, including gene-based and genomic-based methods."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context, it's unclear if a package named `SNPset` exists and if it is used for SNP enrichment analysis. The name suggests it might be related to SNP analysis, but without specific information, the truth of this statement cannot be determined.\n2. FALSE [correction]: The `GSEA` (Gene Set Enrichment Analysis) package is used for gene set enrichment analysis, but it is not typically used for SNP enrichment analysis.\n3. FALSE [correction]: The `enrichr` package is used for gene set enrichment analysis, not specifically for SNP enrichment analysis.\n4. UNKNOWN: Without additional context, it's unclear if a package named `GSEA-SNP` exists. If it does, the statement could be true, but without specific information, the truth of this statement cannot be determined.\n5. TRUE: The `SNPEnrich` package does provide tools for SNP enrichment analysis, including gene-based and genomic-based methods.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "The key players in radial glial specification to ependymal cells are:\n1. Notch signaling: Notch signaling is a critical regulator of radial glial cell fate and differentiation to ependymal cells.\n2. Wnt/β-catenin signaling: Wnt/β-catenin signaling also plays a crucial role in regulating radial glial cell fate and differentiation to ependymal cells.\n3. Shh signaling: Shh signaling is involved in the regulation of radial glial cell fate and differentiation to ependymal cells, particularly in the ventricular zone.\n4. BMP signaling: BMP signaling has been shown to regulate radial glial cell fate and differentiation to ependymal cells in the cerebral cortex.\n5. Ephrin signaling: Ephrin signaling has been implicated in the regulation of radial glial cell fate and differentiation to ependymal cells in the cerebral cortex.\n6. PI3K/Akt signaling: PI3K/Akt signaling has been shown to play a role in regulating radial glial cell fate and differentiation to ependymal cells in the cerebral cortex.\n7. HDACs: Histone deacetylases (HDACs) have been implicated in the regulation of radial glial cell fate and differentiation to ependymal cells.\n8. H3K27ac: Histone 3 lysine 27 acetylation (H3K27ac) has been shown to be involved in the regulation of radial glial cell fate and differentiation to ependymal cells.\n9. H3K4me3: Histone 3 lysine 4 methylation (H3K4me3) has been implicated in the regulation of radial glial cell fate and differentiation to ependymal cells.\n10. Hox genes: Hox genes, particularly Hoxa1 and Hoxb1, have been shown to be involved in the regulation of radial glial cell fate and differentiation to ependymal cells in the cerebral cortex.",
    "llama-2-7b-chat-hf_fact_raw": "1. Notch signaling is a critical regulator of radial glial cell fate and differentiation to ependymal cells.\n2. Wnt/β-catenin signaling plays a crucial role in regulating radial glial cell fate and differentiation to ependymal cells.\n3. Shh signaling is involved in the regulation of radial glial cell fate and differentiation to ependymal cells, particularly in the ventricular zone.\n4. BMP signaling regulates radial glial cell fate and differentiation to ependymal cells in the cerebral cortex.\n5. Hox genes, such as Hoxa1 and Hoxb1, are involved in the regulation of radial glial cell fate and differentiation to ependymal cells in the cerebral cortex.",
    "llama-2-7b-chat-hf_fact": [
      "Notch signaling is a critical regulator of radial glial cell fate and differentiation to ependymal cells.",
      "Wnt/β-catenin signaling plays a crucial role in regulating radial glial cell fate and differentiation to ependymal cells.",
      "Shh signaling is involved in the regulation of radial glial cell fate and differentiation to ependymal cells, particularly in the ventricular zone.",
      "BMP signaling regulates radial glial cell fate and differentiation to ependymal cells in the cerebral cortex.",
      "Hox genes, such as Hoxa1 and Hoxb1, are involved in the regulation of radial glial cell fate and differentiation to ependymal cells in the cerebral cortex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Notch signaling is indeed a critical regulator of radial glial cell fate and their differentiation into various cell types, including ependymal cells.\n2. FALSE [correction]: Wnt/β-catenin signaling is known to play a crucial role in regulating various aspects of neural development, but it is more traditionally associated with the regulation of neuronal differentiation and proliferation rather than specifically radial glial cell fate and differentiation to ependymal cells.\n3. TRUE: Sonic hedgehog (Shh) signaling is involved in the regulation of radial glial cell fate and differentiation, particularly in the ventricular zone, which is a key area for neurogenesis.\n4. UNKNOWN: BMP signaling does regulate aspects of neural development and could influence radial glial cell fate, but the specific role in differentiation to ependymal cells in the cerebral cortex is not as clearly defined and may require more specific context to determine the accuracy of this statement.\n5. UNKNOWN: Hox genes are critical for patterning along the anterior-posterior axis and play roles in neuronal differentiation and regional identity in the central nervous system. However, their specific involvement in the regulation of radial glial cell fate and differentiation to ependymal cells in the cerebral cortex is not well-established and would require more specific information to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). They are also often fast-growing and highly aggressive, and tend to have a poorer prognosis than other types of gliomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack estrogen receptors (ER).\n2. Triple negative gliomas lack progesterone receptors (PR).\n3. Triple negative gliomas lack human epidermal growth factor receptor 2 (HER2).\n4. Triple negative gliomas are often fast-growing and highly aggressive.\n5. Triple negative gliomas tend to have a poorer prognosis than other types of gliomas.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack estrogen receptors (ER).",
      "Triple negative gliomas lack progesterone receptors (PR).",
      "Triple negative gliomas lack human epidermal growth factor receptor 2 (HER2).",
      "Triple negative gliomas are often fast-growing and highly aggressive.",
      "Triple negative gliomas tend to have a poorer prognosis than other types of gliomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas lack expression of IDH1/2 mutations, 1p/19q codeletion, and ATRX loss. The term \"triple negative\" is not typically used in the context of gliomas but rather for breast cancer, where it refers to the lack of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2).\n2. FALSE [correction]: See correction for statement 1. The term \"triple negative\" is not typically associated with gliomas.\n3. FALSE [correction]: See correction for statement 1. The term \"triple negative\" is not typically associated with gliomas.\n4. TRUE: Gliomas, particularly high-grade ones such as glioblastoma multiforme (GBM), are often fast-growing and highly aggressive.\n5. TRUE: High-grade gliomas, such as glioblastoma multiforme, tend to have a poorer prognosis than other types of gliomas. However, the term \"triple negative\" is not standard for gliomas, so this statement's accuracy in that context is not applicable.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 is not a recognized term in gemology or computer programming. It could be a specific identifier in a certain context.\nAs a helpful assistant, I must inform you that TOPAZ is a type of gemstone, a silicate mineral of aluminum and fluorine, commonly found in igneous rocks. It is known for its color, which can range from colorless to yellow, orange, pink, blue, and green. Topaz is often used as a decorative stone in jewelry and is also used in optical devices, such as lenses and prisms, due to its high refractive index.\nIf you have any other questions or if there is anything else I can help you with, please feel free to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is not a recognized term in gemology or computer programming.\n2. TOPAZ is a type of gemstone.\n3. Topaz is a silicate mineral of aluminum and fluorine.\n4. Topaz is commonly found in igneous rocks.\n5. Topaz is used in optical devices due to its high refractive index.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is not a recognized term in gemology or computer programming.",
      "TOPAZ is a type of gemstone.",
      "Topaz is a silicate mineral of aluminum and fluorine.",
      "Topaz is commonly found in igneous rocks.",
      "Topaz is used in optical devices due to its high refractive index."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The GATA-1 gene controls the expression of GATA-1 isoforms. GATA-1 is a transcription factor that plays a crucial role in the regulation of gene expression during erythropoiesis, the process of red blood cell production. There are several isoforms of the GATA-1 protein that are produced through alternative splicing of the GATA-1 gene, and these isoforms have different functions and tissue-specific expressions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene controls the expression of GATA-1 isoforms.\n2. GATA-1 is a transcription factor involved in the regulation of gene expression during erythropoiesis.\n3. Erythropoiesis is the process of red blood cell production.\n4. There are multiple isoforms of the GATA-1 protein.\n5. The isoforms of the GATA-1 protein are produced through alternative splicing of the GATA-1 gene.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene controls the expression of GATA-1 isoforms.",
      "GATA-1 is a transcription factor involved in the regulation of gene expression during erythropoiesis.",
      "Erythropoiesis is the process of red blood cell production.",
      "There are multiple isoforms of the GATA-1 protein.",
      "The isoforms of the GATA-1 protein are produced through alternative splicing of the GATA-1 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a sequencing-based method used to identify and quantify the expression levels of microRNAs (miRNAs) in a sample. MicroRNAs are small non-coding RNAs that play a critical role in regulating gene expression by binding to messenger RNAs (mRNAs) and preventing their translation into proteins. MIRA-seq is a powerful tool for understanding the role of miRNAs in various biological processes and diseases.\nThe MIRA-seq protocol typically involves the following steps:\n1. Sample preparation: The sample is first prepared by isolating the RNA from the cells or tissues of interest. This is typically done using standard RNA isolation techniques.\n2. Library preparation: The isolated RNA is then converted into a sequencing library using a series of enzymatic reactions. This involves the addition of adapter sequences to the RNA molecules to enable sequencing.\n3. Sequencing: The sequencing library is then loaded onto a sequencing instrument, such as an Illumina or PacBio machine, where the RNA molecules are sequenced.\n4. Data analysis: The raw sequencing data is then analyzed using specialized software to identify and quantify the expression levels of the miRNAs in the sample. This typically involves mapping the sequencing reads to a reference genome or transcriptome, and then calculating the expression levels of the miRNAs based on the number of reads that align to each gene.\nMIRA-seq has several advantages over other methods for measuring miRNA expression, including its high sensitivity and specificity, as well as its ability to detect novel miRNAs. However, it can be time-consuming and resource-intensive, and may require specialized equipment and expertise.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is used to identify and quantify the expression levels of microRNAs in a sample.\n2. MicroRNAs are small non-coding RNAs that regulate gene expression by binding to messenger RNAs and preventing their translation into proteins.\n3. The MIRA-seq protocol involves isolating RNA from cells or tissues using standard RNA isolation techniques.\n4. During MIRA-seq, RNA is converted into a sequencing library, which includes adding adapter sequences to the RNA molecules.\n5. MIRA-seq allows for the sequencing of RNA molecules on instruments such as Illumina or PacBio machines.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is used to identify and quantify the expression levels of microRNAs in a sample.",
      "MicroRNAs are small non-coding RNAs that regulate gene expression by binding to messenger RNAs and preventing their translation into proteins.",
      "The MIRA-seq protocol involves isolating RNA from cells or tissues using standard RNA isolation techniques.",
      "During MIRA-seq, RNA is converted into a sequencing library, which includes adding adapter sequences to the RNA molecules.",
      "MIRA-seq allows for the sequencing of RNA molecules on instruments such as Illumina or PacBio machines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq is used to identify and quantify the methylation levels of DNA, not the expression levels of microRNAs. The correct technique for microRNA expression profiling would be miRNA-seq.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), which are a group of rare genetic disorders that are characterized by recurring episodes of fever, pain, and inflammation. Specifically, ARCALYST is approved for the treatment of cryopyrin-associated periodic syndrome (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is used for the treatment of cryopyrin-associated periodic syndromes (CAPS).\n2. CAPS are characterized by recurring episodes of fever, pain, and inflammation.\n3. ARCALYST is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS).\n4. ARCALYST is also approved for the treatment of Muckle-Wells syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is used for the treatment of cryopyrin-associated periodic syndromes (CAPS).",
      "CAPS are characterized by recurring episodes of fever, pain, and inflammation.",
      "ARCALYST is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS).",
      "ARCALYST is also approved for the treatment of Muckle-Wells syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "In humans, the acrocentric chromosomes that are involved in Robertsonian translocation are:\n* Chromosome 13\n* Chromosome 14\n* Chromosome 21\nThese chromosomes are characterized by having a short arm that is much shorter than the long arm, and are therefore more susceptible to translocation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocation.\n2. Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocation.\n3. Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocation.\n4. Acrocentric chromosomes have a short arm that is much shorter than the long arm.\n5. Acrocentric chromosomes are more susceptible to translocation.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocation.",
      "Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocation.",
      "Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocation.",
      "Acrocentric chromosomes have a short arm that is much shorter than the long arm.",
      "Acrocentric chromosomes are more susceptible to translocation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAcrocentric chromosomes, which include chromosomes 13, 14, 15, 21, and 22, have a centromere near one end, creating a short (p) arm that is much shorter than the long (q) arm. These chromosomes are indeed involved in Robertsonian translocations, a type of chromosomal rearrangement that occurs when the long arms of two acrocentric chromosomes fuse at the centromere, forming a single chromosome. Acrocentric chromosomes are more susceptible to such translocations due to their structure.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "The R package \"brainTumor\" can be used for the identification of pediatric brain tumors. This package provides a set of tools for the analysis of brain tumor genomics data, including mutation calling, copy number alteration detection, and survival analysis. It also includes a number of pre-processed datasets of pediatric brain tumors that can be used for training and testing machine learning models.\nSome other R packages that can be used for the analysis of pediatric brain tumors include:\n* \"pediatricBrainTumor\": This package provides a set of tools for the analysis of pediatric brain tumors, including mutation calling, copy number alteration detection, and survival analysis.\n* \"brainTumorMiner\": This package provides a set of tools for the analysis of brain tumor genomics data, including mutation calling, copy number alteration detection, and survival analysis. It also includes a number of pre-processed datasets of pediatric brain tumors that can be used for training and testing machine learning models.\n* \"RNAseqBrainTumor\": This package provides a set of tools for the analysis of RNA sequencing data from brain tumors, including differential expression analysis and pathway analysis.\n* \"brainTumorGenomics\": This package provides a set of tools for the analysis of genomic data from brain tumors, including mutation calling, copy number alteration detection, and survival analysis. It also includes a number of pre-processed datasets of pediatric brain tumors that can be used for training and testing machine learning models.\nIt's worth noting that the specific package you choose will depend on the type of analysis you want to perform and the type of data you have.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"brainTumor\" is used for the identification of pediatric brain tumors.\n2. The \"brainTumor\" package includes tools for mutation calling, copy number alteration detection, and survival analysis.\n3. The \"brainTumor\" package contains pre-processed datasets of pediatric brain tumors for training and testing machine learning models.\n4. The \"pediatricBrainTumor\" package provides tools for mutation calling, copy number alteration detection, and survival analysis for pediatric brain tumors.\n5. The \"RNAseqBrainTumor\" package is used for the analysis of RNA sequencing data from brain tumors, including differential expression analysis and pathway analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"brainTumor\" is used for the identification of pediatric brain tumors.",
      "The \"brainTumor\" package includes tools for mutation calling, copy number alteration detection, and survival analysis.",
      "The \"brainTumor\" package contains pre-processed datasets of pediatric brain tumors for training and testing machine learning models.",
      "The \"pediatricBrainTumor\" package provides tools for mutation calling, copy number alteration detection, and survival analysis for pediatric brain tumors.",
      "The \"RNAseqBrainTumor\" package is used for the analysis of RNA sequencing data from brain tumors, including differential expression analysis and pathway analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific documentation or a reliable source, it is not possible to confirm the purpose of the \"brainTumor\" R package.\n2. UNKNOWN: The specific features of the \"brainTumor\" package cannot be confirmed without further information.\n3. UNKNOWN: Whether the \"brainTumor\" package contains pre-processed datasets for training and testing machine learning models is not verifiable without additional context or source material.\n4. UNKNOWN: The existence and features of a package named \"pediatricBrainTumor\" cannot be confirmed without more information.\n5. UNKNOWN: The purpose and functionality of the \"RNAseqBrainTumor\" package cannot be verified without access to documentation or a reliable source describing the package.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Yes, NEMO (Nuclear Envelope-Associated Protein 1, also known as IKKγ) is a zinc finger protein. It contains multiple zinc finger domains, which are responsible for its DNA-binding and transcriptional activation activities.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is also known as Nuclear Envelope-Associated Protein 1 and IKKγ.\n2. NEMO is a zinc finger protein.\n3. NEMO contains multiple zinc finger domains.\n4. Zinc finger domains in NEMO are responsible for DNA-binding activities.\n5. Zinc finger domains in NEMO are responsible for transcriptional activation activities.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is also known as Nuclear Envelope-Associated Protein 1 and IKKγ.",
      "NEMO is a zinc finger protein.",
      "NEMO contains multiple zinc finger domains.",
      "Zinc finger domains in NEMO are responsible for DNA-binding activities.",
      "Zinc finger domains in NEMO are responsible for transcriptional activation activities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: NEMO is not classified as a zinc finger protein; it is an essential regulatory component of the IκB kinase complex (IKK), which is involved in NF-κB signaling.\n3. FALSE [correction]: NEMO does not contain multiple zinc finger domains; it contains a coiled-coil domain, a leucine zipper, and a zinc finger (ZF) domain, but it is not characterized by multiple zinc finger domains.\n4. FALSE [correction]: The zinc finger domain in NEMO is not responsible for DNA-binding activities; it is involved in the regulation of the NF-κB pathway and protein-protein interactions.\n5. FALSE [correction]: The zinc finger domain in NEMO is not responsible for transcriptional activation activities; it plays a role in the assembly and regulation of the IKK complex, which in turn activates NF-κB leading to transcriptional activation of various genes. However, NEMO itself is not directly involved in transcriptional activation through zinc finger domains.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS can affect nucleosome positioning during transcription elongation. TFIIS is a general transcription factor that plays a crucial role in the initiation and elongation of transcription, and it has been shown to influence nucleosome positioning by altering the chromatin structure and creating a more accessible chromatin environment for RNA polymerase. TFIIS can bind to the DNA template and help to displace nucleosomes, allowing RNA polymerase to access the template and initiate transcription. Additionally, TFIIS can also help to maintain the open chromatin structure during transcription elongation, which can also affect nucleosome positioning.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS can affect nucleosome positioning during transcription elongation.\n2. TFIIS is a general transcription factor involved in the initiation and elongation of transcription.\n3. TFIIS influences nucleosome positioning by altering the chromatin structure.\n4. TFIIS can bind to the DNA template and help to displace nucleosomes.\n5. TFIIS helps maintain the open chromatin structure during transcription elongation.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS can affect nucleosome positioning during transcription elongation.",
      "TFIIS is a general transcription factor involved in the initiation and elongation of transcription.",
      "TFIIS influences nucleosome positioning by altering the chromatin structure.",
      "TFIIS can bind to the DNA template and help to displace nucleosomes.",
      "TFIIS helps maintain the open chromatin structure during transcription elongation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TFIIS is not a general transcription factor involved in the initiation of transcription; it is specifically involved in the elongation phase of transcription by stimulating the intrinsic nuclease activity of RNA polymerase II to assist with the cleavage of the nascent transcript when the polymerase encounters a blockage.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "In yeast, origins of replication located close to centromeres tend to fire earlier than those located further away. This is because the proximity of the origin to the centromere allows for the formation of a specialized structure called the \"replication origin recognition complex\" (ORC), which helps to recruit and activate the enzymes necessary for DNA replication. As a result, origins located near the centromere are more likely to be recognized and activated earlier in the cell cycle, leading to earlier firing of replication origins in these regions.",
    "llama-2-7b-chat-hf_fact_raw": "1. In yeast, origins of replication close to centromeres tend to fire earlier than those located further away.\n2. The proximity of the origin to the centromere allows for the formation of a specialized structure called the \"replication origin recognition complex\" (ORC).\n3. The replication origin recognition complex helps to recruit and activate the enzymes necessary for DNA replication.\n4. Origins located near the centromere are more likely to be recognized and activated earlier in the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "In yeast, origins of replication close to centromeres tend to fire earlier than those located further away.",
      "The proximity of the origin to the centromere allows for the formation of a specialized structure called the \"replication origin recognition complex\" (ORC).",
      "The replication origin recognition complex helps to recruit and activate the enzymes necessary for DNA replication.",
      "Origins located near the centromere are more likely to be recognized and activated earlier in the cell cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The proximity of the origin to the centromere does not allow for the formation of the \"replication origin recognition complex\" (ORC). The ORC is a protein complex that is formed at origins of replication regardless of their proximity to the centromere.\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences are characterized by their high degree of repetition, high mutation rate, and the presence of microsatellites and minisatellites.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences have a high degree of repetition.\n2. Mammalian GA-sequences have a high mutation rate.\n3. Mammalian GA-sequences contain microsatellites.\n4. Mammalian GA-sequences contain minisatellites.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences have a high degree of repetition.",
      "Mammalian GA-sequences have a high mutation rate.",
      "Mammalian GA-sequences contain microsatellites.",
      "Mammalian GA-sequences contain minisatellites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Mammalian GA-sequences, which are a type of simple sequence repeat (SSR) or microsatellite, do have a high degree of repetition.\n2. TRUE: Microsatellites, including GA-sequences, are known to have high mutation rates due to the nature of their repetitive sequences, which can lead to errors during DNA replication.\n3. TRUE: GA-sequences are a type of microsatellite, which are short, repetitive DNA sequences.\n4. FALSE [correction]: Mammalian GA-sequences are considered microsatellites, not minisatellites. Minisatellites are longer tandem repeat sequences compared to microsatellites.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Groucho-related genes (GRG) are a family of transcriptional regulators that are involved in the regulation of gene expression in response to various signals, including nutrient availability and stress. The mouse genome contains approximately 10 Groucho-related genes (Grg1-Grg10).",
    "llama-2-7b-chat-hf_fact_raw": "1. Groucho-related genes (GRG) are involved in the regulation of gene expression.\n2. The mouse genome contains approximately 10 Groucho-related genes.",
    "llama-2-7b-chat-hf_fact": [
      "Groucho-related genes (GRG) are involved in the regulation of gene expression.",
      "The mouse genome contains approximately 10 Groucho-related genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The exact number of Groucho-related genes in the mouse genome is not specified in the provided context, so the precise number cannot be confirmed as true or false. However, in general, the mouse genome contains a family of Groucho/TLE genes, but the statement that there are approximately 10 is not verifiable without additional context or a specific reference.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "The RPB4 subunit of RNA polymerase II carries RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The RPB4 subunit of RNA polymerase II carries RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact": [
      "The RPB4 subunit of RNA polymerase II carries RNA cleavage activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The RPB4 subunit of RNA polymerase II does not carry RNA cleavage activity. It is the RPB9 subunit that has been implicated in RNA cleavage activity in yeast, and in humans, the cleavage activity is associated with other factors like the cleavage and polyadenylation specificity factor (CPSF).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder that is caused by mutations in the PTEN gene. The PTEN gene provides instructions for making a protein called phosphatase and tensin homolog (PTEN), which plays a critical role in regulating cell growth and division. Mutations in the PTEN gene can lead to uncontrolled cell growth and division, which can result in the characteristic features of Ohdo syndrome, including intellectual disability, seizures, and distinctive facial and bodily features.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder.\n2. Ohdo syndrome is caused by mutations in the PTEN gene.\n3. The PTEN gene is responsible for making a protein called phosphatase and tensin homolog (PTEN).\n4. Mutations in the PTEN gene can lead to uncontrolled cell growth and division.\n5. Characteristic features of Ohdo syndrome include intellectual disability, seizures, and distinctive facial and bodily features.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder.",
      "Ohdo syndrome is caused by mutations in the PTEN gene.",
      "The PTEN gene is responsible for making a protein called phosphatase and tensin homolog (PTEN).",
      "Mutations in the PTEN gene can lead to uncontrolled cell growth and division.",
      "Characteristic features of Ohdo syndrome include intellectual disability, seizures, and distinctive facial and bodily features."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Ohdo syndrome is not typically caused by mutations in the PTEN gene. It is often associated with mutations in the SALL1, KAT6B, or MED12 genes, among others.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "The R/Bioconductor package \"psychiatricGeneAnalysis\" has been developed for the analysis of psychiatric disease genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package named \"psychiatricGeneAnalysis\" is developed for analyzing psychiatric disease genes.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package named \"psychiatricGeneAnalysis\" is developed for analyzing psychiatric disease genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout additional context or information about the specific R/Bioconductor package named \"psychiatricGeneAnalysis,\" it is not possible to determine the accuracy of the statement. The name of the package suggests it could be related to psychiatric disease gene analysis, but without confirmation or documentation, the truth of the statement cannot be established.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "The \"swirl sign\" is a radiological sign that is often seen in intracerebral hemorrhage (ICH). It is characterized by a spiral or swirling pattern of blood within the hemisphere of the brain, typically in the distribution of the middle cerebral artery.\nThe swirl sign is caused by the rotation of blood within the hemisphere due to the hemorrhage, which creates a spiral or whirlpool-like pattern on the imaging studies. This sign is often seen on CT or MRI scans and can be an important indicator of the location and severity of the hemorrhage.\nThe swirl sign can be used to help identify the location of the hemorrhage and to determine the extent of brain injury. It can also be used to monitor the progression of the hemorrhage over time and to assess the effectiveness of treatment.\nIt is important to note that the swirl sign is not specific to ICH and can also be seen in other conditions such as subarachnoid hemorrhage, cerebral edema, and stroke. Therefore, it is important to interpret the sign in the context of the patient's clinical presentation and other imaging findings.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"swirl sign\" is a radiological sign often seen in intracerebral hemorrhage (ICH).\n2. It is characterized by a spiral or swirling pattern of blood within the hemisphere of the brain, typically in the distribution of the middle cerebral artery.\n3. The swirl sign is caused by the rotation of blood within the hemisphere due to the hemorrhage.\n4. This sign is often seen on CT or MRI scans.\n5. The swirl sign is not specific to ICH and can also be seen in other conditions such as subarachnoid hemorrhage, cerebral edema, and stroke.",
    "llama-2-7b-chat-hf_fact": [
      "The \"swirl sign\" is a radiological sign often seen in intracerebral hemorrhage (ICH).",
      "It is characterized by a spiral or swirling pattern of blood within the hemisphere of the brain, typically in the distribution of the middle cerebral artery.",
      "The swirl sign is caused by the rotation of blood within the hemisphere due to the hemorrhage.",
      "This sign is often seen on CT or MRI scans.",
      "The swirl sign is not specific to ICH and can also be seen in other conditions such as subarachnoid hemorrhage, cerebral edema, and stroke."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The \"swirl sign\" is characterized by a heterogeneous appearance of blood on a CT scan due to the presence of both hyperdense (fresh) and hypodense (old) blood within a hematoma, not necessarily a spiral or swirling pattern of blood within the hemisphere of the brain.\n3. FALSE [correction]: The swirl sign is not caused by the rotation of blood within the hemisphere. It indicates the presence of active bleeding within the hematoma, where the mixture of different ages of blood gives the appearance of swirls on imaging.\n4. TRUE\n5. FALSE [correction]: The swirl sign is specific to intracerebral hemorrhage and is not typically seen in other conditions such as subarachnoid hemorrhage, cerebral edema, or stroke. It indicates active or ongoing bleeding within a hematoma.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "The expression of Arabidopsis ROF1 gene is induced by light.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 gene expression is induced by light.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 gene expression is induced by light."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout specific scientific literature or context to confirm the statement about Arabidopsis ROF1 gene expression being induced by light, it is not possible to determine the accuracy of this statement. Arabidopsis is a model organism in plant biology, and gene expression can be complex and influenced by multiple factors. Therefore, without additional information, the truthfulness of this statement cannot be ascertained.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common protein associated with hereditary renal amyloidosis is the transthyretin (TTR) protein. TTR amyloidosis, also known as familial amyloid polyneuropathy (FAP), is a group of inherited disorders caused by mutations in the TTR gene. These mutations lead to the misfolding and aggregation of TTR protein, which accumulates in various organs, including the kidneys, and causes progressive damage and failure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Transthyretin (TTR) protein is the most common cause of hereditary renal amyloidosis.\n2. TTR amyloidosis is also known as familial amyloid polyneuropathy (FAP).\n3. Hereditary renal amyloidosis is caused by mutations in the TTR gene.\n4. Mutations in the TTR gene lead to the misfolding and aggregation of TTR protein.\n5. The accumulation of misfolded TTR protein in organs, including the kidneys, can cause progressive damage and failure.",
    "llama-2-7b-chat-hf_fact": [
      "Transthyretin (TTR) protein is the most common cause of hereditary renal amyloidosis.",
      "TTR amyloidosis is also known as familial amyloid polyneuropathy (FAP).",
      "Hereditary renal amyloidosis is caused by mutations in the TTR gene.",
      "Mutations in the TTR gene lead to the misfolding and aggregation of TTR protein.",
      "The accumulation of misfolded TTR protein in organs, including the kidneys, can cause progressive damage and failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common cause of hereditary renal amyloidosis is not the Transthyretin (TTR) protein, but rather mutations in genes encoding for proteins such as fibrinogen A alpha-chain, apolipoprotein A-I, lysozyme, or leukocyte chemotactic factor 2.\n2. TRUE\n3. FALSE [correction]: Hereditary renal amyloidosis can be caused by mutations in several genes, not just the TTR gene. Mutations in the TTR gene are more commonly associated with familial amyloid polyneuropathy (FAP) and cardiomyopathy.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed. The hippocampus is a part of the brain that plays a key role in memory and spatial navigation, and studies have used proteomics to investigate the changes in protein expression that occur in the hippocampus in response to various conditions, such as aging, disease, and drug treatment. These studies have identified a wide range of proteins that are involved in various cellular processes, including synaptic plasticity, neurotransmission, and inflammation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed.\n2. The hippocampus is involved in memory and spatial navigation.\n3. Proteomics has been used to study changes in protein expression in the mouse hippocampus.\n4. Studies have investigated the hippocampus in response to conditions like aging, disease, and drug treatment.\n5. Research has identified proteins in the mouse hippocampus that are involved in synaptic plasticity, neurotransmission, and inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed.",
      "The hippocampus is involved in memory and spatial navigation.",
      "Proteomics has been used to study changes in protein expression in the mouse hippocampus.",
      "Studies have investigated the hippocampus in response to conditions like aging, disease, and drug treatment.",
      "Research has identified proteins in the mouse hippocampus that are involved in synaptic plasticity, neurotransmission, and inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Yes, mouse chromosomes are acrocentric. This means that they have a centromere located near one end of the chromosome, giving them a \"V\" shape.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Acrocentric chromosomes have a centromere located near one end of the chromosome.\n3. Acrocentric chromosomes have a \"V\" shape.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are acrocentric.",
      "Acrocentric chromosomes have a centromere located near one end of the chromosome.",
      "Acrocentric chromosomes have a \"V\" shape."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Acrocentric chromosomes typically have a \"J\" or \"L\" shape, not a \"V\" shape, due to the position of the centromere near one end creating a long arm and a very short arm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "RX-0201.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "HPG (Hydrogen Peroxide Gated) pores are a type of ion channel found in the plasma membrane of certain cells, including nerve cells and immune cells. These pores are gated by hydrogen peroxide, meaning that they open and close in response to changes in the concentration of hydrogen peroxide outside the cell. HPG pores play a role in regulating the flow of ions and small molecules across the cell membrane, and may also be involved in cell signaling and the immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. HPG pores are a type of ion channel found in the plasma membrane of certain cells.\n2. HPG stands for Hydrogen Peroxide Gated.\n3. HPG pores are found in nerve cells and immune cells.\n4. The gating of HPG pores is responsive to changes in the concentration of hydrogen peroxide outside the cell.\n5. HPG pores are involved in regulating the flow of ions and small molecules across the cell membrane.",
    "llama-2-7b-chat-hf_fact": [
      "HPG pores are a type of ion channel found in the plasma membrane of certain cells.",
      "HPG stands for Hydrogen Peroxide Gated.",
      "HPG pores are found in nerve cells and immune cells.",
      "The gating of HPG pores is responsive to changes in the concentration of hydrogen peroxide outside the cell.",
      "HPG pores are involved in regulating the flow of ions and small molecules across the cell membrane."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context, it's unclear what \"HPG pores\" refer to, as this is not a standard term for a type of ion channel. It could be a hypothetical or specific term used in a particular study or context that is not widely recognized.\n2. FALSE [correction]: HPG does not stand for Hydrogen Peroxide Gated. There is no widely recognized ion channel known as HPG that stands for Hydrogen Peroxide Gated. If HPG is an acronym for something in a specific context, it is not a standard term in cell biology.\n3. UNKNOWN: Since the existence and nature of \"HPG pores\" are not clear from the given statements, it is not possible to confirm whether they are found in nerve cells and immune cells.\n4. UNKNOWN: Without clear information on what HPG pores are, it is not possible to determine if their gating is responsive to changes in the concentration of hydrogen peroxide outside the cell.\n5. UNKNOWN: As the existence and characteristics of HPG pores are not established, it is not possible to confirm their involvement in regulating the flow of ions and small molecules across the cell membrane.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale research project aimed at sequencing and analyzing the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in almost every environment on Earth. The project was launched in 2015 and is being conducted by a consortium of researchers from around the world.\nThe goal of the 959 Nematode Genomes initiative is to generate a comprehensive understanding of the evolution, diversity, and biology of nematodes, which are important model organisms in many fields of biology, including parasitology, agriculture, and biomedical research. By sequencing the genomes of such a large number of nematode species, the project aims to identify new genes, regulatory elements, and other genomic features that are unique to nematodes and could have important implications for biology and medicine.\nThe project is using a variety of cutting-edge sequencing technologies, including Illumina and PacBio sequencing, to generate high-quality genome assemblies for each of the 959 nematode species. The genomes are being analyzed using a range of bioinformatic tools and techniques, including gene prediction, transcriptome analysis, and functional annotation.\nThe 959 Nematode Genomes initiative is expected to provide a wealth of new insights into the biology and evolution of nematodes, and could have important implications for the development of new drugs, pesticides, and other tools for controlling nematode-based diseases in plants and animals.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.\n2. The project was launched in 2015.\n3. The initiative is being conducted by a consortium of researchers from around the world.\n4. The initiative employs sequencing technologies such as Illumina and PacBio.\n5. The goal of the project is to enhance understanding of nematode evolution, diversity, and biology, which could impact drug and pesticide development.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.",
      "The project was launched in 2015.",
      "The initiative is being conducted by a consortium of researchers from around the world.",
      "The initiative employs sequencing technologies such as Illumina and PacBio.",
      "The goal of the project is to enhance understanding of nematode evolution, diversity, and biology, which could impact drug and pesticide development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 959 Nematode Genomes project or the 1KITE project (1000 Insect Transcriptome Evolution), was launched in 2011, not 2015.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data, including:\n1. NIPT: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n2. PrenatTest: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n3. NIPTkit: This package provides a comprehensive set of functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n4. PrenatalGenetics: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n5. NIPTAnalysis: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n6. PrenatalTesting: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n7. NIPTData: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n8. PrenatalDiagnostics: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n9. NIPTStatistics: This package provides functions for the analysis of NIPT data, including the calculation of test statistics, confidence intervals, and the detection of trisomy 21, 18, and 13.\n10. PrenatalTestingTools: This package",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"NIPT\" has been developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. The R package \"PrenatTest\" provides functions for the analysis of NIPT data.\n3. The R package \"NIPTkit\" offers a comprehensive set of functions for the analysis of NIPT data.\n4. The R package \"PrenatalGenetics\" is designed for analyzing NIPT data.\n5. The R package \"NIPTAnalysis\" provides functions for the analysis of NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"NIPT\" has been developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "The R package \"PrenatTest\" provides functions for the analysis of NIPT data.",
      "The R package \"NIPTkit\" offers a comprehensive set of functions for the analysis of NIPT data.",
      "The R package \"PrenatalGenetics\" is designed for analyzing NIPT data.",
      "The R package \"NIPTAnalysis\" provides functions for the analysis of NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific knowledge of the R packages and their purposes, it is not possible to verify the accuracy of these statements. The existence and functionality of R packages can be confirmed by checking the Comprehensive R Archive Network (CRAN) or other repositories where R packages are hosted and documented.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach's delusional parasitosis, is a rare psychiatric disorder characterized by the delusional belief that one's body is infested with parasites, such as insects, worms, or other organisms. The delusions are typically persistent and can last for months or even years, causing significant distress and impairment in the individual's daily functioning.\nThe symptoms of Achenbach's syndrome can vary in severity and may include:\n1. Delusions of parasitosis: The individual believes that their body is infested with parasites, despite the absence of any physical evidence or medical findings to support this belief.\n2. Intensive preoccupation with the perceived parasites: The individual may spend excessive time and energy trying to detect, remove, or avoid the perceived parasites, which can interfere with their daily activities and relationships.\n3. Repetitive behaviors: The individual may engage in repetitive behaviors, such as excessive cleaning, grooming, or checking their body for parasites, in an attempt to alleviate their perceived infestation.\n4. Social isolation: The individual may avoid social interactions or become isolated due to their beliefs and behaviors related to the parasites.\n5. Cognitive impairment: In some cases, Achenbach's syndrome can be associated with cognitive impairment, such as difficulty with concentration, memory, or decision-making.\n6. Mood changes: The individual may experience mood changes, such as anxiety, depression, or irritability, due to their beliefs and the distress they cause.\n7. Somatic symptoms: The individual may experience somatic symptoms, such as headaches, fatigue, or muscle pain, which they attribute to the parasites.\nAchenbach's syndrome is often diagnosed based on a combination of clinical interviews, psychological evaluations, and medical examinations. Treatment typically involves a combination of psychotherapy and medication, with the goal of reducing the delusional beliefs and improving the individual's overall quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by the delusional belief that one's body is infested with parasites.\n2. The delusions associated with Achenbach's syndrome can persist for months or even years.\n3. Individuals with Achenbach's syndrome may engage in repetitive behaviors such as excessive cleaning or grooming.\n4. Achenbach's syndrome can lead to social isolation due to the individual's beliefs and behaviors.\n5. Treatment for Achenbach's syndrome typically involves a combination of psychotherapy and medication.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by the delusional belief that one's body is infested with parasites.",
      "The delusions associated with Achenbach's syndrome can persist for months or even years.",
      "Individuals with Achenbach's syndrome may engage in repetitive behaviors such as excessive cleaning or grooming.",
      "Achenbach's syndrome can lead to social isolation due to the individual's beliefs and behaviors.",
      "Treatment for Achenbach's syndrome typically involves a combination of psychotherapy and medication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by spontaneous bruising, typically on the hands or fingers, not by delusional beliefs of infestation with parasites.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements seem to confuse Achenbach's syndrome with Delusional parasitosis, which is the condition where individuals have a delusional belief that they are infested with parasites. Achenbach's syndrome, also known as paroxysmal hand hematoma, does not involve delusions and is a completely different condition. Therefore, the statements about delusions and their consequences are not applicable to Achenbach's syndrome. The treatment for Achenbach's syndrome is also not well-defined as it is for Delusional parasitosis, which may involve psychotherapy and medication.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "The algorithm used for the detection of long repeat expansions is the Repeat Expansion Detection (RED) method. This method is specifically designed to detect and quantify the abundance of repetitive DNA elements, such as microsatellites and minisatellites, in a given DNA sequence. The RED method is widely used in genetics and genomics research to identify and characterize repeat expansions associated with various neurological disorders, including Huntington's disease, myotonic dystrophy, and fragile X syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Repeat Expansion Detection (RED) method is used for the detection of long repeat expansions.\n2. The RED method is designed to detect and quantify repetitive DNA elements like microsatellites and minisatellites.\n3. The RED method is widely used in genetics and genomics research.\n4. The RED method helps identify and characterize repeat expansions associated with neurological disorders.\n5. Huntington's disease, myotonic dystrophy, and fragile X syndrome are examples of disorders associated with repeat expansions that can be studied using the RED method.",
    "llama-2-7b-chat-hf_fact": [
      "The Repeat Expansion Detection (RED) method is used for the detection of long repeat expansions.",
      "The RED method is designed to detect and quantify repetitive DNA elements like microsatellites and minisatellites.",
      "The RED method is widely used in genetics and genomics research.",
      "The RED method helps identify and characterize repeat expansions associated with neurological disorders.",
      "Huntington's disease, myotonic dystrophy, and fragile X syndrome are examples of disorders associated with repeat expansions that can be studied using the RED method."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth of several types of brain tumors, including:\n1. Glioblastoma: Neuroligin-3 is overexpressed in a majority of glioblastomas, and its overexpression has been linked to the aggressive nature of these tumors.\n2. Medulloblastoma: Neuroligin-3 is also overexpressed in medulloblastoma, a type of pediatric brain tumor that arises in the cerebellum.\n3. Astrocytoma: Neuroligin-3 has been shown to promote the growth of astrocytic tumors, including glioblastoma and other types of astrocytoma.\n4. Oligodendroglioma: Neuroligin-3 has also been implicated in the development and progression of oligodendrogliomas, a type of brain tumor that arises from the oligodendrocyte lineage.\nOverall, neuroligin-3 appears to play a role in the development and progression of several types of brain tumors, and its inhibition may be a promising therapeutic strategy for treating these tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in a majority of glioblastomas.\n2. The overexpression of neuroligin-3 has been linked to the aggressive nature of glioblastomas.\n3. Neuroligin-3 is overexpressed in medulloblastoma, which is a pediatric brain tumor.\n4. Neuroligin-3 promotes the growth of astrocytic tumors, including glioblastoma and other types of astrocytoma.\n5. Neuroligin-3 has been implicated in the development and progression of oligodendrogliomas.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in a majority of glioblastomas.",
      "The overexpression of neuroligin-3 has been linked to the aggressive nature of glioblastomas.",
      "Neuroligin-3 is overexpressed in medulloblastoma, which is a pediatric brain tumor.",
      "Neuroligin-3 promotes the growth of astrocytic tumors, including glioblastoma and other types of astrocytoma.",
      "Neuroligin-3 has been implicated in the development and progression of oligodendrogliomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been reported to be overexpressed in a majority of glioblastomas, according to scientific studies.\n2. TRUE: The overexpression of neuroligin-3 has been linked to the aggressive nature and increased malignancy of glioblastomas.\n3. UNKNOWN: Without specific information or studies to confirm the overexpression of neuroligin-3 in medulloblastoma, the statement's accuracy cannot be determined.\n4. TRUE: Neuroligin-3 is known to promote the growth of astrocytic tumors, which includes glioblastoma, one of the most common and aggressive types of astrocytoma.\n5. UNKNOWN: The role of neuroligin-3 in the development and progression of oligodendrogliomas would require specific scientific evidence to confirm, and without that information, the statement's accuracy cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "The size of gas vesicles in bacteria can vary, but they are generally around 20-50 nanometers in diameter. However, some gas vesicles can be as small as 10 nanometers or as large as 100 nanometers in diameter.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in bacteria are generally around 20-50 nanometers in diameter.\n2. Some gas vesicles can be as small as 10 nanometers in diameter.\n3. Some gas vesicles can be as large as 100 nanometers in diameter.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in bacteria are generally around 20-50 nanometers in diameter.",
      "Some gas vesicles can be as small as 10 nanometers in diameter.",
      "Some gas vesicles can be as large as 100 nanometers in diameter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles in bacteria are generally around 45-200 nanometers in diameter.\n2. FALSE [correction]: Some gas vesicles can be smaller than the general range, but 10 nanometers is below the typical size reported for bacterial gas vesicles.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of transcriptional regulators that play important roles in various cellular processes, including gene expression, cell signaling, and epigenetic regulation. Here are some examples of BET proteins:\n1. BET1 (Bromodomain-Containing Protein 1): Also known as BRD1, this protein is a key regulator of gene expression and is involved in the development and maintenance of various tissues, including the nervous system, immune system, and cancer.\n2. BET2 (Bromodomain-Containing Protein 2): Similar to BRD1, BET2 is also involved in the regulation of gene expression and is implicated in various cellular processes, including cell proliferation, differentiation, and survival.\n3. BET3 (Bromodomain-Containing Protein 3): This protein is a key regulator of gene expression and is involved in the development and maintenance of various tissues, including the nervous system, immune system, and cancer.\n4. BET4 (Bromodomain-Containing Protein 4): Similar to the other BET proteins, BET4 is involved in the regulation of gene expression and is implicated in various cellular processes, including cell proliferation, differentiation, and survival.\n5. BRD4 (Bromodomain-Containing Protein 4): This protein is a key regulator of gene expression and is involved in the development and maintenance of various tissues, including the nervous system, immune system, and cancer.\n6. BRDT (Bromodomain-Containing Protein Dendritic Cell Transmembrane): This protein is a transmembrane protein that is involved in the regulation of dendritic cell function and the immune response.\n7. BRD7 (Bromodomain-Containing Protein 7): Similar to the other BET proteins, BRD7 is involved in the regulation of gene expression and is implicated in various cellular processes, including cell proliferation, differentiation, and survival.\n8. BRD9 (Bromodomain-Containing Protein 9): This protein is a key regulator of gene",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are a family of transcriptional regulators involved in various cellular processes.\n2. BRD1, also known as BET1, is involved in the development and maintenance of various tissues, including the nervous system and immune system.\n3. BET2 is implicated in cellular processes such as cell proliferation, differentiation, and survival.\n4. BRD4, also referred to as BET4, is a key regulator of gene expression involved in tissue development and maintenance.\n5. BRDT is involved in the regulation of dendritic cell function and the immune response.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are a family of transcriptional regulators involved in various cellular processes.",
      "BRD1, also known as BET1, is involved in the development and maintenance of various tissues, including the nervous system and immune system.",
      "BET2 is implicated in cellular processes such as cell proliferation, differentiation, and survival.",
      "BRD4, also referred to as BET4, is a key regulator of gene expression involved in tissue development and maintenance.",
      "BRDT is involved in the regulation of dendritic cell function and the immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: BRD1 is a member of the BET protein family, but it is not known as BET1. BET proteins are typically referred to by their specific names (e.g., BRD2, BRD3, BRD4, and BRDT).\n3. UNKNOWN (The statement is vague because it does not specify which BET protein is being referred to as \"BET2.\" If it refers to BRD2, the statement could be considered true, as BRD2 is involved in cell cycle progression and transcription regulation. However, without clear identification, the accuracy of the statement cannot be determined.)\n4. FALSE [correction]: BRD4 is a member of the BET protein family, but it is not referred to as BET4. BRD4 is indeed a key regulator of gene expression involved in various processes, including tissue development and maintenance.\n5. FALSE [correction]: BRDT is a BET protein that is primarily involved in spermatogenesis and is expressed in the testis, not in the regulation of dendritic cell function and the immune response.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for the prediction of protein subcellular localization using deep learning is the \"DeepLoc\" algorithm. DeepLoc is a deep learning-based method that uses a convolutional neural network (CNN) to predict the subcellular localization of a protein based on its amino acid sequence. It was developed by the Bioinformatics and Computational Biology Group at the University of Cambridge and has been shown to be highly accurate in predicting protein localization in various organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" algorithm is developed for the prediction of protein subcellular localization using deep learning.\n2. DeepLoc uses a convolutional neural network (CNN) for prediction.\n3. The algorithm predicts the subcellular localization of a protein based on its amino acid sequence.\n4. The Bioinformatics and Computational Biology Group at the University of Cambridge developed DeepLoc.\n5. DeepLoc has been shown to be highly accurate in predicting protein localization in various organisms.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" algorithm is developed for the prediction of protein subcellular localization using deep learning.",
      "DeepLoc uses a convolutional neural network (CNN) for prediction.",
      "The algorithm predicts the subcellular localization of a protein based on its amino acid sequence.",
      "The Bioinformatics and Computational Biology Group at the University of Cambridge developed DeepLoc.",
      "DeepLoc has been shown to be highly accurate in predicting protein localization in various organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Bioinformatics and Computational Biology Group at the University of Copenhagen developed DeepLoc.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "I apologize, but there is no such term as \"MULTOVL\". It is possible that you may have misspelled the term or that it is a term that is not widely used or recognized. Can you please provide more context or information about where you encountered this term?",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for assessing the effectiveness of metformin treatment in patients with type 2 diabetes. Studies have shown that GDF15 levels are associated with insulin sensitivity and glucose metabolism, and may be useful in monitoring the response to metformin therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Growth Differentiation Factor 15 (GDF15) is identified as a potential biomarker for metformin treatment.\n2. GDF15 levels are associated with insulin sensitivity and glucose metabolism.\n3. GDF15 may be useful in monitoring the response to metformin therapy in patients with type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Growth Differentiation Factor 15 (GDF15) is identified as a potential biomarker for metformin treatment.",
      "GDF15 levels are associated with insulin sensitivity and glucose metabolism.",
      "GDF15 may be useful in monitoring the response to metformin therapy in patients with type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "No, recursive splicing is not necessarily more common in short introns. It can occur in both short and long introns.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a genome editing method that is used to identify specific locations in the genome where a particular DNA sequence is present. It is a technique that combines the CRISPR/Cas9 system with a DNA sequencing method to identify the location of a specific DNA sequence in the genome.\nThe TALE-iD method works by using a TALE (transcription activator-like effector) protein as a guide to find the target DNA sequence. The TALE protein is engineered to recognize a specific DNA sequence, and when it finds a match, it triggers the Cas9 enzyme to cut the DNA at that location. The cut DNA is then sequenced using a DNA sequencing method, such as next-generation sequencing (NGS), to determine the location of the target DNA sequence.\nThe TALE-iD method is useful for identifying specific genetic variations that are associated with certain diseases or traits, and it can be used to study the function of specific genes in a variety of organisms, including humans. It is also being used to develop new gene therapies and to improve our understanding of the genetic basis of complex diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is a genome editing method used to identify specific locations in the genome where a particular DNA sequence is present.\n2. The TALE-iD method combines the CRISPR/Cas9 system with a DNA sequencing method.\n3. TALE (transcription activator-like effector) proteins are engineered to recognize specific DNA sequences in the TALE-iD method.\n4. The Cas9 enzyme cuts the DNA at the location identified by the TALE protein in the TALE-iD method.\n5. The TALE-iD method can be used to study the function of specific genes in a variety of organisms, including humans.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is a genome editing method used to identify specific locations in the genome where a particular DNA sequence is present.",
      "The TALE-iD method combines the CRISPR/Cas9 system with a DNA sequencing method.",
      "TALE (transcription activator-like effector) proteins are engineered to recognize specific DNA sequences in the TALE-iD method.",
      "The Cas9 enzyme cuts the DNA at the location identified by the TALE protein in the TALE-iD method.",
      "The TALE-iD method can be used to study the function of specific genes in a variety of organisms, including humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TALE-iD is not a genome editing method but rather a technique used for identifying the locations of specific DNA sequences within the genome. It does not edit these sequences.\n2. FALSE [correction]: TALE-iD does not combine the CRISPR/Cas9 system with a DNA sequencing method. It is based on TALE (transcription activator-like effector) proteins and does not involve CRISPR/Cas9.\n3. TRUE\n4. FALSE [correction]: In the TALE-iD method, the Cas9 enzyme is not involved. TALE proteins are used for DNA sequence identification, not for cutting DNA.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "CLisp (Common Lisp Image Processing System)",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Saccharomyces cerevisiae, also known as baker's yeast, has undergone a whole genome duplication event in its evolutionary history. This event is believed to have occurred around 1,000-2,000 million years ago, and it resulted in the duplication of approximately 1,000 genes. These duplicated genes are known as \"ancient duplications\" and they are thought to have played a significant role in the evolution of the modern yeast genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae is also known as baker's yeast.\n2. Saccharomyces cerevisiae has experienced a whole genome duplication event in its evolutionary history.\n3. The whole genome duplication event in Saccharomyces cerevisiae is believed to have occurred around 1,000-2,000 million years ago.\n4. The whole genome duplication event resulted in the duplication of approximately 1,000 genes in Saccharomyces cerevisiae.\n5. The duplicated genes from the event are referred to as \"ancient duplications\".",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae is also known as baker's yeast.",
      "Saccharomyces cerevisiae has experienced a whole genome duplication event in its evolutionary history.",
      "The whole genome duplication event in Saccharomyces cerevisiae is believed to have occurred around 1,000-2,000 million years ago.",
      "The whole genome duplication event resulted in the duplication of approximately 1,000 genes in Saccharomyces cerevisiae.",
      "The duplicated genes from the event are referred to as \"ancient duplications\"."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The whole genome duplication event in Saccharomyces cerevisiae is believed to have occurred around 100-150 million years ago.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Esrrb is a transcription factor that binds to specific DNA sequences in the promoter regions of target genes, thereby regulating their expression. Some of the complexes that Esrrb binds to include:\n1. Coactivator complexes: Esrrb can interact with coactivator proteins like p300 and CBP (CREB-binding protein), which enhance the transcriptional activity of Esrrb.\n2. Corepressor complexes: Esrrb can also interact with corepressor proteins like N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors), which can repress the transcriptional activity of Esrrb.\n3. Chromatin-modifying complexes: Esrrb can also interact with chromatin-modifying complexes like histone acetyltransferases (HATs) and histone deacetylases (HDACs), which can alter the chromatin structure and accessibility to transcription factors like Esrrb.\n4. Transcriptional coactivators: Esrrb can also interact with transcriptional coactivators like TIF-1 (thyroid hormone interacting factor 1) and TCF-1 (transcription factor 1), which can enhance the transcriptional activity of Esrrb.\n5. Transcriptional repressors: Esrrb can also interact with transcriptional repressors like mSin3A (mouse sin3A) and histone deacetylases (HDACs), which can repress the transcriptional activity of Esrrb.\nThese complexes play important roles in regulating the expression of target genes involved in various cellular processes, including cell growth, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. Esrrb is a transcription factor that binds to specific DNA sequences in the promoter regions of target genes.\n2. Esrrb can interact with coactivator proteins like p300 and CBP (CREB-binding protein).\n3. Esrrb can interact with corepressor proteins like N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors).\n4. Esrrb can interact with chromatin-modifying complexes like histone acetyltransferases (HATs) and histone deacetylases (HDACs).\n5. Esrrb can interact with transcriptional coactivators like TIF-1 (thyroid hormone interacting factor 1) and TCF-1 (transcription factor 1).",
    "llama-2-7b-chat-hf_fact": [
      "Esrrb is a transcription factor that binds to specific DNA sequences in the promoter regions of target genes.",
      "Esrrb can interact with coactivator proteins like p300 and CBP (CREB-binding protein).",
      "Esrrb can interact with corepressor proteins like N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors).",
      "Esrrb can interact with chromatin-modifying complexes like histone acetyltransferases (HATs) and histone deacetylases (HDACs).",
      "Esrrb can interact with transcriptional coactivators like TIF-1 (thyroid hormone interacting factor 1) and TCF-1 (transcription factor 1)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: TIF-1 and TCF-1 are not commonly known as transcriptional coactivators associated with Esrrb. TIF-1 refers to TRIM24 (tripartite motif-containing 24), a different protein that can act as a transcriptional regulator, and TCF-1 generally refers to TCF7, which is part of the Wnt signaling pathway and not directly related to Esrrb's function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a gene that provides instructions for making a protein called zinc finger CCHC-type histone triad-containing protein 17 (ZCCHC17). This protein is involved in the regulation of gene expression, particularly in the development and maintenance of stem cells. It is also involved in the process of cellular differentiation, where it helps to determine the fate of cells and their specific functions. Additionally, ZCCHC17 has been implicated in the development of certain cancers, and it is thought to play a role in the regulation of the immune system.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a gene that provides instructions for making a protein known as zinc finger CCHC-type histone triad-containing protein 17 (ZCCHC17).\n2. The protein ZCCHC17 is involved in the regulation of gene expression.\n3. ZCCHC17 plays a role in the development and maintenance of stem cells.\n4. ZCCHC17 is involved in the process of cellular differentiation.\n5. ZCCHC17 has been implicated in the development of certain cancers and is thought to play a role in the regulation of the immune system.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a gene that provides instructions for making a protein known as zinc finger CCHC-type histone triad-containing protein 17 (ZCCHC17).",
      "The protein ZCCHC17 is involved in the regulation of gene expression.",
      "ZCCHC17 plays a role in the development and maintenance of stem cells.",
      "ZCCHC17 is involved in the process of cellular differentiation.",
      "ZCCHC17 has been implicated in the development of certain cancers and is thought to play a role in the regulation of the immune system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are true as ZCCHC17 is indeed a gene that encodes a protein with the described name, and such proteins are often involved in the regulation of gene expression. However, without specific scientific literature or context to confirm the roles of ZCCHC17 in stem cell development and maintenance, cellular differentiation, cancer development, and immune system regulation, the veracity of statements 3, 4, and 5 cannot be determined. These areas are typically subject to ongoing research and would require specific citations to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket in human cells is formed by a protein complex called Nuclear Pore Complex (NPC). The NPC is composed of several proteins, including nucleoporins, which are the main structural components of the pore, and other proteins that regulate the transport of molecules across the nuclear membrane.",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore basket in human cells is formed by a protein complex known as the Nuclear Pore Complex (NPC).\n2. Nucleoporins are the main structural components of the Nuclear Pore Complex.\n3. The Nuclear Pore Complex includes proteins that regulate the transport of molecules across the nuclear membrane.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore basket in human cells is formed by a protein complex known as the Nuclear Pore Complex (NPC).",
      "Nucleoporins are the main structural components of the Nuclear Pore Complex.",
      "The Nuclear Pore Complex includes proteins that regulate the transport of molecules across the nuclear membrane."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a topoisomerase inhibitor, but it specifically targets bacterial type II topoisomerases, topoisomerase IV, and DNA gyrase (topoisomerase II), not human topoisomerase II.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas Student Portal (SPW) is a web-based platform designed to provide students with a personalized and streamlined learning experience. It is a part of the Canvas learning management system (LMS) and offers a range of features and tools to help students manage their coursework, communicate with instructors, and access course materials.\nSome of the key features of Canvas SPW include:\n1. Course Access: Students can access their courses and course materials, including assignments, quizzes, and discussions, through the SPW portal.\n2. Calendar: The SPW calendar provides students with a centralized location to view and manage their course schedules, deadlines, and important dates.\n3. To-Do List: The To-Do List feature helps students keep track of their assignments, deadlines, and tasks by providing a personalized list of tasks that need to be completed.\n4. Messaging: Students can communicate with their instructors and classmates through the SPW messaging system, which allows for real-time communication and collaboration.\n5. Announcements: Instructors can post important announcements and updates to the SPW portal, which students can access at any time.\n6. Resources: The SPW portal provides students with access to course resources, including readings, videos, and other materials, which can be accessed from any device with an internet connection.\n7. Progress Tracking: The SPW portal allows students to track their progress in their courses, including grades, assignments, and quizzes.\n8. Personalized Learning: The SPW portal provides students with a personalized learning experience, tailored to their individual needs and learning style.\n9. Mobile Accessibility: The SPW portal is accessible from any device with an internet connection, making it easy for students to access their courses and course materials on the go.\n10. Integration with Other Canvas Tools: The SPW portal integrates with other Canvas tools, such as the Canvas mobile app, allowing students to access their courses and course materials from any device.\nOverall, the Canvas SPW portal is designed to provide students with a user-friendly and personalized learning experience that helps them stay organized, engaged, and on track with their coursework.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas Student Portal (SPW) is a web-based platform that is part of the Canvas learning management system (LMS).\n2. Canvas SPW allows students to access their courses and course materials, including assignments, quizzes, and discussions.\n3. The SPW portal includes a calendar feature for students to view and manage their course schedules and important dates.\n4. Students can communicate with instructors and classmates through the SPW messaging system.\n5. The SPW portal is accessible from any device with an internet connection.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas Student Portal (SPW) is a web-based platform that is part of the Canvas learning management system (LMS).",
      "Canvas SPW allows students to access their courses and course materials, including assignments, quizzes, and discussions.",
      "The SPW portal includes a calendar feature for students to view and manage their course schedules and important dates.",
      "Students can communicate with instructors and classmates through the SPW messaging system.",
      "The SPW portal is accessible from any device with an internet connection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The term \"Canvas Student Portal (SPW)\" is not a standard term associated with the Canvas learning management system. The acronym \"SPW\" is not commonly used in reference to Canvas, so the accuracy of this statement cannot be determined without additional context.\n2. TRUE: Canvas allows students to access their courses and course materials, including assignments, quizzes, and discussions.\n3. TRUE: Canvas includes a calendar feature that allows students to view and manage their course schedules and important dates.\n4. TRUE: Students can communicate with instructors and classmates through the Canvas messaging system, often referred to as \"Inbox\" or \"Conversations.\"\n5. TRUE: The Canvas portal is accessible from any device with an internet connection, as it is a web-based platform.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING agonists are a class of drugs that activate the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in the immune system's response to viral infections. Here are some examples of STING agonists:\n1. Cyclic dinucleotides (CDNs): CDNs are small molecules that activate the STING pathway by binding to the STING protein. Examples of CDNs include cGAMP (6-cyano-5-acetyl-2-oxo-4-trifluoromethyl-imidazoline) and CPPD (cytidine-phosphate-phosphodiamidate).\n2. STING agonist peptides: These are small peptides that mimic the natural ligands of the STING protein and activate the pathway. Examples include peptides derived from the herpes simplex virus protein ICP0 and the HIV protein gp41.\n3. Small molecule agonists: There are several small molecules that have been identified as STING agonists, including the compound BX795.\n4. Antisense oligonucleotides: Certain antisense oligonucleotides have been shown to activate the STING pathway by binding to the mRNA of the STING protein and preventing its degradation.\n5. DNA-based STING agonists: Some DNA-based molecules, such as DNA-based cyclic dinucleotides (cCDNs), have been shown to activate the STING pathway.\n6. Peptide-conjugated antibodies: Some peptide-conjugated antibodies have been developed as STING agonists, including the antibody-peptide conjugate BMS-986177.\n7. Small molecule-conjugated antibodies: Some small molecule-conjugated antibodies have been developed as STING agonists, including the antibody-small molecule conjugate MEDI3039.\n8. Immunoadhesins: Immunoadhesins are protein",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclic dinucleotides (CDNs) are a class of STING agonists that activate the STING pathway by binding to the STING protein.\n2. STING agonist peptides are small peptides that activate the STING pathway, with examples including peptides derived from the herpes simplex virus protein ICP0 and the HIV protein gp41.\n3. BX795 is identified as a small molecule STING agonist.\n4. Certain antisense oligonucleotides can activate the STING pathway by binding to the mRNA of the STING protein and preventing its degradation.\n5. DNA-based cyclic dinucleotides (cCDNs) are DNA-based molecules that have been shown to activate the STING pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclic dinucleotides (CDNs) are a class of STING agonists that activate the STING pathway by binding to the STING protein.",
      "STING agonist peptides are small peptides that activate the STING pathway, with examples including peptides derived from the herpes simplex virus protein ICP0 and the HIV protein gp41.",
      "BX795 is identified as a small molecule STING agonist.",
      "Certain antisense oligonucleotides can activate the STING pathway by binding to the mRNA of the STING protein and preventing its degradation.",
      "DNA-based cyclic dinucleotides (cCDNs) are DNA-based molecules that have been shown to activate the STING pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: STING agonist peptides are not typically described as small peptides that activate the STING pathway. Instead, STING agonists are usually small molecules or cyclic dinucleotides that activate the pathway by binding to the STING protein directly. Peptides derived from viral proteins like herpes simplex virus ICP0 or HIV gp41 are not commonly referred to as STING agonists.\n3. FALSE [correction]: BX795 is not identified as a STING agonist. It is actually known as an inhibitor of TBK1, which is a kinase that acts downstream of STING in the STING pathway.\n4. FALSE [correction]: Antisense oligonucleotides typically work by binding to mRNA and preventing its translation into protein, not by preventing its degradation. Moreover, they are not known for activating the STING pathway through this mechanism.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Spatially-resolved, Long-read, Isothermal, Combinatorial, Adenine-Guanine-rich, Chromatin-associated Genomics by Electrophoresis) is a genomics technique used to analyze the spatial organization of chromatin structures in cells. It is a combination of several techniques, including:\n1. Spatially-resolved: This refers to the ability to map the location of specific genomic regions within the cell.\n2. Long-read: This refers to the ability to generate reads that are longer than those produced by other sequencing technologies, allowing for a more detailed view of the genome.\n3. Isothermal: This refers to the fact that the technique is performed at a constant temperature, which makes it more efficient and cost-effective.\n4. Combinatorial: This refers to the use of multiple techniques and methods to generate a more comprehensive view of the genome.\n5. Adenine-Guanine-rich: This refers to the specific type of DNA sequence that is targeted by the technique.\n6. Chromatin-associated: This refers to the fact that the technique is used to analyze the genomic regions that are associated with chromatin, which is the complex of DNA and proteins that make up the chromosomes.\nThe technique involves the following steps:\n1. Sample preparation: The sample is prepared by isolating the chromatin from the cells of interest and fragmenting it into smaller pieces.\n2. Electrophoresis: The fragments are then separated based on their size using electrophoresis, which is a technique that uses an electric field to separate charged particles.\n3. Imaging: The separated fragments are then imaged using a technique called capillary electrophoresis, which allows for the visualization of the fragments.\n4. Data analysis: The images are then analyzed using specialized software to generate a map of the chromatin structure.\nSLIC-CAGE provides a detailed view of the spatial organization of chromatin structures in cells, which can be used to understand the regulation of gene expression and the role of chromatin in various cellular processes. It has a wide range of applications, including the study of gene expression, chromatin remodeling, and the development of new drugs.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a genomics technique used to analyze the spatial organization of chromatin structures in cells.\n2. The technique involves isolating chromatin from cells and fragmenting it into smaller pieces for sample preparation.\n3. Electrophoresis is used in SLIC-CAGE to separate chromatin fragments based on their size.\n4. Capillary electrophoresis is used to image the separated fragments in SLIC-CAGE.\n5. SLIC-CAGE includes a data analysis step where specialized software is used to generate a map of the chromatin structure.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a genomics technique used to analyze the spatial organization of chromatin structures in cells.",
      "The technique involves isolating chromatin from cells and fragmenting it into smaller pieces for sample preparation.",
      "Electrophoresis is used in SLIC-CAGE to separate chromatin fragments based on their size.",
      "Capillary electrophoresis is used to image the separated fragments in SLIC-CAGE.",
      "SLIC-CAGE includes a data analysis step where specialized software is used to generate a map of the chromatin structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Electrophoresis is not specifically mentioned as part of the SLIC-CAGE technique. SLIC-CAGE typically involves capturing chromatin interactions and sequencing to identify the genomic regions that are in close spatial proximity.\n4. FALSE [correction]: Capillary electrophoresis is not typically used to image separated fragments in SLIC-CAGE. Instead, sequencing is used to identify the genomic regions after capturing chromatin interactions.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM domain-containing protein 3) is a protein that plays several important roles in the cell, including:\n1. Chromatin remodeling: LEM-3 is involved in the remodeling of chromatin structure, which is important for regulating gene expression.\n2. Transcriptional elongation: LEM-3 helps to facilitate the elongation of RNA polymerase during transcription by removing obstacles and allowing the enzyme to move along the DNA template.\n3. DNA repair: LEM-3 has been shown to be involved in the repair of DNA double-strand breaks, particularly through its interaction with the DNA repair protein, 53BP1.\n4. Cell cycle regulation: LEM-3 has been implicated in the regulation of the cell cycle, particularly in the G1/S checkpoint, where it helps to ensure that cells are ready to enter the S phase of the cell cycle.\n5. Apoptosis: LEM-3 has been shown to play a role in the regulation of programmed cell death (apoptosis), particularly through its interaction with the pro-apoptotic protein, BAX.\n6. Nuclear organization: LEM-3 helps to maintain the proper organization of the nucleus and the chromatin within it, which is important for proper cellular function.\n7. Interaction with other proteins: LEM-3 interacts with a number of other proteins, including transcription factors, chromatin-modifying enzymes, and DNA repair proteins, which highlights its importance in the regulation of various cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the remodeling of chromatin structure.\n2. LEM-3 facilitates the elongation of RNA polymerase during transcription.\n3. LEM-3 is involved in the repair of DNA double-strand breaks and interacts with the DNA repair protein 53BP1.\n4. LEM-3 is implicated in the regulation of the cell cycle, particularly at the G1/S checkpoint.\n5. LEM-3 plays a role in the regulation of programmed cell death (apoptosis) and interacts with the pro-apoptotic protein BAX.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the remodeling of chromatin structure.",
      "LEM-3 facilitates the elongation of RNA polymerase during transcription.",
      "LEM-3 is involved in the repair of DNA double-strand breaks and interacts with the DNA repair protein 53BP1.",
      "LEM-3 is implicated in the regulation of the cell cycle, particularly at the G1/S checkpoint.",
      "LEM-3 plays a role in the regulation of programmed cell death (apoptosis) and interacts with the pro-apoptotic protein BAX."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: LEM-3 is known to be involved in chromatin remodeling, which is a process that affects chromatin structure to regulate access to the genetic material.\n2. FALSE [correction]: There is no direct evidence that LEM-3 facilitates the elongation of RNA polymerase during transcription. LEM-3 is primarily known for its role in DNA repair processes.\n3. TRUE: LEM-3 is indeed involved in the repair of DNA double-strand breaks and has been shown to interact with various DNA repair proteins, including 53BP1.\n4. UNKNOWN: While LEM-3 is involved in DNA repair, which can influence the cell cycle, there is not enough specific information provided to confirm its role at the G1/S checkpoint without additional context.\n5. UNKNOWN: The role of LEM-3 in apoptosis and its interaction with the pro-apoptotic protein BAX is not well-established without further context or specific studies to support this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "TMVar is a database of transcriptome variants, and it has been updated several times since its inception. Here are some of the notable releases of TMVar:\n1. TMVar 1.0: This was the initial release of TMVar, which contained approximately 100,000 transcripts from 12 organisms.\n2. TMVar 2.0: Released in 2012, this version included over 300,000 transcripts from 20 organisms, with improved annotation and filtering capabilities.\n3. TMVar 3.0: Released in 2016, this version included over 500,000 transcripts from 30 organisms, with improved gene prediction and transcript assembly capabilities.\n4. TMVar 4.0: Released in 2020, this version included over 700,000 transcripts from 40 organisms, with improved annotation and filtering capabilities, as well as new features such as transcript-level gene expression data and alternative splicing events.\n5. TMVar 5.0: Released in 2022, this version includes over 1 million transcripts from 50 organisms, with improved annotation and filtering capabilities, as well as new features such as transcript-level gene expression data and alternative splicing events.\nIt's worth noting that TMVar is a dynamic database, and new releases are constantly being updated with new data and improvements.",
    "llama-2-7b-chat-hf_fact_raw": "1. TMVar 1.0 was the initial release of TMVar, which contained approximately 100,000 transcripts from 12 organisms.\n2. TMVar 2.0 was released in 2012 and included over 300,000 transcripts from 20 organisms.\n3. TMVar 3.0 was released in 2016 and included over 500,000 transcripts from 30 organisms.\n4. TMVar 4.0 was released in 2020 and included over 700,000 transcripts from 40 organisms.\n5. TMVar 5.0 was released in 2022 and includes over 1 million transcripts from 50 organisms.",
    "llama-2-7b-chat-hf_fact": [
      "TMVar 1.0 was the initial release of TMVar, which contained approximately 100,000 transcripts from 12 organisms.",
      "TMVar 2.0 was released in 2012 and included over 300,000 transcripts from 20 organisms.",
      "TMVar 3.0 was released in 2016 and included over 500,000 transcripts from 30 organisms.",
      "TMVar 4.0 was released in 2020 and included over 700,000 transcripts from 40 organisms.",
      "TMVar 5.0 was released in 2022 and includes over 1 million transcripts from 50 organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or a reliable source of information about TMVar and its version history, it is not possible to determine the accuracy of these statements. TMVar could refer to a database or software tool related to transcriptomics or genetic variation, but without additional details, the truthfulness of the statements regarding the number of transcripts and organisms in each release cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases of somatic mutations in normal cells, including:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. The database contains RNA sequencing data and clinical information for thousands of cancer samples, including normal tissue samples.\n2. The 1000 Genomes Project: This project aims to catalogue the genetic variation in the human population. The database contains whole-genome sequencing data from thousands of individuals, including normal tissue samples.\n3. The ExAC database: The ExAC database is a collection of whole-genome sequencing data from over 60,000 individuals, including normal tissue samples.\n4. The ClinVar database: ClinVar is a curated database of human genetic variation, including somatic mutations in normal tissues.\n5. The MutationTaster database: MutationTaster is a web-based tool that allows users to search for somatic mutations in their own DNA sequences.\n6. The dbVar database: dbVar is a curated database of genetic variation, including somatic mutations in normal tissues.\n7. The HGMD database: HGMD is a comprehensive database of human genetic variation, including somatic mutations in normal tissues.\n8. The Mutation Research Database: This database contains a collection of somatic mutations identified in various types of cancer, including normal tissues.\n9. The Cancer Cell Line Encyclopedia (CCLE): CCLE is a collection of genomic and transcriptomic data from over 1,000 cancer cell lines, including normal cell lines.\n10. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. The database contains RNA sequencing data and clinical information for thousands of cancer samples, including normal tissue samples.\nIt's worth noting that these databases are constantly being updated and expanded, so the list may not be exhaustive, and new databases",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project aims to catalogue genetic variation in the human population and includes whole-genome sequencing data from thousands of individuals.\n3. The ExAC database contains whole-genome sequencing data from over 60,000 individuals.\n4. ClinVar is a curated database of human genetic variation that includes somatic mutations in normal tissues.\n5. The Cancer Cell Line Encyclopedia (CCLE) contains genomic and transcriptomic data from over 1,000 cancer cell lines, including normal cell lines.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project aims to catalogue genetic variation in the human population and includes whole-genome sequencing data from thousands of individuals.",
      "The ExAC database contains whole-genome sequencing data from over 60,000 individuals.",
      "ClinVar is a curated database of human genetic variation that includes somatic mutations in normal tissues.",
      "The Cancer Cell Line Encyclopedia (CCLE) contains genomic and transcriptomic data from over 1,000 cancer cell lines, including normal cell lines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ExAC database contains exome sequencing data from over 60,000 individuals, not whole-genome sequencing data.\n4. FALSE [correction]: ClinVar is a curated database of human genetic variation that includes information about the relationships among genotype and phenotype, not specifically somatic mutations in normal tissues.\n5. FALSE [correction]: The Cancer Cell Line Encyclopedia (CCLE) contains genomic and transcriptomic data from over 1,000 cancer cell lines, but it does not include normal cell lines as it is focused on cancerous lines.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in JAVA, including:\n1. JGraphT: A Java implementation of the Graph Theory Kit (GTK) library, which provides a wide range of graph algorithms and data structures.\n2. Graphiti: A Java library for graph theory and network analysis, which provides a simple and efficient API for working with graphs.\n3. JGraph: A lightweight Java library for graph processing, which provides a simple API for creating, manipulating, and querying graphs.\n4. GraphStream: A Java library for graph processing, which provides a flexible and efficient API for working with large graphs.\n5. Jena: A Java library for semantic web and ontology processing, which provides a powerful API for working with RDF data and reasoning.\n6. Gephi: A Java library for network data analysis, which provides a user-friendly API for working with large networks.\n7. NetworkX: A Python library for creating, manipulating, and querying networks, which also has a Java interface.\n8. Javalin: A Java library for building web services, which provides a simple and efficient API for working with RESTful web services.\n9. Java-Graph: A Java library for graph theory and network analysis, which provides a simple and efficient API for working with graphs.\n10. JGrapht: A Java library for graph theory and network analysis, which provides a simple and efficient API for working with graphs.\nPlease note that this is not an exhaustive list, and there may be other graph kernel libraries available implemented in JAVA.",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java implementation of the Graph Theory Kit (GTK) library.\n2. Graphiti is a Java library for graph theory and network analysis.\n3. JGraph is a lightweight Java library for graph processing.\n4. GraphStream is a Java library for graph processing that can handle large graphs.\n5. Jena is a Java library for semantic web and ontology processing, with capabilities for RDF data and reasoning.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java implementation of the Graph Theory Kit (GTK) library.",
      "Graphiti is a Java library for graph theory and network analysis.",
      "JGraph is a lightweight Java library for graph processing.",
      "GraphStream is a Java library for graph processing that can handle large graphs.",
      "Jena is a Java library for semantic web and ontology processing, with capabilities for RDF data and reasoning."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: JGraphT is a free Java graph library that provides mathematical graph-theory objects and algorithms.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform is a next-generation diagnostic tool that integrates four advanced technologies to enable fast, sensitive, and multiplexed detection of pathogens:\n1. CRISPR-Cas13: A novel RNA-guided DNA endonuclease that can be programmed to target specific pathogen DNA sequences, leading to the degradation of the target DNA.\n2. Multiplexed PCR: The ability to perform multiple PCR reactions in parallel, allowing for the detection of multiple pathogens in a single reaction.\n3. Nucleic acid sequencing: The ability to determine the sequence of nucleic acids (DNA or RNA) in a sample, which can be used to identify the presence of specific pathogens.\n4. Machine learning: The use of machine learning algorithms to analyze the data generated by the SHERLOCKv2 platform and accurately identify the presence of specific pathogens.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform uses CRISPR-Cas13 technology.\n2. The platform has the capability to perform multiplexed PCR.\n3. It includes nucleic acid sequencing technology for identifying pathogens.\n4. Machine learning algorithms are utilized to analyze data on the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_fact": [
      "The SHERLOCKv2 platform uses CRISPR-Cas13 technology.",
      "The platform has the capability to perform multiplexed PCR.",
      "It includes nucleic acid sequencing technology for identifying pathogens.",
      "Machine learning algorithms are utilized to analyze data on the SHERLOCKv2 platform."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The SHERLOCKv2 platform does not perform multiplexed PCR; it is a CRISPR-based technology for detecting nucleic acid sequences.\n3. FALSE [correction]: The SHERLOCKv2 platform does not include nucleic acid sequencing technology; it uses CRISPR-Cas13 for specific RNA or DNA detection.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a simple algorithm for solving the producer-consumer problem in computer science. It is a synchronization algorithm that ensures mutual exclusion for the producer and consumer processes, allowing only one process to access the shared resource (such as a buffer) at a time.\nThe algorithm works as follows:\n1. The producer process requests access to the buffer by sending a signal to the bartender (a special process that manages access to the buffer).\n2. The bartender checks if the buffer is currently being consumed by another process. If it is, the bartender waits until the consumer process is finished with the buffer.\n3. Once the bartender has obtained the buffer, it grants the producer process access to the buffer for a short time (called a time slice).\n4. During the time slice, the producer process can write data to the buffer.\n5. When the producer process is finished with the buffer, it signals the bartender, which then grants access to the buffer to the next consumer process in line.\n6. Steps 3-5 are repeated until all processes have finished using the buffer.\nThe Bartender algorithm is a simple and efficient solution to the producer-consumer problem, but it has some limitations. For example, it can only handle a fixed number of processes, and it can lead to starvation if the buffer is too small or the processes are highly variable in their usage patterns.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is used for solving the producer-consumer problem in computer science.\n2. It is a synchronization algorithm that ensures mutual exclusion for the producer and consumer processes.\n3. The algorithm allows only one process to access the shared resource at a time.\n4. The Bartender algorithm can only handle a fixed number of processes.\n5. The algorithm can lead to starvation if the buffer is too small or the processes are highly variable in their usage patterns.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is used for solving the producer-consumer problem in computer science.",
      "It is a synchronization algorithm that ensures mutual exclusion for the producer and consumer processes.",
      "The algorithm allows only one process to access the shared resource at a time.",
      "The Bartender algorithm can only handle a fixed number of processes.",
      "The algorithm can lead to starvation if the buffer is too small or the processes are highly variable in their usage patterns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no widely recognized algorithm in computer science known as the \"Bartender algorithm\" for solving the producer-consumer problem. Common algorithms for this problem include the use of semaphores, monitors, or condition variables for synchronization.\n2. UNKNOWN: Since the \"Bartender algorithm\" is not a recognized term, it's unclear whether it would ensure mutual exclusion for producer and consumer processes.\n3. UNKNOWN: Without clear information on the \"Bartender algorithm,\" it cannot be determined if it allows only one process to access the shared resource at a time.\n4. UNKNOWN: There is no information available on the \"Bartender algorithm\" and its capabilities, including whether it can handle a fixed number of processes.\n5. UNKNOWN: Since the \"Bartender algorithm\" is not established, it's not possible to determine if it can lead to starvation under certain conditions. However, in general, starvation can be a problem in producer-consumer scenarios if not properly managed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Some web-based pedigree editors include Pedigree Chart Maker, Family Tree Pedigree, and Pedigree Online.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Chart Maker is a web-based pedigree editor.\n2. Family Tree Pedigree is a web-based pedigree editor.\n3. Pedigree Online is a web-based pedigree editor.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Chart Maker is a web-based pedigree editor.",
      "Family Tree Pedigree is a web-based pedigree editor.",
      "Pedigree Online is a web-based pedigree editor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases for spider-venom toxins, including:\n1. Spider Toxin Database (STD): This database contains information on the structural and functional properties of spider venom toxins, including their chemical structure, pharmacological activities, and evolutionary relationships.\n2. VenomTox: This database provides information on the venomous animals of the world, including spiders, snakes, scorpions, and insects, and their venom toxins. It includes data on the toxin composition, structure, and function, as well as information on the venomous animals' distribution and behavior.\n3. Toxinology: This database contains information on various types of toxins, including spider venom toxins, and their structural and functional properties. It also includes data on the pharmacological activities of these toxins and their potential applications in medicine.\n4. Natural Products Database (NPDB): This database contains information on natural products, including those found in spider venom, and their structural and functional properties. It also includes data on the isolation, characterization, and biological activities of these compounds.\n5. ToxinTeach: This database provides information on toxins from various sources, including spiders, snakes, and insects, and their structural and functional properties. It also includes data on the pharmacological activities of these toxins and their potential applications in medicine.\n6. VenomToxin: This database contains information on the venom toxins of various animals, including spiders, snakes, and scorpions, and their structural and functional properties. It also includes data on the pharmacological activities of these toxins and their potential applications in medicine.\n7. Toxinology Database (TDB): This database contains information on various types of toxins, including spider venom toxins, and their structural and functional properties. It also includes data on the pharmacological activities of these toxins and their potential applications in medicine.\n8. Venomous Animals Database (VAD): This database provides information on the venomous animals of the world, including spiders, snakes, scorpions, and insects, and their venom toxins. It includes data on the toxin composition,",
    "llama-2-7b-chat-hf_fact_raw": "1. The Spider Toxin Database (STD) contains information on the structural and functional properties of spider venom toxins.\n2. VenomTox is a database that provides information on venomous animals, including spiders, and their venom toxins.\n3. Toxinology is a database that includes information on various types of toxins, such as spider venom toxins, and their potential applications in medicine.\n4. The Natural Products Database (NPDB) contains information on natural products, including those found in spider venom.\n5. ToxinTeach is a database that provides information on toxins from various sources, including spiders, and their potential applications in medicine.",
    "llama-2-7b-chat-hf_fact": [
      "The Spider Toxin Database (STD) contains information on the structural and functional properties of spider venom toxins.",
      "VenomTox is a database that provides information on venomous animals, including spiders, and their venom toxins.",
      "Toxinology is a database that includes information on various types of toxins, such as spider venom toxins, and their potential applications in medicine.",
      "The Natural Products Database (NPDB) contains information on natural products, including those found in spider venom.",
      "ToxinTeach is a database that provides information on toxins from various sources, including spiders, and their potential applications in medicine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Natural Products Database (NPDB) does not specifically focus on spider venom but rather includes a wide variety of natural products from different sources.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, Axitinib has been shown to prolong survival in patients with advanced pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through its interaction with F-actin and the protein Capping protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP stands for Microtubule-associated protein.\n2. MLP regulates F-actin dynamics.\n3. MLP interacts with F-actin.\n4. MLP interacts with the protein Capping protein.",
    "llama-2-7b-chat-hf_fact": [
      "MLP stands for Microtubule-associated protein.",
      "MLP regulates F-actin dynamics.",
      "MLP interacts with F-actin.",
      "MLP interacts with the protein Capping protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP often stands for \"Muscle LIM Protein,\" especially in the context of muscle and cardiac biology. However, without additional context, it's unclear if MLP refers to Muscle LIM Protein or another protein, as acronyms can have multiple meanings.\n2. UNKNOWN: Without additional context, it's unclear if MLP refers to Muscle LIM Protein or another protein. If MLP is indeed Muscle LIM Protein, it is involved in the cytoskeletal heart muscle structure and not directly in regulating F-actin dynamics. If MLP refers to something else, the statement's accuracy cannot be determined.\n3. UNKNOWN: Similar to statement 2, without additional context, it's unclear if MLP refers to Muscle LIM Protein or another protein. If MLP is Muscle LIM Protein, it is known to interact with cytoskeletal elements, but its direct interaction with F-actin would need to be confirmed with specific scientific evidence.\n4. UNKNOWN: The interaction between MLP and Capping protein cannot be confirmed without additional context or specific scientific references. If MLP refers to Muscle LIM Protein, the statement would need to be supported by literature specific to that interaction.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "There are approximately 60 pseudokinases in the human kinome.\nIt's worth noting that the number of pseudokinases can vary depending on the source and methodology used to identify them, as well as the specific organism being studied. However, the general consensus is that pseudokinases are a significant proportion of the kinome, and play important roles in cellular signaling and regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are approximately 60 pseudokinases in the human kinome.",
    "llama-2-7b-chat-hf_fact": [
      "There are approximately 60 pseudokinases in the human kinome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein that plays a crucial role in lipid metabolism and is associated with various diseases, including Alzheimer's disease. Here are three examples of apoE mimetics:\n1. ApoE4-mimetic peptides: These are peptides that mimic the structure and function of the apoE4 isoform, which is associated with increased risk of Alzheimer's disease. ApoE4-mimetic peptides have been shown to have neuroprotective effects and may be useful in the treatment of Alzheimer's disease.\n2. ApoE-mimetic small molecules: These are small molecules that mimic the structure and function of apoE, and have been shown to have lipid-lowering and anti-inflammatory effects. Examples of apoE-mimetic small molecules include drugs such as torcetrapib and dalcetrapib, which have been developed for the treatment of dyslipidemia and cardiovascular disease.\n3. ApoE-mimetic nanoparticles: These are nanoparticles that mimic the structure and function of apoE, and have been shown to have anti-inflammatory and neuroprotective effects. ApoE-mimetic nanoparticles have been developed for the treatment of various diseases, including Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoE4-mimetic peptides are designed to mimic the structure and function of the apoE4 isoform.\n2. ApoE4-mimetic peptides may have neuroprotective effects and could be useful in treating Alzheimer's disease.\n3. ApoE-mimetic small molecules like torcetrapib and dalcetrapib have been developed for treating dyslipidemia and cardiovascular disease.\n4. ApoE-mimetic nanoparticles have been shown to have anti-inflammatory and neuroprotective effects.\n5. ApoE-mimetic nanoparticles are being developed for the treatment of diseases such as Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "ApoE4-mimetic peptides are designed to mimic the structure and function of the apoE4 isoform.",
      "ApoE4-mimetic peptides may have neuroprotective effects and could be useful in treating Alzheimer's disease.",
      "ApoE-mimetic small molecules like torcetrapib and dalcetrapib have been developed for treating dyslipidemia and cardiovascular disease.",
      "ApoE-mimetic nanoparticles have been shown to have anti-inflammatory and neuroprotective effects.",
      "ApoE-mimetic nanoparticles are being developed for the treatment of diseases such as Alzheimer's disease and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ApoE4-mimetic peptides are designed to mimic the structure and function of the apoE protein, but not specifically the apoE4 isoform, which is associated with an increased risk of Alzheimer's disease. They are generally intended to mimic the beneficial properties of the apoE2 or apoE3 isoforms.\n2. TRUE\n3. FALSE [correction]: Torcetrapib and dalcetrapib are not ApoE-mimetic small molecules. They are CETP inhibitors that were developed to raise HDL cholesterol and potentially reduce cardiovascular risk, but they are not designed to mimic ApoE.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. There is evidence to suggest that there are sex differences in SAMHD1 activity, which may impact the immune response to viral infections. Here are some of the sex differences in SAMHD1 activity that have been observed:\n1. Lower SAMHD1 activity in females: Studies have shown that females have lower levels of SAMHD1 activity compared to males, which may contribute to the higher susceptibility of females to certain viral infections.\n2. Sex-specific regulation of SAMHD1 expression: The expression of SAMHD1 is regulated by sex-specific factors, with higher levels of SAMHD1 expression observed in males compared to females.\n3. Differential response to viral infection: SAMHD1 activity has been shown to differ between males and females in response to viral infection. For example, females have been shown to have higher levels of SAMHD1 activity in response to HIV infection compared to males.\n4. Role of estrogen: Estrogen has been shown to play a role in regulating SAMHD1 activity, with estrogen levels influencing the activity of this enzyme.\n5. Impact of pregnancy: Pregnancy has been shown to impact SAMHD1 activity, with levels decreasing during pregnancy.\nOverall, these sex differences in SAMHD1 activity may have important implications for the immune response to viral infections and may contribute to the differences in disease susceptibility between males and females.",
    "llama-2-7b-chat-hf_fact_raw": "1. Females have lower levels of SAMHD1 activity compared to males.\n2. The expression of SAMHD1 is regulated by sex-specific factors, with higher levels of expression observed in males.\n3. Females have been shown to have higher levels of SAMHD1 activity in response to HIV infection compared to males.\n4. Estrogen influences the activity of the SAMHD1 enzyme.\n5. SAMHD1 activity levels decrease during pregnancy.",
    "llama-2-7b-chat-hf_fact": [
      "Females have lower levels of SAMHD1 activity compared to males.",
      "The expression of SAMHD1 is regulated by sex-specific factors, with higher levels of expression observed in males.",
      "Females have been shown to have higher levels of SAMHD1 activity in response to HIV infection compared to males.",
      "Estrogen influences the activity of the SAMHD1 enzyme.",
      "SAMHD1 activity levels decrease during pregnancy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Females have higher levels of SAMHD1 activity compared to males.\n2. FALSE [correction]: The expression of SAMHD1 is regulated by sex-specific factors, with higher levels of expression observed in females.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 has been shown to inhibit astrocyte differentiation. RUNX2 is a transcription factor that plays a crucial role in the regulation of cellular differentiation, including the differentiation of astrocytes. Studies have shown that RUNX2 can repress the expression of genes involved in astrocyte differentiation and inhibit the process of astrocyte maturation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 inhibits astrocyte differentiation.\n2. RUNX2 is a transcription factor that regulates cellular differentiation.\n3. RUNX2 can repress the expression of genes involved in astrocyte differentiation.\n4. RUNX2 inhibits the process of astrocyte maturation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 inhibits astrocyte differentiation.",
      "RUNX2 is a transcription factor that regulates cellular differentiation.",
      "RUNX2 can repress the expression of genes involved in astrocyte differentiation.",
      "RUNX2 inhibits the process of astrocyte maturation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RUNX2 promotes astrocyte differentiation.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is performed on the knee joint. Specifically, it is performed on the medial compartment of the knee, which is the inner part of the knee joint. The procedure involves removing a portion of the bone and cartilage in the medial compartment and replacing it with an implant to restore the function of the knee joint.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. The procedure specifically targets the medial compartment of the knee, which is the inner part of the knee joint.\n3. The Cobb-Stainsby excision arthroplasty involves removing a portion of the bone and cartilage in the medial compartment.\n4. An implant is used to replace the removed bone and cartilage in the Cobb-Stainsby excision arthroplasty to restore knee joint function.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "The procedure specifically targets the medial compartment of the knee, which is the inner part of the knee joint.",
      "The Cobb-Stainsby excision arthroplasty involves removing a portion of the bone and cartilage in the medial compartment.",
      "An implant is used to replace the removed bone and cartilage in the Cobb-Stainsby excision arthroplasty to restore knee joint function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the knee joint.\n2. UNKNOWN (The statement is likely false given the correction to statement 1, but without additional context about the procedure being specifically for the hip, the details about targeting a specific compartment are not applicable.)\n3. UNKNOWN (Given the correction to statement 1, this statement is about the knee joint and is likely false as the procedure is for the hip joint. However, without further context, the specifics of the procedure cannot be confirmed.)\n4. UNKNOWN (Since the procedure is for the hip joint and not the knee joint, the details about an implant replacing bone and cartilage cannot be confirmed without additional context.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including breast cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT).\n2. GRHL2 over-expression has been observed in various cell types.\n3. Breast cancer cells are among the cell types where GRHL2 over-expression can lead to EMT.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT).",
      "GRHL2 over-expression has been observed in various cell types.",
      "Breast cancer cells are among the cell types where GRHL2 over-expression can lead to EMT."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 typically suppresses epithelial-to-mesenchymal transition (EMT).\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Several T-UCRs have been implicated in lung cancer, including:\n1. T-UCR-1: This T-UCR is located on chromosome 3p21 and has been shown to be overexpressed in several types of lung cancer, including non-small cell lung cancer (NSCLC) and adenocarcinoma. Overexpression of T-UCR-1 has been associated with poor prognosis in these cancers.\n2. T-UCR-2: This T-UCR is located on chromosome 6p21 and has been implicated in the development and progression of lung cancer, particularly in adenocarcinoma.\n3. T-UCR-3: This T-UCR is located on chromosome 11q13 and has been shown to be overexpressed in NSCLC. Overexpression of T-UCR-3 has been associated with poor prognosis in these cancers.\n4. T-UCR-4: This T-UCR is located on chromosome 17p13 and has been implicated in the development and progression of lung cancer, particularly in squamous cell carcinoma.\n5. T-UCR-5: This T-UCR is located on chromosome 1q21 and has been shown to be overexpressed in NSCLC. Overexpression of T-UCR-5 has been associated with poor prognosis in these cancers.\n6. T-UCR-6: This T-UCR is located on chromosome 6q25 and has been implicated in the development and progression of lung cancer, particularly in adenocarcinoma.\n7. T-UCR-7: This T-UCR is located on chromosome 15q21 and has been shown to be overexpressed in NSCLC. Overexpression of T-UCR-7 has been associated with poor prognosis in these cancers.\n8. T-UCR-8: This T-UCR is located on chromosome 16q12 and has been implicated in the development and progression of lung cancer, particularly in adenocarcinoma.\n9. T-UCR-9: This T-UCR is located on chromosome 17p",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCR-1 is located on chromosome 3p21 and is overexpressed in several types of lung cancer, including non-small cell lung cancer (NSCLC) and adenocarcinoma.\n2. T-UCR-2 is located on chromosome 6p21 and has been implicated in the development and progression of lung cancer, particularly in adenocarcinoma.\n3. T-UCR-3 is located on chromosome 11q13 and is overexpressed in non-small cell lung cancer (NSCLC).\n4. T-UCR-4 is located on chromosome 17p13 and has been implicated in the development and progression of lung cancer, particularly in squamous cell carcinoma.\n5. T-UCR-5 is located on chromosome 1q21 and is overexpressed in non-small cell lung cancer (NSCLC).",
    "llama-2-7b-chat-hf_fact": [
      "T-UCR-1 is located on chromosome 3p21 and is overexpressed in several types of lung cancer, including non-small cell lung cancer (NSCLC) and adenocarcinoma.",
      "T-UCR-2 is located on chromosome 6p21 and has been implicated in the development and progression of lung cancer, particularly in adenocarcinoma.",
      "T-UCR-3 is located on chromosome 11q13 and is overexpressed in non-small cell lung cancer (NSCLC).",
      "T-UCR-4 is located on chromosome 17p13 and has been implicated in the development and progression of lung cancer, particularly in squamous cell carcinoma.",
      "T-UCR-5 is located on chromosome 1q21 and is overexpressed in non-small cell lung cancer (NSCLC)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and pertain to the field of genetics and cancer research. Without access to the latest scientific literature or databases that contain information on the chromosomal locations and expressions of these hypothetical T-UCR genes in lung cancer, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, research has shown that GPR151 is involved in the regulation of various physiological processes, including:\n1. Inflammation: GPR151 has been shown to play a role in the regulation of inflammatory responses, including the activation of immune cells and the production of pro-inflammatory cytokines.\n2. Pain: GPR151 has been implicated in the regulation of pain perception, with studies suggesting that it may play a role in the modulation of pain sensitivity.\n3. Neuroprotection: GPR151 has been shown to protect against neurodegeneration in various animal models of neurological disorders, including Alzheimer's disease and Parkinson's disease.\n4. Cardiovascular health: GPR151 has been implicated in the regulation of cardiovascular function, including the regulation of blood pressure and the modulation of vascular tone.\n5. Metabolism: GPR151 has been shown to play a role in the regulation of glucose and lipid metabolism, with studies suggesting that it may be involved in the development of insulin resistance and metabolic disorders.\nOverall, while the exact function of GPR151 is still not fully understood, research suggests that it plays a complex and multifaceted role in the regulation of various physiological processes, and may be a promising target for the development of new therapeutic strategies for a range of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan receptor without a well-defined endogenous ligand or clear physiological function.\n2. GPR151 is involved in the regulation of inflammatory responses.\n3. GPR151 has been implicated in the regulation of pain perception.\n4. GPR151 has been shown to protect against neurodegeneration in animal models of neurological disorders.\n5. GPR151 plays a role in the regulation of glucose and lipid metabolism.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan receptor without a well-defined endogenous ligand or clear physiological function.",
      "GPR151 is involved in the regulation of inflammatory responses.",
      "GPR151 has been implicated in the regulation of pain perception.",
      "GPR151 has been shown to protect against neurodegeneration in animal models of neurological disorders.",
      "GPR151 plays a role in the regulation of glucose and lipid metabolism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely accepted evidence that GPR151 is involved in the regulation of inflammatory responses. It is an orphan receptor, which means its physiological functions are not well-defined.\n3. UNKNOWN: Without specific context or references, it's unclear whether GPR151 has been implicated in the regulation of pain perception.\n4. UNKNOWN: Similarly, without specific context or references, it's unclear whether GPR151 has been shown to protect against neurodegeneration in animal models of neurological disorders.\n5. UNKNOWN: There is no clear evidence provided to support the statement that GPR151 plays a role in the regulation of glucose and lipid metabolism. As an orphan receptor, its roles are not well-defined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone intradermal quadrivalent vaccine contains the following attenuated live viruses:\n* Influenza A (H1N1) virus\n* Influenza A (H3N2) virus\n* Influenza B (Victoria lineage) virus\n* Influenza B (Yamagata lineage) virus.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene contains several variants that have been genetically associated with Systemic Lupus Erythematosus (SLE), including:\n* TNFR2 gene mutations in the 3' untranslated region (UTR)\nIt's worth noting that the genetic associations with SLE are complex and multiple genetic variants contribute to the risk of developing the disease. Additionally, the TNFR2 gene is just one of many genes that have been implicated in the development of SLE, and the genetic architecture of the disease is not yet fully understood.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants in the TNFR2 gene have been genetically associated with Systemic Lupus Erythematosus (SLE).\n2. Mutations in the 3' untranslated region (UTR) of the TNFR2 gene are associated with SLE.\n3. Multiple genetic variants contribute to the risk of developing SLE.\n4. The TNFR2 gene is one of many genes implicated in the development of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "Variants in the TNFR2 gene have been genetically associated with Systemic Lupus Erythematosus (SLE).",
      "Mutations in the 3' untranslated region (UTR) of the TNFR2 gene are associated with SLE.",
      "Multiple genetic variants contribute to the risk of developing SLE.",
      "The TNFR2 gene is one of many genes implicated in the development of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Currently, there is no FDA-approved vaccine for peanut allergy. Researchers are working on developing a peanut allergy vaccine, but it is still in the experimental stage and has not yet been proven to be effective in clinical trials.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no FDA-approved vaccine for peanut allergy as of the knowledge cutoff date.\n2. Researchers are working on developing a peanut allergy vaccine.\n3. The peanut allergy vaccine is still in the experimental stage.\n4. The peanut allergy vaccine has not yet been proven to be effective in clinical trials.",
    "llama-2-7b-chat-hf_fact": [
      "There is no FDA-approved vaccine for peanut allergy as of the knowledge cutoff date.",
      "Researchers are working on developing a peanut allergy vaccine.",
      "The peanut allergy vaccine is still in the experimental stage.",
      "The peanut allergy vaccine has not yet been proven to be effective in clinical trials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome, which is unusual because most genes in mammals are located on autosomal chromosomes (chromosomes other than the sex chromosomes).",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. Most genes in mammals are located on autosomal chromosomes.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "Most genes in mammals are located on autosomal chromosomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the use of a modified version of the methidiumpropyl (Mpe) reagent to label and capture DNA fragments in a targeted sequencing reaction. The Mpe reagent reacts with the phosphate groups on the 5' end of the DNA fragment, allowing for the selective capture of the fragment and its subsequent sequencing.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPE-seq method uses a modified version of the methidiumpropyl (Mpe) reagent.\n2. The Mpe reagent is used to label and capture DNA fragments in a targeted sequencing reaction.\n3. The Mpe reagent reacts with the phosphate groups on the 5' end of the DNA fragment.\n4. The reaction with the phosphate groups allows for the selective capture of the DNA fragment.\n5. After capture, the DNA fragment can be sequenced.",
    "llama-2-7b-chat-hf_fact": [
      "MPE-seq method uses a modified version of the methidiumpropyl (Mpe) reagent.",
      "The Mpe reagent is used to label and capture DNA fragments in a targeted sequencing reaction.",
      "The Mpe reagent reacts with the phosphate groups on the 5' end of the DNA fragment.",
      "The reaction with the phosphate groups allows for the selective capture of the DNA fragment.",
      "After capture, the DNA fragment can be sequenced."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The Mpe reagent reacts with the phosphate groups on the 3' end of the DNA fragment.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR is a fictional language, so it has not been implemented in any programming language. GWAR is a parody of science fiction and fantasy languages, created by the band GWAR as a part of their stage show and mythology. It is not a real language and does not have a programming language equivalent.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAR is a fictional language.\n2. GWAR was created by the band GWAR.\n3. GWAR is part of the band's stage show and mythology.\n4. GWAR is a parody of science fiction and fantasy languages.\n5. GWAR has not been implemented in any programming language.",
    "llama-2-7b-chat-hf_fact": [
      "GWAR is a fictional language.",
      "GWAR was created by the band GWAR.",
      "GWAR is part of the band's stage show and mythology.",
      "GWAR is a parody of science fiction and fantasy languages.",
      "GWAR has not been implemented in any programming language."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GWAR is not a language; it is a rock band known for its elaborate science fiction-themed costumes and stage performances.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "There is currently no evidence to suggest that xaliproden (also known as masitinib) improves the prognosis of amyotrophic lateral sclerosis (ALS). While some studies have suggested that masitinib may slow the progression of ALS, the overall evidence is mixed and more research is needed to fully understand its effectiveness. It is important to note that ALS is a complex and progressive disease, and there is currently no cure.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no evidence that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).\n2. Some studies have suggested that masitinib may slow the progression of ALS.\n3. The overall evidence on the effectiveness of masitinib for ALS is mixed.\n4. More research is needed to fully understand the effectiveness of masitinib for ALS.\n5. There is currently no cure for amyotrophic lateral sclerosis (ALS).",
    "llama-2-7b-chat-hf_fact": [
      "There is no evidence that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).",
      "Some studies have suggested that masitinib may slow the progression of ALS.",
      "The overall evidence on the effectiveness of masitinib for ALS is mixed.",
      "More research is needed to fully understand the effectiveness of masitinib for ALS.",
      "There is currently no cure for amyotrophic lateral sclerosis (ALS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The transgenes are inserted into chromosome 1 in the LiPS-A3S line.",
    "llama-2-7b-chat-hf_fact_raw": "1. Transgenes are inserted into chromosome 1 in the LiPS-A3S line.",
    "llama-2-7b-chat-hf_fact": [
      "Transgenes are inserted into chromosome 1 in the LiPS-A3S line."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout additional context or specific information about the LiPS-A3S line and the procedures used to create it, it is not possible to determine the accuracy of the statement regarding the insertion of transgenes into chromosome 1.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several tools and software that use deep learning for predicting drug synergy, including:\n1. DeepSynth: This is a deep learning-based tool for predicting drug synergy and adverse drug interactions. It uses a combination of molecular descriptors and machine learning algorithms to predict the interactions between drugs.\n2. Drug2Drug: This tool uses a deep learning model to predict drug-drug interactions, including synergy and adverse interactions. It takes into account both molecular descriptors and clinical data to make predictions.\n3. DrugCombo: This tool uses a combination of machine learning algorithms and molecular descriptors to predict drug synergy and adverse interactions. It also includes a feature called \"DrugComboScore\" which predicts the likelihood of synergy or adverse interactions based on the molecular properties of the drugs.\n4. Synergizer: This tool uses a deep learning model to predict drug synergy and adverse interactions. It takes into account both molecular descriptors and clinical data to make predictions.\n5. DrugDiscovery: This tool uses a combination of machine learning algorithms and molecular descriptors to predict drug-drug interactions, including synergy and adverse interactions. It also includes a feature called \"DrugDiscoveryScore\" which predicts the likelihood of synergy or adverse interactions based on the molecular properties of the drugs.\n6. DeepDrug: This tool uses a deep learning model to predict drug-drug interactions, including synergy and adverse interactions. It takes into account both molecular descriptors and clinical data to make predictions.\n7. DrugInteractome: This tool uses a combination of machine learning algorithms and molecular descriptors to predict drug-drug interactions, including synergy and adverse interactions. It also includes a feature called \"DrugInteractomeScore\" which predicts the likelihood of synergy or adverse interactions based on the molecular properties of the drugs.\n8. DrugPredictor: This tool uses a combination of machine learning algorithms and molecular descriptors to predict drug-drug interactions, including synergy and adverse interactions. It also includes a feature called \"DrugPredictorScore\" which predicts the likelihood of synergy or adverse interactions based on the molecular",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynth is a tool that predicts drug synergy and adverse drug interactions using deep learning.\n2. Drug2Drug is a deep learning tool designed to predict drug-drug interactions, including synergy and adverse interactions, utilizing molecular descriptors and clinical data.\n3. DrugCombo is a tool that predicts drug synergy and adverse interactions, featuring a \"DrugComboScore\" for assessing the likelihood of these interactions.\n4. Synergizer is a deep learning-based tool that predicts drug synergy and adverse interactions, considering molecular descriptors and clinical data.\n5. DeepDrug is a deep learning model used to predict drug-drug interactions, including synergy and adverse interactions, by analyzing molecular descriptors and clinical data.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynth is a tool that predicts drug synergy and adverse drug interactions using deep learning.",
      "Drug2Drug is a deep learning tool designed to predict drug-drug interactions, including synergy and adverse interactions, utilizing molecular descriptors and clinical data.",
      "DrugCombo is a tool that predicts drug synergy and adverse interactions, featuring a \"DrugComboScore\" for assessing the likelihood of these interactions.",
      "Synergizer is a deep learning-based tool that predicts drug synergy and adverse interactions, considering molecular descriptors and clinical data.",
      "DeepDrug is a deep learning model used to predict drug-drug interactions, including synergy and adverse interactions, by analyzing molecular descriptors and clinical data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are about specific tools and models used for predicting drug interactions and synergy. Without specific information about these tools or models, it is not possible to verify the accuracy of the statements. They could be true if such tools exist and have the described functionalities, but without additional context or sources, their truth cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing Genome-Wide Association Studies (GWAS). Some of the popular options include:\n1. AWS GLAM: Amazon Web Services (AWS) provides a cloud-based platform called GLAM (Genomics, Life Sciences, and Analytics on the Medical Cloud) for analyzing and interpreting GWAS data.\n2. Google Genomics: Google Cloud Platform offers a suite of tools and services for genomics analysis, including GWAS analysis.\n3. Microsoft Azure Genomics: Microsoft Azure provides a range of genomics tools and services, including GWAS analysis, through its Azure Genomics platform.\n4. Cloud Genomics: Cloud Genomics is a cloud-based platform developed by the University of California, San Diego, for analyzing and interpreting GWAS data.\n5. DREAM: DREAM (Dialogue for Reverse Engineering Assessments and Methods) is a cloud-based platform developed by the University of California, San Diego, for analyzing and interpreting GWAS data.\n6. OpenGWAS: OpenGWAS is an open-source, cloud-based platform for GWAS analysis.\n7. GWAS Cloud: GWAS Cloud is a cloud-based platform developed by the University of California, San Diego, for analyzing and interpreting GWAS data.\n8. Cloud-GWAS: Cloud-GWAS is a cloud-based platform developed by the University of California, San Diego, for analyzing and interpreting GWAS data.\nPlease note that this is not an exhaustive list and there may be other cloud-based platforms available for GWAS analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. AWS GLAM is a cloud-based platform provided by Amazon Web Services for analyzing and interpreting GWAS data.\n2. Google Cloud Platform offers tools and services for genomics analysis, including GWAS analysis.\n3. Microsoft Azure provides genomics tools and services, including GWAS analysis, through its Azure Genomics platform.\n4. The University of California, San Diego has developed Cloud Genomics, a cloud-based platform for analyzing and interpreting GWAS data.\n5. OpenGWAS is an open-source, cloud-based platform for GWAS analysis.",
    "llama-2-7b-chat-hf_fact": [
      "AWS GLAM is a cloud-based platform provided by Amazon Web Services for analyzing and interpreting GWAS data.",
      "Google Cloud Platform offers tools and services for genomics analysis, including GWAS analysis.",
      "Microsoft Azure provides genomics tools and services, including GWAS analysis, through its Azure Genomics platform.",
      "The University of California, San Diego has developed Cloud Genomics, a cloud-based platform for analyzing and interpreting GWAS data.",
      "OpenGWAS is an open-source, cloud-based platform for GWAS analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AWS GLAM is not a known service provided by Amazon Web Services for analyzing and interpreting GWAS data. AWS does offer various services that could be used for genomics analysis, but GLAM is not a recognized acronym for any of their services.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Yes, CMB305 is a drug that is being investigated for the treatment of sarcomas, which are a type of cancer that develops in the soft tissue of the body, such as muscles, tendons, and connective tissue. CMB305 is a small molecule inhibitor of the protein MDM2, which is overexpressed in many types of cancer, including sarcomas. By inhibiting the activity of MDM2, CMB305 can help to restore the activity of the tumor suppressor protein p53, which is often mutated or inactivated in sarcomas. This can lead to the inhibition of sarcoma cell growth and the induction of cell death. CMB305 is currently being studied in clinical trials as a potential treatment for various types of sarcomas, including soft tissue sarcoma and osteosarcoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is being investigated for the treatment of sarcomas.\n2. Sarcomas are a type of cancer that develops in the soft tissue of the body.\n3. CMB305 is a small molecule inhibitor of the protein MDM2.\n4. MDM2 is overexpressed in many types of cancer, including sarcomas.\n5. CMB305 is currently being studied in clinical trials as a potential treatment for various types of sarcomas, including soft tissue sarcoma and osteosarcoma.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is being investigated for the treatment of sarcomas.",
      "Sarcomas are a type of cancer that develops in the soft tissue of the body.",
      "CMB305 is a small molecule inhibitor of the protein MDM2.",
      "MDM2 is overexpressed in many types of cancer, including sarcomas.",
      "CMB305 is currently being studied in clinical trials as a potential treatment for various types of sarcomas, including soft tissue sarcoma and osteosarcoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: CMB305 is not a small molecule inhibitor; it is an investigational cancer vaccine targeting the NY-ESO-1 protein and is designed to stimulate the immune system.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the \"Three Signs of the Saint,\" is a concept in Hinduism and Buddhism that refers to the three main symptoms or manifestations of enlightenment or spiritual awakening. These three signs are:\n1. Insight into the nature of reality (or \"true nature\"): This refers to the ability to see things as they really are, without being deluded by superficial appearances.\n2. The abandonment of craving and attachment: This refers to the ability to let go of attachment to things that are impermanent and unreliable, and to cultivate a sense of detachment or non-attachment.\n3. The cultivation of compassion and loving-kindness: This refers to the ability to cultivate a sense of compassion and loving-kindness towards oneself and others, and to act in a way that is beneficial and helpful to others.\nTogether, these three signs are seen as the hallmarks of spiritual awakening, and are considered to be the result of intense meditation and spiritual practice.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, overexpression of LY6K is often associated with a better prognosis in non-small cell lung cancer (NSCLC) patients. Studies have shown that high levels of LY6K expression are associated with improved overall survival, disease-free survival, and response to chemotherapy in NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is often associated with a better prognosis in non-small cell lung cancer patients.\n2. High levels of LY6K expression are associated with improved overall survival in NSCLC patients.\n3. High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.\n4. High levels of LY6K expression are associated with an improved response to chemotherapy in NSCLC patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is often associated with a better prognosis in non-small cell lung cancer patients.",
      "High levels of LY6K expression are associated with improved overall survival in NSCLC patients.",
      "High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.",
      "High levels of LY6K expression are associated with an improved response to chemotherapy in NSCLC patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is often associated with a poorer prognosis in non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are generally associated with a poorer overall survival in NSCLC patients.\n3. FALSE [correction]: High levels of LY6K expression are generally associated with a poorer disease-free survival in NSCLC patients.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, several Cdk (Cyclin-dependent kinase) targets are dephosphorylated, leading to the activation of key cell division proteins and the progression of the cell cycle. Here are some examples of Cdk targets that are dephosphorylated during cytokinesis:\n1. Cdc25A: Cdc25A is a phosphatase that dephosphorylates and activates Cdk1, which is essential for the progression of the cell cycle. During cytokinesis, Cdc25A is dephosphorylated and inactivated, leading to the activation of Cdk1 and the progression of the cell cycle.\n2. Cyclin B: Cyclin B is a regulatory protein that binds to and activates Cdk1 during the G2/M transition. During cytokinesis, Cyclin B is dephosphorylated and inactivated, leading to the activation of Cdk1 and the progression of the cell cycle.\n3. Cyclin D: Cyclin D is a regulatory protein that binds to and activates Cdk4/6 during the G1 phase of the cell cycle. During cytokinesis, Cyclin D is dephosphorylated and inactivated, leading to the activation of Cdk4/6 and the progression of the cell cycle.\n4. Caspases: Caspases are a family of cysteine proteases that play a central role in the execution of apoptosis. During cytokinesis, caspases are activated and degrade cellular components, leading to the death of the cell.\n5. Bcl-2: Bcl-2 is a regulatory protein that inhibits the activity of Cdk1 and promotes cell survival. During cytokinesis, Bcl-2 is dephosphorylated and inactivated, leading to the activation of Cdk1 and the progression of the cell cycle.\nThese are just a few examples of the many proteins that are dephosphorylated during cytokinesis. The dephosphorylation of these proteins is crucial for the proper progression of the cell cycle and the execution of apoptosis during cytokinesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cdc25A is dephosphorylated during cytokinesis, which leads to the activation of Cdk1.\n2. Cyclin B is dephosphorylated during cytokinesis, which leads to the activation of Cdk1.\n3. Cyclin D is dephosphorylated during cytokinesis, which leads to the activation of Cdk4/6.\n4. Caspases are activated during cytokinesis and degrade cellular components.\n5. Bcl-2 is dephosphorylated during cytokinesis, which leads to the activation of Cdk1.",
    "llama-2-7b-chat-hf_fact": [
      "Cdc25A is dephosphorylated during cytokinesis, which leads to the activation of Cdk1.",
      "Cyclin B is dephosphorylated during cytokinesis, which leads to the activation of Cdk1.",
      "Cyclin D is dephosphorylated during cytokinesis, which leads to the activation of Cdk4/6.",
      "Caspases are activated during cytokinesis and degrade cellular components.",
      "Bcl-2 is dephosphorylated during cytokinesis, which leads to the activation of Cdk1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cdc25A is a phosphatase that dephosphorylates and activates Cdk1 during the earlier phase of the cell cycle, not specifically during cytokinesis.\n2. FALSE [correction]: Cyclin B binds to Cdk1 to form the mitotic cyclin-Cdk1 complex, which is activated by dephosphorylation, but this process occurs before cytokinesis to trigger the onset of mitosis.\n3. FALSE [correction]: Cyclin D binds to and activates Cdk4/6 during the G1 phase of the cell cycle, not during cytokinesis.\n4. FALSE [correction]: Caspases are typically activated during apoptosis, not cytokinesis, and are responsible for the degradation of cellular components during programmed cell death.\n5. FALSE [correction]: Bcl-2 is an anti-apoptotic protein and does not have a direct role in the activation of Cdk1 during cytokinesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is an investigational drug being developed by Actinogen Medical for the treatment of Alzheimer's disease. It is a small molecule inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that is involved in the production of cortisol in the brain. Cortisol is a hormone that is involved in the body's response to stress, but excessive levels of cortisol have been linked to the progression of Alzheimer's disease. By inhibiting 11β-HSD1, Xanamem is thought to reduce the amount of cortisol produced in the brain, which may help to slow down the progression of Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is an investigational drug developed by Actinogen Medical.\n2. Xanamem is being developed for the treatment of Alzheimer's disease.\n3. Xanamem is a small molecule inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).\n4. 11β-HSD1 is involved in the production of cortisol in the brain.\n5. High levels of cortisol have been linked to the progression of Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is an investigational drug developed by Actinogen Medical.",
      "Xanamem is being developed for the treatment of Alzheimer's disease.",
      "Xanamem is a small molecule inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).",
      "11β-HSD1 is involved in the production of cortisol in the brain.",
      "High levels of cortisol have been linked to the progression of Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "The Hof1-Cyk3 interaction plays a crucial role in regulating the cell cycle progression and cell division in yeast, particularly in the G2/M checkpoint.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction is involved in regulating the cell cycle progression in yeast.\n2. The Hof1-Cyk3 interaction is involved in regulating cell division in yeast.\n3. The Hof1-Cyk3 interaction has a role in the G2/M checkpoint in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction is involved in regulating the cell cycle progression in yeast.",
      "The Hof1-Cyk3 interaction is involved in regulating cell division in yeast.",
      "The Hof1-Cyk3 interaction has a role in the G2/M checkpoint in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n\nThe Hof1-Cyk3 interaction is known to be involved in the regulation of cytokinesis in yeast, which is a part of cell division. However, without specific information on its role in the G2/M checkpoint, the third statement cannot be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated microRNAs) that have been implicated in gastric cancer include:\n1. miR-145\n2. miR-15a\n3. miR-16\n4. miR-21\n5. miR-24-3p\n6. miR-26a\n7. miR-29a\n8. miR-31\n9. miR-34a\n10. miR-100\nThese T-UCRs have been shown to play a role in the development and progression of gastric cancer by regulating the expression of genes involved in cell proliferation, apoptosis, and angiogenesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. miR-145 has been implicated in gastric cancer.\n2. miR-15a has been implicated in gastric cancer.\n3. miR-16 has been implicated in gastric cancer.\n4. miR-21 has been implicated in gastric cancer.\n5. miR-24-3p has been implicated in gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "miR-145 has been implicated in gastric cancer.",
      "miR-15a has been implicated in gastric cancer.",
      "miR-16 has been implicated in gastric cancer.",
      "miR-21 has been implicated in gastric cancer.",
      "miR-24-3p has been implicated in gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: miR-145 has been implicated in various types of cancer, including gastric cancer, where it is often found to be downregulated.\n2. TRUE: miR-15a has also been implicated in the pathogenesis of several cancers, including gastric cancer.\n3. TRUE: miR-16 is known to be involved in the regulation of cell cycle and apoptosis and has been implicated in gastric cancer as well.\n4. TRUE: miR-21 is one of the most extensively studied microRNAs and has been frequently associated with gastric cancer, often being upregulated and acting as an oncomiR.\n5. UNKNOWN: The role of miR-24-3p in gastric cancer is less clear without specific context or references, and its implication in gastric cancer would require validation from scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease, based on a combination of physical examination findings, laboratory test results, and patient-reported symptoms, providing a comprehensive evaluation of disease activity and organ involvement.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is a clinical tool used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI evaluates disease activity and organ involvement in SLE.\n3. The LSI incorporates physical examination findings, laboratory test results, and patient-reported symptoms for assessment.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is a clinical tool used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI evaluates disease activity and organ involvement in SLE.",
      "The LSI incorporates physical examination findings, laboratory test results, and patient-reported symptoms for assessment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific information about the Lupus Severity Index (LSI), it is not possible to confirm the accuracy of these statements. The LSI is not a widely recognized tool in the context of systemic lupus erythematosus (SLE) management, as of my last update. Commonly used tools for assessing SLE include the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index. If the LSI is a newly developed or less commonly used tool, further information would be required to verify these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several neurological disorders, including:\n1. Zellweger syndrome: A rare genetic disorder characterized by delayed development, intellectual disability, and a distinctive facial appearance.\n2. ZSWIM6-related disorder: A recently identified disorder that shares many clinical features with Zellweger syndrome, but with a milder phenotype.\n3. Neuronal ceroid lipofuscinosis 6 (NCL6): A type of Batten disease, a group of rare genetic disorders that affect the brain and nervous system.\nIt's important to note that these disorders are rare and the prevalence of de novo mutations in ZSWIM6 that cause these disorders is not well established.",
    "llama-2-7b-chat-hf_fact_raw": "1. Zellweger syndrome is a rare genetic disorder associated with the ZSWIM6 gene.\n2. ZSWIM6-related disorder is a recently identified disorder with clinical features similar to Zellweger syndrome but milder.\n3. Neuronal ceroid lipofuscinosis 6 (NCL6) is a type of Batten disease associated with the ZSWIM6 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Zellweger syndrome is a rare genetic disorder associated with the ZSWIM6 gene.",
      "ZSWIM6-related disorder is a recently identified disorder with clinical features similar to Zellweger syndrome but milder.",
      "Neuronal ceroid lipofuscinosis 6 (NCL6) is a type of Batten disease associated with the ZSWIM6 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Zellweger syndrome is a rare genetic disorder associated with mutations in any one of the PEX genes, which are responsible for the normal functioning of peroxisomes.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is used to classify osteosarcoma, a type of bone cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify osteosarcoma.\n2. Osteosarcoma is a type of bone cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify osteosarcoma.",
      "Osteosarcoma is a type of bone cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Enneking system is used to classify osteosarcoma, not the Koos Classification.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "In vivo studies have shown that AZD8601 can improve cardiovascular function and reduce tissue damage in various animal models of ischemic disease, including myocardial infarction and peripheral artery disease. Specifically, AZD8601 has been shown to:\n1. Increase blood flow: AZD8601 has been shown to increase blood flow in the ischemic tissue, reducing the severity of tissue damage and improving cardiovascular function.\n2. Promote angiogenesis: AZD8601 has been shown to promote the formation of new blood vessels, which can help to restore blood flow to the ischemic tissue.\n3. Reduce inflammation: AZD8601 has been shown to reduce inflammation in the ischemic tissue, which can help to reduce tissue damage and improve cardiovascular function.\n4. Improve cardiac function: AZD8601 has been shown to improve cardiac function in animal models of myocardial infarction, reducing the severity of heart failure and improving survival rates.\n5. Reduce scar size: AZD8601 has been shown to reduce the size of scar tissue in the ischemic tissue, improving cardiovascular function and reducing the risk of complications such as heart failure.\n6. Improve ventricular function: AZD8601 has been shown to improve ventricular function in animal models of myocardial infarction, reducing the severity of heart failure and improving survival rates.\n7. Reduce infarct size: AZD8601 has been shown to reduce the size of the infarct area in animal models of myocardial infarction, improving cardiovascular function and reducing the risk of complications such as heart failure.\n8. Improve coronary flow: AZD8601 has been shown to improve coronary flow in animal models of myocardial infarction, reducing the severity of tissue damage and improving cardiovascular function.\n9. Reduce apoptosis: AZD8601 has been shown to reduce apoptosis (cell death) in the",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 has been shown to improve cardiovascular function in various animal models of ischemic disease.\n2. AZD8601 has been demonstrated to increase blood flow in ischemic tissue.\n3. AZD8601 has been shown to promote angiogenesis, the formation of new blood vessels.\n4. AZD8601 has been found to reduce inflammation in ischemic tissue.\n5. AZD8601 has been shown to reduce the size of scar tissue in ischemic tissue.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 has been shown to improve cardiovascular function in various animal models of ischemic disease.",
      "AZD8601 has been demonstrated to increase blood flow in ischemic tissue.",
      "AZD8601 has been shown to promote angiogenesis, the formation of new blood vessels.",
      "AZD8601 has been found to reduce inflammation in ischemic tissue.",
      "AZD8601 has been shown to reduce the size of scar tissue in ischemic tissue."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that while these statements are generally consistent with the potential effects of a therapeutic agent like AZD8601, which is designed to promote tissue repair and regeneration, the specific outcomes can vary depending on the study and the model used. Without specific references to the studies or data supporting these statements, it is assumed that they are based on published scientific research. If the statements were not supported by research, then the responses would need to be corrected accordingly.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFS (Safety Data Sheets) are created by manufacturers or importers of chemical products, in accordance with the Globally Harmonized System of Classification and Labeling of Chemicals (GHS). The process involves gathering information on the chemical product's physical and chemical properties, health and environmental hazards, and safety precautions, and then organizing this information into a standardized format. The resulting SAHFS provides information on the safe handling, use, storage, and disposal of the chemical product.",
    "llama-2-7b-chat-hf_fact_raw": "1. Safety Data Sheets (SDS) are created by manufacturers or importers of chemical products.\n2. The creation of SDS is in accordance with the Globally Harmonized System of Classification and Labeling of Chemicals (GHS).\n3. The process of creating SDS involves gathering information on the chemical product's physical and chemical properties.\n4. SDS also includes information on health and environmental hazards associated with the chemical product.\n5. Safety Data Sheets provide information on the safe handling, use, storage, and disposal of the chemical product.",
    "llama-2-7b-chat-hf_fact": [
      "Safety Data Sheets (SDS) are created by manufacturers or importers of chemical products.",
      "The creation of SDS is in accordance with the Globally Harmonized System of Classification and Labeling of Chemicals (GHS).",
      "The process of creating SDS involves gathering information on the chemical product's physical and chemical properties.",
      "SDS also includes information on health and environmental hazards associated with the chemical product.",
      "Safety Data Sheets provide information on the safe handling, use, storage, and disposal of the chemical product."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ domain in SATB1 is responsible for the protein's ability to bind to specific phosphorylated serine/threonine-containing sequences in other proteins, which is crucial for its role in regulating gene expression and cellular behavior.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 binds to specific phosphorylated serine/threonine-containing sequences in other proteins.\n2. The PDZ domain's binding function is crucial for SATB1's role in regulating gene expression and cellular behavior.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 binds to specific phosphorylated serine/threonine-containing sequences in other proteins.",
      "The PDZ domain's binding function is crucial for SATB1's role in regulating gene expression and cellular behavior."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is not a feature of SATB1; SATB1 contains a PDZ-like domain that binds to nuclear matrix attachment regions of DNA, not to phosphorylated serine/threonine-containing sequences in other proteins.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The basis of the BLISS technique is to prioritize and manage the backlog of work items in a product development process, with the goal of delivering a potentially shippable product increment at the end of each sprint. BLISS stands for:\n* B - Backlog: The list of work items to be completed\n* L - Limit WIP: Limit the amount of work in progress to avoid overburdening the team and ensure that each item is completed to a minimum viable product (MVP) standard\n* I - Inspect and Adapt: Regularly review and adapt the backlog and sprint plan based on feedback and changing requirements\n* S - Sprint: A time-boxed period of work, typically 2-4 weeks, during which the team completes a set of work items from the backlog\n* S - Scrum: A framework for managing and completing complex projects, which includes the roles of Scrum Master, Product Owner, and Development Team, as well as the ceremonies of Sprint Planning, Daily Scrum, Sprint Review, and Sprint Retrospective.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is used to prioritize and manage the backlog of work items in a product development process.\n2. The goal of the BLISS technique is to deliver a potentially shippable product increment at the end of each sprint.\n3. BLISS includes limiting the amount of work in progress to ensure that each item is completed to a minimum viable product standard.\n4. The BLISS technique involves regular reviews and adaptations of the backlog and sprint plan.\n5. Sprints in the BLISS technique are typically 2-4 weeks long.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is used to prioritize and manage the backlog of work items in a product development process.",
      "The goal of the BLISS technique is to deliver a potentially shippable product increment at the end of each sprint.",
      "BLISS includes limiting the amount of work in progress to ensure that each item is completed to a minimum viable product standard.",
      "The BLISS technique involves regular reviews and adaptations of the backlog and sprint plan.",
      "Sprints in the BLISS technique are typically 2-4 weeks long."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The BLISS technique is not a recognized standard technique in product development or agile methodologies. It may be a term used in a specific organization or a misinterpretation of an existing technique such as Scrum or Kanban.\n2. UNKNOWN: Since the BLISS technique is not a recognized standard technique, it's unclear whether its goal is to deliver a potentially shippable product increment at the end of each sprint. This is a goal of the Scrum framework, however.\n3. UNKNOWN: Without clear information on what the BLISS technique entails, it's difficult to determine if it includes limiting the amount of work in progress. Limiting work in progress is a principle commonly associated with Kanban.\n4. UNKNOWN: Regular reviews and adaptations of the backlog and sprint plan are part of Scrum and other agile methodologies, but it's unclear if this is a component of the BLISS technique due to the lack of information on what BLISS entails.\n5. UNKNOWN: Sprints that are 2-4 weeks long are typical in Scrum, but since the BLISS technique's details are not clear, it's unknown if this applies to BLISS.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Three NK3R (neurokinin 3 receptor) antagonists are:\n1. A-83-017\n2. GR 89696\n3. L-733,005",
    "llama-2-7b-chat-hf_fact_raw": "1. A-83-017 is an NK3R antagonist.\n2. GR 89696 is an NK3R antagonist.\n3. L-733,005 is an NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "A-83-017 is an NK3R antagonist.",
      "GR 89696 is an NK3R antagonist.",
      "L-733,005 is an NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "There is no oral ghrelin receptor inverse agonist that has been approved for use in humans, so there is no drug that has been \"profiled\" in healthy subjects for this mechanism of action. Ghrelin receptor inverse agonists are a relatively new class of drugs that are being developed for the treatment of various conditions, including obesity and related metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, the cholera vaccine, has been shown to be highly effective in preventing moderate to severe cholera in clinical trials. According to the manufacturer's data, Vaxchora has a protective efficacy of 80-90% against moderate to severe cholera, including 77-87% against moderate cholera and 84-92% against severe cholera. It is important to note that these figures are based on the vaccine's performance in controlled clinical trials, and the actual effectiveness of the vaccine in real-world settings may vary.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a vaccine for cholera.\n2. Vaxchora has a protective efficacy of 80-90% against moderate to severe cholera according to the manufacturer's data.\n3. The protective efficacy of Vaxchora is 77-87% against moderate cholera.\n4. The protective efficacy of Vaxchora is 84-92% against severe cholera.\n5. The efficacy figures for Vaxchora are based on controlled clinical trials.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a vaccine for cholera.",
      "Vaxchora has a protective efficacy of 80-90% against moderate to severe cholera according to the manufacturer's data.",
      "The protective efficacy of Vaxchora is 77-87% against moderate cholera.",
      "The protective efficacy of Vaxchora is 84-92% against severe cholera.",
      "The efficacy figures for Vaxchora are based on controlled clinical trials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (The exact efficacy percentage is not provided, and without specific data from the manufacturer or a reliable source, the statement's accuracy cannot be confirmed.)\n3. UNKNOWN (Similar to statement 2, the exact efficacy percentage against moderate cholera is not provided, and without specific data, the statement's accuracy cannot be confirmed.)\n4. UNKNOWN (As with statements 2 and 3, the exact efficacy percentage against severe cholera is not provided, and without specific data, the statement's accuracy cannot be confirmed.)\n5. TRUE (Vaccine efficacy figures are typically based on controlled clinical trials, and this is a standard practice in determining the efficacy of vaccines like Vaxchora.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the Shanchol vaccine, which was approved by the Food and Drug Administration (FDA) in 1991.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was the Shanchol vaccine.\n2. The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 1991.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was the Shanchol vaccine.",
      "The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 1991."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was Vaxchora, not Shanchol.\n2. FALSE [correction]: The Shanchol vaccine has not been approved by the Food and Drug Administration (FDA) for use in the United States. Vaxchora, the first cholera vaccine approved in the US, was approved by the FDA in 2016.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the CD40LG gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. A mutation in the CD40LG gene is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
    "llama-2-7b-chat-hf_fact": [
      "A mutation in the CD40LG gene is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the CD40LG gene are associated with X-linked hyper IgM syndrome, not common variable immunodeficiency (CVID). The most common genetic defects causing CVID in Europeans are mutations in the genes ICOS, TNFRSF13B (also known as TACI), and TNFRSF13C (also known as BAFF-R).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to be mutated in some cases of Systemic Lupus Erythematosus (SLE), an autoimmune disease that can affect multiple organs and tissues in the body. The IFIT1 gene provides instructions for making a protein that helps regulate the immune system and prevent the overproduction of inflammatory molecules. Mutations in the IFIT1 gene can lead to an overactive immune response and the production of excessive inflammatory molecules, which can contribute to the development of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene provides instructions for making a protein that helps regulate the immune system.\n2. Mutations in the IFIT1 gene can lead to an overactive immune response.\n3. Excessive production of inflammatory molecules can contribute to the development of Systemic Lupus Erythematosus (SLE).\n4. The IFIT1 gene has been found to be mutated in some cases of Systemic Lupus Erythematosus (SLE).\n5. Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect multiple organs and tissues in the body.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene provides instructions for making a protein that helps regulate the immune system.",
      "Mutations in the IFIT1 gene can lead to an overactive immune response.",
      "Excessive production of inflammatory molecules can contribute to the development of Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene has been found to be mutated in some cases of Systemic Lupus Erythematosus (SLE).",
      "Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect multiple organs and tissues in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nExplanation:\n1. The IFIT1 gene does provide instructions for making a protein involved in the immune response, particularly in the context of viral infection.\n2. While mutations in genes can lead to an overactive immune response, it is not clear from the provided statements whether mutations in the IFIT1 gene specifically are known to cause this without additional context or scientific evidence.\n3. Excessive production of inflammatory molecules is a known mechanism that can contribute to autoimmune diseases like Systemic Lupus Erythematosus (SLE).\n4. Without specific scientific evidence provided in the statements, it is not possible to confirm whether the IFIT1 gene has been found to be mutated in some cases of SLE.\n5. Systemic Lupus Erythematosus (SLE) is indeed an autoimmune disease that can affect multiple organs and tissues in the body.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure used to assess the outcome of elbow surgery, specifically for patients with lateral epicondylitis (golfer's elbow) or medial epicondylitis (baseball elbow). The LES evaluates the severity of symptoms, functional ability, and overall satisfaction with the affected elbow. It is used to assess the effectiveness of treatment and to monitor changes in symptoms over time. The LES consists of 50 questions and takes approximately 5-10 minutes to complete.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the outcome of elbow surgery.\n2. The LES is specifically for patients with lateral epicondylitis (golfer's elbow) or medial epicondylitis (baseball elbow).\n3. The LES evaluates the severity of symptoms, functional ability, and overall satisfaction with the affected elbow.\n4. The LES is used to monitor changes in symptoms over time.\n5. The LES consists of 50 questions and takes approximately 5-10 minutes to complete.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the outcome of elbow surgery.",
      "The LES is specifically for patients with lateral epicondylitis (golfer's elbow) or medial epicondylitis (baseball elbow).",
      "The LES evaluates the severity of symptoms, functional ability, and overall satisfaction with the affected elbow.",
      "The LES is used to monitor changes in symptoms over time.",
      "The LES consists of 50 questions and takes approximately 5-10 minutes to complete."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The LES is not specifically for patients with lateral epicondylitis (golfer's elbow) or medial epicondylitis (baseball elbow); it is used to assess various conditions related to elbow surgery.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project has contributed significantly to the understanding of sarcoma, a rare and complex cancer. Here are some key efforts and findings:\n1. Identification of new genetic mutations: The project has identified novel genetic mutations in sarcoma, including those in genes not previously associated with the disease. These findings have expanded our understanding of the genetic landscape of sarcoma and may lead to the development of new diagnostic markers and targeted therapies.\n2. Improved diagnosis and prognosis: The project has enabled researchers to develop more accurate diagnostic tests and predictive models for sarcoma. By analyzing the genomic data of patients with sarcoma, scientists have been able to identify specific genetic markers that can help doctors diagnose the disease more precisely and predict its progression.\n3. Development of personalized treatment strategies: The project has provided insights into the genetic mutations that drive sarcoma growth and resistance to treatment. By analyzing the genomic data of individual patients, doctors can identify the specific genetic mutations driving their cancer and develop personalized treatment strategies tailored to their unique genetic profile.\n4. Enhanced understanding of sarcoma subtypes: The project has helped to identify distinct subtypes of sarcoma, each with its unique genetic characteristics. This knowledge can be used to develop targeted therapies and improve treatment outcomes for patients with specific subtypes of sarcoma.\n5. Collaboration and data sharing: The 100,000 Genomes Project has fostered collaboration and data sharing among researchers, clinicians, and patient advocacy groups. This collaboration has accelerated the pace of research and enabled researchers to pool their expertise and resources to tackle the complex challenges of sarcoma research.\nIn summary, the 100,000 Genomes Project has significantly advanced our understanding of sarcoma, leading to improved diagnosis, prognosis, and treatment strategies. By analyzing the genomic data of thousands of patients with sarcoma, researchers have identified new genetic mutations, developed personalized treatment strategies, and improved our understanding of the disease's genetic landscape. These findings have the potential to transform the way we diagnose and treat sarcoma, improving",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project has identified novel genetic mutations in sarcoma.\n2. The project has enabled the development of more accurate diagnostic tests and predictive models for sarcoma.\n3. Insights from the project have led to the development of personalized treatment strategies for sarcoma based on individual genetic mutations.\n4. The project has helped to identify distinct subtypes of sarcoma with unique genetic characteristics.\n5. The 100,000 Genomes Project has fostered collaboration and data sharing among researchers, clinicians, and patient advocacy groups in the field of sarcoma research.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project has identified novel genetic mutations in sarcoma.",
      "The project has enabled the development of more accurate diagnostic tests and predictive models for sarcoma.",
      "Insights from the project have led to the development of personalized treatment strategies for sarcoma based on individual genetic mutations.",
      "The project has helped to identify distinct subtypes of sarcoma with unique genetic characteristics.",
      "The 100,000 Genomes Project has fostered collaboration and data sharing among researchers, clinicians, and patient advocacy groups in the field of sarcoma research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The 100,000 Genomes Project has indeed identified novel genetic mutations in various diseases, including sarcoma.\n2. TRUE: The project's findings have contributed to the development of more accurate diagnostic tests and predictive models for various diseases, including sarcoma.\n3. TRUE: Insights from the project have the potential to lead to the development of personalized treatment strategies for diseases like sarcoma, based on individual genetic mutations.\n4. TRUE: The project has helped to identify distinct subtypes of various diseases, including sarcoma, with unique genetic characteristics.\n5. TRUE: The 100,000 Genomes Project has encouraged collaboration and data sharing among researchers, clinicians, and patient advocacy groups, which is a key goal in the field of genomic research and can be applied to sarcoma research as well.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, ALEX1 (also known as ARM repeat-containing protein 1) is a protein that contains armadillo repeats. ALEX1 is a protein that is involved in the regulation of cell adhesion and signaling, and it contains multiple armadillo repeats in its structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. ALEX1 is also known as ARM repeat-containing protein 1.\n2. ALEX1 contains armadillo repeats.\n3. ALEX1 is involved in the regulation of cell adhesion and signaling.",
    "llama-2-7b-chat-hf_fact": [
      "ALEX1 is also known as ARM repeat-containing protein 1.",
      "ALEX1 contains armadillo repeats.",
      "ALEX1 is involved in the regulation of cell adhesion and signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Histone-modifying enzymes, such as histone acetyltransferases (HATs) and histone deacetylases (HDACs), play a crucial role in removing histone modifications by adding or removing acetyl groups from histone proteins. Here are some examples of enzymes that remove histone modifications:\n1. Histone deacetylases (HDACs): HDACs remove acetyl groups from histone proteins, leading to the repression of gene expression.\n2. Histone acetyltransferases (HATs): HATs add acetyl groups to histone proteins, leading to the activation of gene expression.\n3. Histone demethylases: Histone demethylases remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression.\n4. Histone-lysine N-methyltransferases: These enzymes remove methyl groups from lysine residues on histone proteins, leading to changes in chromatin structure and gene expression.\n5. Histone-arginine methyltransferases: These enzymes add methyl groups to arginine residues on histone proteins, leading to changes in chromatin structure and gene expression.\n6. Histone-phosphatases: These enzymes remove phosphate groups from histone proteins, leading to changes in chromatin structure and gene expression.\n7. Histone-ubiquitin ligases: These enzymes ubiquitinate histone proteins, leading to their degradation and changes in chromatin structure and gene expression.\n8. Histone-SUMO ligases: These enzymes ligate SUMO proteins to histone proteins, leading to changes in chromatin structure and gene expression.\n9. Histone-protein degradation pathways: These pathways involve the degradation of histone proteins by the ubiquitin-proteasome system or other protein degradation pathways, leading to changes in chromatin structure and gene expression.\nIt's worth noting that these enzymes can work together in complex pathways to remove histone modifications and regulate gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n2. Histone demethylases remove methyl groups from histone proteins.\n3. Histone-lysine N-methyltransferases remove methyl groups from lysine residues on histone proteins.\n4. Histone-phosphatases remove phosphate groups from histone proteins.\n5. Histone-ubiquitin ligases ubiquitinate histone proteins, leading to their degradation.",
    "llama-2-7b-chat-hf_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Histone demethylases remove methyl groups from histone proteins.",
      "Histone-lysine N-methyltransferases remove methyl groups from lysine residues on histone proteins.",
      "Histone-phosphatases remove phosphate groups from histone proteins.",
      "Histone-ubiquitin ligases ubiquitinate histone proteins, leading to their degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Histone-lysine N-methyltransferases add methyl groups to lysine residues on histone proteins.\n4. UNKNOWN (While there are enzymes that can remove phosphate groups from proteins, they are generally referred to as protein phosphatases, not specifically \"histone-phosphatases\". Without more context, it's unclear if this term is used correctly here.)\n5. FALSE [correction]: Histone-ubiquitin ligases add ubiquitin to histone proteins, which can lead to different outcomes, not necessarily degradation. Ubiquitination can affect gene expression, DNA repair, and other cellular processes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Yes, there is a small risk of developing a brain tumor after undergoing a head CT scan. However, the risk is very low and is generally considered to be less than 1 in 1,000. The risk is higher for people who have had multiple head CT scans, and for those who are exposed to high levels of radiation from CT scans at a young age. It is important to discuss the risks and benefits of head CT scans with your doctor and to follow their recommendations for minimizing radiation exposure.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is a small risk of developing a brain tumor after undergoing a head CT scan.\n2. The risk of developing a brain tumor from a head CT scan is generally considered to be less than 1 in 1,000.\n3. The risk of developing a brain tumor is higher for people who have had multiple head CT scans.\n4. The risk of developing a brain tumor from CT scans is higher for those exposed to high levels of radiation at a young age.\n5. It is recommended to discuss the risks and benefits of head CT scans with a doctor.",
    "llama-2-7b-chat-hf_fact": [
      "There is a small risk of developing a brain tumor after undergoing a head CT scan.",
      "The risk of developing a brain tumor from a head CT scan is generally considered to be less than 1 in 1,000.",
      "The risk of developing a brain tumor is higher for people who have had multiple head CT scans.",
      "The risk of developing a brain tumor from CT scans is higher for those exposed to high levels of radiation at a young age.",
      "It is recommended to discuss the risks and benefits of head CT scans with a doctor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: There is a small risk of developing a brain tumor after undergoing a head CT scan due to the ionizing radiation used in the procedure.\n2. TRUE: The risk of developing a brain tumor from a head CT scan is generally considered to be low, often quoted as less than 1 in 1,000, although the exact risk can vary based on several factors.\n3. TRUE: The risk of developing a brain tumor is generally considered to be higher for people who have had multiple head CT scans, as the cumulative radiation exposure increases.\n4. TRUE: The risk of developing a brain tumor from CT scans is indeed higher for those exposed to high levels of radiation at a young age, as children are more sensitive to the effects of radiation.\n5. TRUE: It is recommended to discuss the risks and benefits of head CT scans with a doctor to make an informed decision based on individual health needs and circumstances.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with naive pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with naive pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with naive pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region has several DNaseI hypersensitive sites (DHS), which are regions of chromatin that are more accessible to DNaseI digestion and are associated with active gene transcription. The exact number of DHS sites at the murine beta globin locus region can vary depending on the specific strain of mouse and the method used to identify them, but there are typically several dozen to several hundred DHS sites in this region. Some of the well-characterized DHS sites at the murine beta globin locus include:\n* DHS1: located upstream of the beta globin gene cluster and is involved in the regulation of beta globin gene expression\n* DHS2: located near the 5' end of the beta globin gene cluster and is involved in the regulation of beta globin gene expression\n* DHS3: located near the 3' end of the beta globin gene cluster and is involved in the regulation of beta globin gene expression\n* DHS4: located in the intron of the beta globin gene and is involved in the regulation of beta globin gene expression\n* DHS5: located in the 5' untranslated region (5' UTR) of the beta globin gene and is involved in the regulation of beta globin gene expression\n* DHS6: located in the 3' untranslated region (3' UTR) of the beta globin gene and is involved in the regulation of beta globin gene expression.\nThese DHS sites are known to be occupied by specific transcription factors and other regulatory proteins that play a crucial role in the regulation of beta globin gene expression and erythropoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. DNaseI hypersensitive sites (DHS) are regions of chromatin that are more accessible to DNaseI digestion.\n2. DHS sites are associated with active gene transcription.\n3. The number of DHS sites at the murine beta globin locus region can vary, with typically several dozen to several hundred DHS sites present.\n4. DHS1 is located upstream of the beta globin gene cluster and is involved in the regulation of beta globin gene expression.\n5. DHS sites at the murine beta globin locus are occupied by specific transcription factors and regulatory proteins that regulate beta globin gene expression and erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "DNaseI hypersensitive sites (DHS) are regions of chromatin that are more accessible to DNaseI digestion.",
      "DHS sites are associated with active gene transcription.",
      "The number of DHS sites at the murine beta globin locus region can vary, with typically several dozen to several hundred DHS sites present.",
      "DHS1 is located upstream of the beta globin gene cluster and is involved in the regulation of beta globin gene expression.",
      "DHS sites at the murine beta globin locus are occupied by specific transcription factors and regulatory proteins that regulate beta globin gene expression and erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The number of DHS sites at the murine beta globin locus region is not typically described as several dozen to several hundred. Instead, there are specific key DHS sites that are well-characterized, such as DHS1, DHS2, etc., but not in the range of dozens to hundreds.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Sure! Here are some European influenza vaccines that are commonly used:\n1. Fluarix Tetra (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus.\n2. Fluvirin (Novartis): This is a trivalent vaccine that protects against three strains of the influenza virus.\n3. Fluad (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus, including an adjuvanted formulation of the A/H1N1 strain.\n4. Fluarix (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of the influenza virus.\n5. FluMist (Sanofi Pasteur): This is a quadrivalent nasal spray vaccine that protects against four strains of the influenza virus.\n6. Afluria (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of the influenza virus.\n7. Fluvirin Quadrivalent (Novartis): This is a quadrivalent vaccine that protects against four strains of the influenza virus.\n8. Fluad Quadrivalent (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus, including an adjuvanted formulation of the A/H1N1 strain.\n9. Fluarix Tetra (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus.\n10. FluMist Quadrivalent (Sanofi Pasteur): This is a quadrivalent nasal spray vaccine that protects against four strains of the influenza virus.\nPlease note that this is not an exhaustive list, and there may be other influenza vaccines available in Europe that are not listed here. Additionally, the availability and composition of these vaccines may vary by country and region.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent influenza vaccine produced by GlaxoSmithKline.\n2. Fluvirin is a trivalent influenza vaccine produced by Novartis.\n3. Fluad is a quadrivalent influenza vaccine with an adjuvanted formulation of the A/H1N1 strain produced by GlaxoSmithKline.\n4. FluMist is a quadrivalent nasal spray influenza vaccine produced by Sanofi Pasteur.\n5. Afluria is a trivalent influenza vaccine produced by GlaxoSmithKline.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent influenza vaccine produced by GlaxoSmithKline.",
      "Fluvirin is a trivalent influenza vaccine produced by Novartis.",
      "Fluad is a quadrivalent influenza vaccine with an adjuvanted formulation of the A/H1N1 strain produced by GlaxoSmithKline.",
      "FluMist is a quadrivalent nasal spray influenza vaccine produced by Sanofi Pasteur.",
      "Afluria is a trivalent influenza vaccine produced by GlaxoSmithKline."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Fluad is a trivalent or quadrivalent (depending on the formulation) influenza vaccine with an adjuvanted formulation produced by Seqirus, not GlaxoSmithKline.\n4. FALSE [correction]: FluMist is a quadrivalent nasal spray influenza vaccine produced by AstraZeneca, not Sanofi Pasteur.\n5. FALSE [correction]: Afluria is a trivalent or quadrivalent influenza vaccine produced by Seqirus, not GlaxoSmithKline.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus genome is segmented, negative-sense RNA.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast Cream is effective for treating plaque psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast Cream is used to treat plaque psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast Cream is used to treat plaque psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Tools like HISAT2, STAR, and TopHat have been developed for identifying and visualising ncRNA promoters. These tools use techniques such as RNA-seq and spliced alignments to identify and map ncRNA transcripts and their promoters.",
    "llama-2-7b-chat-hf_fact_raw": "1. HISAT2 is a tool developed for identifying and visualising ncRNA promoters.\n2. STAR is a tool developed for identifying and visualising ncRNA promoters.\n3. TopHat is a tool developed for identifying and visualising ncRNA promoters.\n4. These tools use RNA-seq for identifying and mapping ncRNA transcripts and their promoters.\n5. These tools use spliced alignments to identify and map ncRNA transcripts and their promoters.",
    "llama-2-7b-chat-hf_fact": [
      "HISAT2 is a tool developed for identifying and visualising ncRNA promoters.",
      "STAR is a tool developed for identifying and visualising ncRNA promoters.",
      "TopHat is a tool developed for identifying and visualising ncRNA promoters.",
      "These tools use RNA-seq for identifying and mapping ncRNA transcripts and their promoters.",
      "These tools use spliced alignments to identify and map ncRNA transcripts and their promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HISAT2 is a fast and sensitive alignment program for mapping next-generation sequencing reads (whole-genome, transcriptome, and targeted sequencing data) to a population of human genomes or to a single reference genome, but it is not specifically developed for identifying and visualising ncRNA promoters.\n2. FALSE [correction]: STAR (Spliced Transcripts Alignment to a Reference) is a tool specifically designed for efficiently aligning RNA sequencing reads to a reference genome, but it is not specifically developed for identifying and visualising ncRNA promoters.\n3. FALSE [correction]: TopHat is a tool that was used for aligning RNA-Seq reads to a genome in order to identify splice junctions, but it is not specifically developed for identifying and visualising ncRNA promoters.\n4. TRUE: These tools use RNA-seq data for identifying and mapping ncRNA transcripts, which includes the identification of their promoters.\n5. TRUE: These tools use spliced alignments, which is a method that allows the alignment of RNA-seq reads that span splice junctions, to identify and map ncRNA transcripts and their promoters.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM tool has identified several genes that are down-regulated in glioblastoma. Here are some examples:\n1. TP53: TP53 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified TP53 as one of the most significantly down-regulated genes in glioblastoma.\n2. PTEN: PTEN is a tumor suppressor gene that is commonly mutated or deleted in glioblastoma. SWIM analysis has identified PTEN as one of the most significantly down-regulated genes in glioblastoma.\n3. CDKN2A: CDKN2A is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified CDKN2A as one of the most significantly down-regulated genes in glioblastoma.\n4. STK11: STK11 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified STK11 as one of the most significantly down-regulated genes in glioblastoma.\n5. BRCA1: BRCA1 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified BRCA1 as one of the most significantly down-regulated genes in glioblastoma.\n6. BRCA2: BRCA2 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified BRCA2 as one of the most significantly down-regulated genes in glioblastoma.\n7. MLH1: MLH1 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified MLH1 as one of the most significantly down-regulated genes in glioblastoma.\n8. MSH2: MSH2 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified MSH2 as one of the most significantly down-regulated genes in glioblastoma.\n9. MSH6: MSH6 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has identified MSH6 as one of the most",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool has identified TP53 as a significantly down-regulated gene in glioblastoma.\n2. The SWIM tool has identified PTEN as a significantly down-regulated gene in glioblastoma.\n3. The SWIM tool has identified CDKN2A as a significantly down-regulated gene in glioblastoma.\n4. The SWIM tool has identified STK11 as a significantly down-regulated gene in glioblastoma.\n5. The SWIM tool has identified BRCA1 as a significantly down-regulated gene in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool has identified TP53 as a significantly down-regulated gene in glioblastoma.",
      "The SWIM tool has identified PTEN as a significantly down-regulated gene in glioblastoma.",
      "The SWIM tool has identified CDKN2A as a significantly down-regulated gene in glioblastoma.",
      "The SWIM tool has identified STK11 as a significantly down-regulated gene in glioblastoma.",
      "The SWIM tool has identified BRCA1 as a significantly down-regulated gene in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific data or results from the SWIM (Survival Weighted Integrative Method) tool regarding the gene expression in glioblastoma, it is not possible to determine the accuracy of these statements. The SWIM tool is a bioinformatics tool used to analyze gene expression data, but without the actual output or a reference to a study that used the SWIM tool to identify these genes as significantly down-regulated in glioblastoma, the truthfulness of these statements cannot be assessed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Transcriptional Activity Detection (TADs), including:\n1. TADA: TADA is a package for the analysis of TADs, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.\n2. TSSminer: TSSminer is a package for the analysis of transcription start site (TSS) and TADs, including the detection of TSSs, the estimation of TAD sizes, and the identification of TAD-associated genes.\n3. TADbit: TADbit is a package for the analysis of TADs, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.\n4. TADtrack: TADtrack is a package for the analysis of TADs, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.\n5. TADseq: TADseq is a package for the analysis of TADs in RNA-seq data, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.\n6. TAD-seq: TAD-seq is a package for the analysis of TADs in RNA-seq data, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.\n7. TAD-detector: TAD-detector is a package for the detection of TADs in ChIP-seq data, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.\n8. TAD-finder: TAD-finder is a package for the detection of TADs in ChIP-seq data, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.\n9. TAD-hunter: TAD-hunter is a package for the detection of TADs in ChIP-seq data, including the detection of TAD boundaries, the estimation of TAD sizes, and the identification of TAD-associated genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. TADA is an R package developed for the analysis of Transcriptional Activity Detection (TADs).\n2. TSSminer is an R package that analyzes transcription start site (TSS) and TADs.\n3. TADbit is an R package designed for the analysis of TADs.\n4. TADtrack is an R package that focuses on the analysis of TADs.\n5. TADseq and TAD-seq are R packages for analyzing TADs in RNA-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "TADA is an R package developed for the analysis of Transcriptional Activity Detection (TADs).",
      "TSSminer is an R package that analyzes transcription start site (TSS) and TADs.",
      "TADbit is an R package designed for the analysis of TADs.",
      "TADtrack is an R package that focuses on the analysis of TADs.",
      "TADseq and TAD-seq are R packages for analyzing TADs in RNA-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TADA is not an R package; TADs refer to Topologically Associating Domains, and TAD analysis is often associated with genomic data rather than transcriptional activity. There is a Python package named TADbit for TAD analysis.\n2. UNKNOWN: Without specific information about an R package named TSSminer, it is unclear whether it analyzes transcription start sites (TSS) and TADs. TSS analysis is common, but the package's existence and its functions are not confirmed.\n3. TRUE: TADbit is indeed a software package, but it is written in Python, not R, and is designed for the analysis of TADs in genomic data.\n4. UNKNOWN: There is no widely recognized R package named TADtrack specifically for TAD analysis. Without additional context, the existence and purpose of TADtrack cannot be confirmed.\n5. FALSE [correction]: TADseq and TAD-seq are not known as R packages for analyzing TADs in RNA-seq data. TAD-seq is a method for identifying TADs, but it is not an R package. RNA-seq data is typically analyzed for gene expression, not specifically for TADs.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The Bioconductor package \"RulesMiner\" has been developed for accessing bacterial regulatory networks. RulesMiner is a tool for the analysis and mining of bacterial regulatory networks, and it provides a comprehensive framework for the analysis of transcriptional regulation in bacteria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bioconductor package \"RulesMiner\" is developed for accessing bacterial regulatory networks.\n2. RulesMiner is a tool designed for the analysis and mining of bacterial regulatory networks.\n3. RulesMiner provides a framework for the analysis of transcriptional regulation in bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "The Bioconductor package \"RulesMiner\" is developed for accessing bacterial regulatory networks.",
      "RulesMiner is a tool designed for the analysis and mining of bacterial regulatory networks.",
      "RulesMiner provides a framework for the analysis of transcriptional regulation in bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific information about the Bioconductor package \"RulesMiner,\" it is not possible to verify the accuracy of these statements. Bioconductor does host various packages for biological computation, but without additional context or access to the current Bioconductor repository, the details about \"RulesMiner\" cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are aromatic amino acids, including phenylalanine, tyrosine, and tryptophan, as well as the precursor molecule erythrose-4-phosphate.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids.\n2. Phenylalanine is an end product of the shikimate pathway.\n3. Tyrosine is an end product of the shikimate pathway.\n4. Tryptophan is an end product of the shikimate pathway.\n5. Erythrose-4-phosphate is a precursor molecule produced by the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids.",
      "Phenylalanine is an end product of the shikimate pathway.",
      "Tyrosine is an end product of the shikimate pathway.",
      "Tryptophan is an end product of the shikimate pathway.",
      "Erythrose-4-phosphate is a precursor molecule produced by the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Erythrose-4-phosphate is a precursor molecule used in the shikimate pathway, not produced by it.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome. Cabergoline is a dopamine receptor agonist that can help reduce the size of the pituitary tumor and alleviate symptoms such as hormonal imbalances, headaches, and visual disturbances. It is usually used in cases where the tumor is causing symptoms or is growing despite previous treatments. However, it is important to note that cabergoline is not a cure for Nelson's syndrome and may not completely eliminate the tumor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Cabergoline is a dopamine receptor agonist.\n3. Cabergoline can help reduce the size of the pituitary tumor associated with Nelson's syndrome.\n4. Cabergoline is used to alleviate symptoms such as hormonal imbalances, headaches, and visual disturbances in Nelson's syndrome patients.\n5. Cabergoline is usually used when the pituitary tumor is causing symptoms or is growing despite previous treatments.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline can help reduce the size of the pituitary tumor associated with Nelson's syndrome.",
      "Cabergoline is used to alleviate symptoms such as hormonal imbalances, headaches, and visual disturbances in Nelson's syndrome patients.",
      "Cabergoline is usually used when the pituitary tumor is causing symptoms or is growing despite previous treatments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is used to treat conditions like hyperprolactinemia, Parkinson's disease, and acromegaly, but not Nelson's syndrome. Nelson's syndrome involves the growth of a pituitary tumor after the removal of the adrenal glands and is typically treated with surgery or radiation therapy.\n2. TRUE\n3. FALSE [correction]: Cabergoline can help reduce the size of pituitary tumors associated with conditions like prolactinomas, but there is no evidence to suggest it is effective for tumors associated with Nelson's syndrome.\n4. FALSE [correction]: While cabergoline is used to alleviate symptoms such as hormonal imbalances and headaches in conditions like hyperprolactinemia, it is not specifically used for Nelson's syndrome symptoms. Treatment for Nelson's syndrome typically involves surgery or radiation, not cabergoline.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that primarily affects the nervous system. The main manifestation of Liebenberg syndrome is a combination of intellectual disability, seizures, and abnormalities in the structure and function of the brain and spinal cord. These abnormalities can lead to a range of symptoms, including:\n1. Developmental delays: Children with Liebenberg syndrome may experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n2. Intellectual disability: Individuals with Liebenberg syndrome often have mild to moderate intellectual disability, which can affect their ability to learn and adapt to new situations.\n3. Seizures: Seizures are a common symptom of Liebenberg syndrome, and can range from mild to severe.\n4. Abnormal brain and spinal cord structure: MRI scans have shown that individuals with Liebenberg syndrome often have abnormalities in the structure of the brain and spinal cord, including enlarged ventricles and abnormalities in the white matter.\n5. Sensory problems: Some individuals with Liebenberg syndrome may experience sensory problems, such as hearing loss or visual impairments.\n6. Autism-like behaviors: Some individuals with Liebenberg syndrome may exhibit autism-like behaviors, such as difficulty with social interactions and repetitive behaviors.\n7. Speech and language difficulties: Individuals with Liebenberg syndrome may experience difficulties with speech and language development, including delayed language acquisition and difficulty with articulation.\n8. Growth delays: Children with Liebenberg syndrome may experience delays in growth and development, including short stature and delayed puberty.\n9. Other symptoms: Other symptoms of Liebenberg syndrome can include scoliosis, hip dislocation, and other skeletal abnormalities.\nIt's important to note that the severity and range of symptoms can vary widely between individuals with Liebenberg syndrome, and some individuals may experience only a few of these symptoms. A comprehensive diagnostic evaluation and ongoing monitoring by a multidisciplinary team of healthcare professionals is essential for managing the condition and providing appropriate support and care.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that primarily affects the nervous system.\n2. The main manifestation of Liebenberg syndrome includes intellectual disability, seizures, and abnormalities in the structure and function of the brain and spinal cord.\n3. Children with Liebenberg syndrome may experience developmental delays in reaching milestones such as sitting, standing, and walking.\n4. MRI scans have shown that individuals with Liebenberg syndrome often have abnormalities in the structure of the brain and spinal cord, including enlarged ventricles and abnormalities in the white matter.\n5. Some individuals with Liebenberg syndrome may exhibit autism-like behaviors, such as difficulty with social interactions and repetitive behaviors.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder that primarily affects the nervous system.",
      "The main manifestation of Liebenberg syndrome includes intellectual disability, seizures, and abnormalities in the structure and function of the brain and spinal cord.",
      "Children with Liebenberg syndrome may experience developmental delays in reaching milestones such as sitting, standing, and walking.",
      "MRI scans have shown that individuals with Liebenberg syndrome often have abnormalities in the structure of the brain and spinal cord, including enlarged ventricles and abnormalities in the white matter.",
      "Some individuals with Liebenberg syndrome may exhibit autism-like behaviors, such as difficulty with social interactions and repetitive behaviors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Explanation]: Liebenberg syndrome is not a recognized medical condition in the scientific literature as of my knowledge cutoff date in 2023. Therefore, the statements provided cannot be verified as true or false, and no corrections can be made for any of the statements. If Liebenberg syndrome is a fictional or hypothetical disorder created for the purpose of this task, there is no factual basis to assess the statements. If it is a very recent discovery or extremely rare and not widely documented, there may not be enough information available to confirm or refute the statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "There are currently no orally bioavailable MPS1 kinase inhibitors that have been approved for clinical use. However, some MPS1 kinase inhibitors are being investigated in clinical trials for various diseases, including cancer. Here are some examples of MPS1 kinase inhibitors that are being studied in clinical trials:\n1. BAY 80-6946: This is an orally available MPS1 kinase inhibitor that is being investigated for the treatment of various cancers, including breast, lung, and ovarian cancer.\n2. GS-9973: This is an orally available MPS1 kinase inhibitor that is being investigated for the treatment of various cancers, including non-small cell lung cancer and pancreatic cancer.\n3. LY3023414: This is an orally available MPS1 kinase inhibitor that is being investigated for the treatment of various cancers, including breast cancer and ovarian cancer.\n4. MLN0128: This is an orally available MPS1 kinase inhibitor that is being investigated for the treatment of various cancers, including breast cancer and ovarian cancer.\n5. PF-04499184: This is an orally available MPS1 kinase inhibitor that is being investigated for the treatment of various cancers, including non-small cell lung cancer and pancreatic cancer.\nIt's important to note that these are just a few examples of MPS1 kinase inhibitors that are being studied in clinical trials, and there may be other compounds in various stages of development. Additionally, it's important to note that the availability of these compounds for clinical use may vary depending on the country and region.",
    "llama-2-7b-chat-hf_fact_raw": "1. BAY 80-6946 is an orally available MPS1 kinase inhibitor being investigated for the treatment of various cancers.\n2. GS-9973 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers such as non-small cell lung cancer and pancreatic cancer.\n3. LY3023414 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers including breast cancer and ovarian cancer.\n4. MLN0128 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers such as breast cancer and ovarian cancer.\n5. PF-04499184 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers including non-small cell lung cancer and pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "BAY 80-6946 is an orally available MPS1 kinase inhibitor being investigated for the treatment of various cancers.",
      "GS-9973 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers such as non-small cell lung cancer and pancreatic cancer.",
      "LY3023414 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers including breast cancer and ovarian cancer.",
      "MLN0128 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers such as breast cancer and ovarian cancer.",
      "PF-04499184 is an orally available MPS1 kinase inhibitor being investigated for the treatment of cancers including non-small cell lung cancer and pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: GS-9973, also known as entospletinib, is an orally available SYK kinase inhibitor being investigated for the treatment of certain hematologic cancers, not an MPS1 kinase inhibitor.\n3. UNKNOWN\n4. FALSE [correction]: MLN0128, also known as sapanisertib, is an orally available mTOR kinase inhibitor being investigated for the treatment of various cancers, not an MPS1 kinase inhibitor.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Yes, golimumab has been tested and approved for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, but it has not been specifically approved for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab has been tested for the treatment of moderate-to-severe rheumatoid arthritis.\n2. Golimumab is approved for the treatment of psoriatic arthritis.\n3. Golimumab is approved for the treatment of ankylosing spondylitis.\n4. Golimumab has not been specifically approved for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab has been tested for the treatment of moderate-to-severe rheumatoid arthritis.",
      "Golimumab is approved for the treatment of psoriatic arthritis.",
      "Golimumab is approved for the treatment of ankylosing spondylitis.",
      "Golimumab has not been specifically approved for the treatment of diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria is caused by an autosomal recessive gene mutation. This means that a person must inherit two copies of the mutated gene, one from each parent, in order to develop the condition. If a person inherits only one mutated copy of the gene, they will be a carrier of the condition but are unlikely to develop symptoms themselves.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is caused by an autosomal recessive gene mutation.\n2. A person must inherit two copies of the mutated gene to develop progeria, one from each parent.\n3. If a person inherits only one mutated copy of the gene, they will be a carrier of the condition.\n4. Carriers of one mutated copy of the gene for progeria are unlikely to develop symptoms themselves.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is caused by an autosomal recessive gene mutation.",
      "A person must inherit two copies of the mutated gene to develop progeria, one from each parent.",
      "If a person inherits only one mutated copy of the gene, they will be a carrier of the condition.",
      "Carriers of one mutated copy of the gene for progeria are unlikely to develop symptoms themselves."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Progeria is caused by a mutation in the LMNA gene, which is typically a de novo (new) mutation rather than an inherited autosomal recessive gene mutation.\n2. FALSE [correction]: Progeria is not inherited in an autosomal recessive manner; it usually occurs as a new mutation, and individuals typically do not inherit the condition from their parents.\n3. FALSE [correction]: Since progeria is not typically inherited and is usually caused by a new mutation, the concept of being a \"carrier\" in the traditional sense does not apply.\n4. TRUE (Given the context of the previous statements, this statement is consistent with the fact that progeria is not inherited in a typical autosomal recessive manner, and carriers of autosomal recessive conditions generally do not develop symptoms. However, it's important to note that this statement is based on the incorrect premise that progeria is inherited as an autosomal recessive condition, which it is not.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "The 12q14 and 12q24 regions of the human genome have been associated with a variety of diseases and conditions, including:\n12q14:\n* DiGeorge syndrome: a congenital disorder characterized by defects in the thymus, parathyroid glands, and facial abnormalities.\n* Velocardiofacial syndrome: a rare genetic disorder characterized by heart defects, facial abnormalities, and developmental delays.\n* CdLS: a genetic disorder characterized by intellectual disability, delayed speech and language development, and distinctive facial features.\n* Williams syndrome: a rare genetic disorder characterized by cardiovascular problems, developmental delays, and a distinctive facial appearance.\n12q24:\n* Colorectal cancer: several genes in the 12q24 region have been associated with an increased risk of colorectal cancer.\n* Breast cancer: several genes in the 12q24 region have been associated with an increased risk of breast cancer.\n* Prostate cancer: several genes in the 12q24 region have been associated with an increased risk of prostate cancer.\n* Ovarian cancer: several genes in the 12q24 region have been associated with an increased risk of ovarian cancer.\n* Melanoma: several genes in the 12q24 region have been associated with an increased risk of melanoma.\nIt's important to note that the presence of a variant in these regions does not necessarily mean that an individual will develop one of these diseases, and many people with these variants will not develop any of these conditions. Additionally, the frequency and distribution of these variants can vary depending on the population being studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 12q14 region of the human genome has been associated with DiGeorge syndrome, a congenital disorder.\n2. Velocardiofacial syndrome, characterized by heart defects and facial abnormalities, is associated with the 12q14 region.\n3. Cornelia de Lange Syndrome (CdLS), which includes intellectual disability and distinctive facial features, is associated with the 12q14 region.\n4. The 12q24 region has been associated with an increased risk of colorectal cancer.\n5. Several genes in the 12q24 region have been associated with an increased risk of breast cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The 12q14 region of the human genome has been associated with DiGeorge syndrome, a congenital disorder.",
      "Velocardiofacial syndrome, characterized by heart defects and facial abnormalities, is associated with the 12q14 region.",
      "Cornelia de Lange Syndrome (CdLS), which includes intellectual disability and distinctive facial features, is associated with the 12q14 region.",
      "The 12q24 region has been associated with an increased risk of colorectal cancer.",
      "Several genes in the 12q24 region have been associated with an increased risk of breast cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DiGeorge syndrome, a congenital disorder, is associated with a deletion in the 22q11.2 region of the human genome, not the 12q14 region.\n2. FALSE [correction]: Velocardiofacial syndrome, which is also known as 22q11.2 deletion syndrome, is associated with the 22q11.2 region, not the 12q14 region.\n3. FALSE [correction]: Cornelia de Lange Syndrome (CdLS) is most commonly associated with mutations in the NIPBL gene on chromosome 5, not the 12q14 region.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The ligands of the Roundabout (Robo) receptors are Robo1 and Robo2.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "There is evidence to suggest that TFII-I may play a role in megakaryopoiesis, the process by which platelets are produced in the bone marrow.\nOne study published in the journal Nature Communications in 2018 found that TFII-I is required for the proper differentiation of megakaryocytes, which are the cells that give rise to platelets. The study found that mice lacking TFII-I had impaired platelet production and a higher risk of bleeding.\nAnother study published in the journal Blood in 2019 found that TFII-I regulates the expression of genes involved in platelet function and survival. The study found that TFII-I binds to specific DNA sequences in the promoter regions of these genes and enhances their transcription.\nOverall, these studies suggest that TFII-I plays a critical role in regulating the process of megakaryopoiesis and the production of platelets in the bone marrow.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I may play a role in megakaryopoiesis, the process by which platelets are produced in the bone marrow.\n2. A study published in Nature Communications in 2018 indicated that TFII-I is required for the proper differentiation of megakaryocytes.\n3. Mice lacking TFII-I had impaired platelet production and a higher risk of bleeding, according to the 2018 study.\n4. A study published in the journal Blood in 2019 found that TFII-I regulates the expression of genes involved in platelet function and survival.\n5. The 2019 study reported that TFII-I binds to specific DNA sequences in the promoter regions of genes and enhances their transcription.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I may play a role in megakaryopoiesis, the process by which platelets are produced in the bone marrow.",
      "A study published in Nature Communications in 2018 indicated that TFII-I is required for the proper differentiation of megakaryocytes.",
      "Mice lacking TFII-I had impaired platelet production and a higher risk of bleeding, according to the 2018 study.",
      "A study published in the journal Blood in 2019 found that TFII-I regulates the expression of genes involved in platelet function and survival.",
      "The 2019 study reported that TFII-I binds to specific DNA sequences in the promoter regions of genes and enhances their transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the context provided, all statements seem to be consistent with scientific findings regarding the role of TFII-I in megakaryopoiesis and platelet production. However, without access to the specific studies mentioned, it is not possible to verify the exact details of the findings. Assuming the statements accurately reflect the content of the studies, they are marked as true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by CYP2D6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by CYP2D6.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by CYP2D6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and does not undergo significant metabolism by cytochrome P450 enzymes such as CYP2D6. It is primarily excreted unchanged in urine.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a software tool developed by Adobe, and there are several versions of it available, including:\n1. ExpansionHunter 1.0 (2007) - This was the initial release of the tool, which allowed users to search for and download plug-ins for Adobe Creative Suite applications.\n2. ExpansionHunter 2.0 (2009) - This version added new features such as the ability to search for plug-ins by category, and the ability to rate and review plug-ins.\n3. ExpansionHunter 3.0 (2011) - This version introduced a new user interface and improved search functionality, making it easier for users to find the right plug-ins for their needs.\n4. ExpansionHunter 4.0 (2013) - This version added support for Adobe Creative Cloud, allowing users to search for and install plug-ins directly within the cloud-based application.\n5. ExpansionHunter 5.0 (2015) - This version introduced a new user interface and improved search functionality, making it easier for users to find the right plug-ins for their needs.\n6. ExpansionHunter 6.0 (2017) - This version added support for Adobe XD, a new user experience design application, and improved search functionality for all Adobe Creative Cloud applications.\n7. ExpansionHunter 7.0 (2019) - This version added support for Adobe Fresco, a new drawing and painting application, and improved search functionality for all Adobe Creative Cloud applications.\n8. ExpansionHunter 8.0 (2020) - This version added support for Adobe XD 2020, a new version of the user experience design application, and improved search functionality for all Adobe Creative Cloud applications.\nPlease note that the versions listed above are the ones that are publicly available, and there might be other versions of ExpansionHunter that are not publicly available or have been discontinued.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter is a software tool developed by Adobe.\n2. ExpansionHunter 1.0 was released in 2007.\n3. ExpansionHunter 4.0 added support for Adobe Creative Cloud.\n4. ExpansionHunter 6.0 added support for Adobe XD.\n5. ExpansionHunter 7.0 added support for Adobe Fresco.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter is a software tool developed by Adobe.",
      "ExpansionHunter 1.0 was released in 2007.",
      "ExpansionHunter 4.0 added support for Adobe Creative Cloud.",
      "ExpansionHunter 6.0 added support for Adobe XD.",
      "ExpansionHunter 7.0 added support for Adobe Fresco."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ExpansionHunter is not developed by Adobe; it is a software tool designed to analyze regions of the genome for repeat expansions, often used in genomic research, not by a software company like Adobe.\n2. UNKNOWN\n3. FALSE [correction]: ExpansionHunter does not have support for Adobe Creative Cloud as it is not related to Adobe software products; it is a genomics tool.\n4. FALSE [correction]: ExpansionHunter does not have support for Adobe XD as it is not related to Adobe software products; it is a genomics tool.\n5. FALSE [correction]: ExpansionHunter does not have support for Adobe Fresco as it is not related to Adobe software products; it is a genomics tool.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (A Disintegrin and Metalloproteinase Domain-Containing Protein 18) is a protein that plays a crucial role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) signaling.\nAdamts18 is a secreted protein that is primarily expressed in the endothelium and is involved in the regulation of angiogenesis, the formation of new blood vessels. However, recent studies have shown that Adamts18 also plays a role in hormone receptor signaling, particularly in the regulation of ER signaling.\nAdamts18 has been shown to interact with the ER and modulate its activity by inhibiting the binding of estrogen to the receptor, thereby reducing the activation of ER-mediated signaling pathways. This suggests that Adamts18 may play a role in regulating the response to estrogen in various tissues, including the breast, uterus, and bone.\nIn addition, Adamts18 has been shown to interact with other hormone receptors, including the progesterone receptor (PR) and the retinoic acid receptor (RAR), and may play a role in regulating their activity as well.\nOverall, the role of Adamts18 in hormone receptor signaling is complex and multifaceted, and further research is needed to fully understand its mechanisms of action and its potential as a therapeutic target in various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is involved in the regulation of estrogen receptor (ER) signaling.\n2. Adamts18 is a secreted protein primarily expressed in the endothelium.\n3. Adamts18 plays a role in the regulation of angiogenesis.\n4. Adamts18 can inhibit the binding of estrogen to the estrogen receptor, reducing the activation of ER-mediated signaling pathways.\n5. Adamts18 has been shown to interact with other hormone receptors, including the progesterone receptor (PR) and the retinoic acid receptor (RAR).",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is involved in the regulation of estrogen receptor (ER) signaling.",
      "Adamts18 is a secreted protein primarily expressed in the endothelium.",
      "Adamts18 plays a role in the regulation of angiogenesis.",
      "Adamts18 can inhibit the binding of estrogen to the estrogen receptor, reducing the activation of ER-mediated signaling pathways.",
      "Adamts18 has been shown to interact with other hormone receptors, including the progesterone receptor (PR) and the retinoic acid receptor (RAR)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE: ADAMTS18 has been implicated in the regulation of angiogenesis, which is the formation of new blood vessels from pre-existing ones.\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding ADAMTS18's specific interactions with hormone receptors and its role in estrogen receptor signaling are highly specific and would require access to current scientific literature to confirm. Without specific references to research studies or reviews, the truthfulness of statements 1, 2, 4, and 5 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a novel, orally available, small molecule that acts as a potent and selective inhibitor of the enzyme p38 alpha (MAPK14) with a mechanism of action that involves the inhibition of the p38 signaling pathway.\nThe p38 signaling pathway is a key regulator of inflammation and stress responses in cells, and it is activated in response to a wide range of stimuli, including bacterial lipopolysaccharides, cytokines, and UV radiation. Activation of p38 MAPK leads to the phosphorylation and activation of downstream effectors, including pro-inflammatory cytokines, adhesion molecules, and ion channels, which can contribute to the development of inflammation and tissue damage.\nThiazovivin works by selectively inhibiting the p38 MAPK enzyme, thereby reducing the activation of downstream effectors and the production of pro-inflammatory cytokines. This can lead to a reduction in inflammation and tissue damage, and may be useful in the treatment of a variety of inflammatory disorders, including arthritis, asthma, and inflammatory bowel disease.\nIn addition to its anti-inflammatory effects, thiazovivin has also been shown to have neuroprotective effects, and may be useful in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.\nOverall, the mode of action of thiazovivin is to inhibit the p38 MAPK signaling pathway, which is involved in the regulation of inflammation and stress responses in cells. By selectively inhibiting this pathway, thiazovivin can reduce inflammation and tissue damage, and may be useful in the treatment of a variety of inflammatory disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is an orally available small molecule that inhibits the enzyme p38 alpha (MAPK14).\n2. The p38 signaling pathway is involved in regulating inflammation and stress responses in cells.\n3. Inhibition of the p38 MAPK enzyme by Thiazovivin leads to reduced activation of downstream effectors and production of pro-inflammatory cytokines.\n4. Thiazovivin may be useful in the treatment of inflammatory disorders such as arthritis, asthma, and inflammatory bowel disease.\n5. Thiazovivin has been shown to have neuroprotective effects and may be useful in treating neurodegenerative disorders like Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is an orally available small molecule that inhibits the enzyme p38 alpha (MAPK14).",
      "The p38 signaling pathway is involved in regulating inflammation and stress responses in cells.",
      "Inhibition of the p38 MAPK enzyme by Thiazovivin leads to reduced activation of downstream effectors and production of pro-inflammatory cytokines.",
      "Thiazovivin may be useful in the treatment of inflammatory disorders such as arthritis, asthma, and inflammatory bowel disease.",
      "Thiazovivin has been shown to have neuroprotective effects and may be useful in treating neurodegenerative disorders like Alzheimer's disease and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not known to inhibit the enzyme p38 alpha (MAPK14); it is actually a ROCK inhibitor that is often used to enhance the survival of stem cells during cell reprogramming and culturing.\n2. TRUE\n3. FALSE [correction]: Since Thiazovivin is not an inhibitor of the p38 MAPK enzyme, it does not lead to reduced activation of downstream effectors and production of pro-inflammatory cytokines through this pathway. The statement would be true for a p38 MAPK inhibitor, but not for Thiazovivin.\n4. UNKNOWN: While the statement could be true for a p38 MAPK inhibitor, there is no evidence provided that Thiazovivin, a ROCK inhibitor, is useful in the treatment of these inflammatory disorders. More research would be needed to support this claim.\n5. UNKNOWN: While Thiazovivin has been shown to have effects on stem cell survival, the statement regarding its neuroprotective effects and potential use in treating neurodegenerative disorders like Alzheimer's disease and Parkinson's disease is not substantiated here. Further research would be required to validate this claim.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  }
]